{
  "meta": {
    "id": "test3",
    "title": "Communicable Diseases",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "In a global health lecture, the topic of smallpox eradication is discussed, highlighting one of the major public health achievements of the 20th century. The eradication of smallpox was declared at different times in various countries. A medical student interested in the history of infectious diseases asks about the year in which India, a country with a large population and diverse geographic regions, was declared smallpox-free. In which year was India officially declared free of smallpox?",
      "options": [
        {
          "label": "A",
          "text": "May 1975",
          "correct": false
        },
        {
          "label": "B",
          "text": "April 1977",
          "correct": true
        },
        {
          "label": "C",
          "text": "August 1979",
          "correct": false
        },
        {
          "label": "D",
          "text": "May 1980",
          "correct": false
        }
      ],
      "correct_answer": "B. April 1977",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. April 1977</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The last known case of smallpox in India occurred on 24th May 1975 . India was declared smallpox free on 5th July 1975 .</li><li>\u2022 last known case of smallpox</li><li>\u2022 24th May 1975</li><li>\u2022 India</li><li>\u2022 smallpox free on 5th July 1975</li><li>\u2022 Epidemiological reasons/basis for Smallpox eradication:</li><li>\u2022 Epidemiological reasons/basis for Smallpox eradication:</li><li>\u2022 No known animal reservoir</li><li>\u2022 No</li><li>\u2022 animal reservoir</li><li>\u2022 No long term carrier state</li><li>\u2022 No long term carrier state</li><li>\u2022 Infection provides lifelong immunity</li><li>\u2022 Infection</li><li>\u2022 lifelong immunity</li><li>\u2022 Case detection simple due to characteristic rash</li><li>\u2022 Case detection simple</li><li>\u2022 rash</li><li>\u2022 Subclinical cases did not transmit the disease</li><li>\u2022 Subclinical cases</li><li>\u2022 not transmit</li><li>\u2022 disease</li><li>\u2022 A highly effective vaccine was available</li><li>\u2022 highly effective vaccine</li><li>\u2022 International cooperation</li><li>\u2022 Important Pointers about Small Pox -</li><li>\u2022 Important Pointers about Small Pox -</li><li>\u2022 Last indigenous case of Small pox in India: 17th May 1975 Last [importation] case of Small pox in India: 24th May 1975 India declared Small pox-free : 23 April, 1977 Last case of Small pox globally : 26th October 1977 ( Somalia ) Actual last case of small pox [ Laboratory accident ]: 1978 Global eradication of Small pox: 8th May 1980</li><li>\u2022 Last indigenous case of Small pox in India: 17th May 1975</li><li>\u2022 Last indigenous</li><li>\u2022 Small pox</li><li>\u2022 17th May 1975</li><li>\u2022 Last [importation] case of Small pox in India: 24th May 1975</li><li>\u2022 Last</li><li>\u2022 case of Small pox</li><li>\u2022 24th May 1975</li><li>\u2022 India declared Small pox-free : 23 April, 1977</li><li>\u2022 India</li><li>\u2022 Small pox-free</li><li>\u2022 23 April, 1977</li><li>\u2022 Last case of Small pox globally : 26th October 1977 ( Somalia )</li><li>\u2022 Last case</li><li>\u2022 Small pox</li><li>\u2022 globally</li><li>\u2022 26th October 1977</li><li>\u2022 Somalia</li><li>\u2022 Actual last case of small pox [ Laboratory accident ]: 1978</li><li>\u2022 last case</li><li>\u2022 Laboratory accident</li><li>\u2022 1978</li><li>\u2022 Global eradication of Small pox: 8th May 1980</li><li>\u2022 Global eradication of Small pox: 8th May 1980</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 India was declared small pox free on - 23 April, 1977</li><li>\u27a4 India</li><li>\u27a4 declared small pox free</li><li>\u27a4 23 April, 1977</li><li>\u27a4 Global eradication of Small pox : 8th May 1980</li><li>\u27a4 Global eradication</li><li>\u27a4 Small pox</li><li>\u27a4 8th May 1980</li><li>\u27a4 Ref : Park 26 th edition (page 158)</li><li>\u27a4 Ref : Park 26 th edition (page 158)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5a605cec",
      "audio": ""
    },
    {
      "text": "During an infectious disease rotation, a medical resident is learning about varicella (chickenpox), a highly contagious infection caused by the varicella-zoster virus. The resident is tasked with assessing the risk of transmission within households and communities. A key concept in understanding the spread of chickenpox is the secondary attack rate, which measures the likelihood of the disease spreading to susceptible individuals after exposure to a primary case. What is the secondary attack rate typically associated with chickenpox?",
      "options": [
        {
          "label": "A",
          "text": "60%",
          "correct": false
        },
        {
          "label": "B",
          "text": "45%",
          "correct": false
        },
        {
          "label": "C",
          "text": "25%",
          "correct": false
        },
        {
          "label": "D",
          "text": "90%",
          "correct": true
        }
      ],
      "correct_answer": "D. 90%",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-161226.png"
      ],
      "explanation": "<p><strong>Ans. D. 90%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 SAR is approximately 90 % in susceptible household contacts of chicken pox case .</li><li>\u2022 SAR</li><li>\u2022 90 %</li><li>\u2022 susceptible household contacts</li><li>\u2022 chicken pox case</li><li>\u2022 Secondary Attack Rate (SAR): Is no. of exposed persons developing the disease within range of incubation period , following exposure to the primary case . The denominator includes only those susceptible to disease . The primary case is always excluded both from numerator and denominator for SAR calculation.</li><li>\u2022 Secondary Attack Rate (SAR):</li><li>\u2022 no. of exposed persons</li><li>\u2022 disease</li><li>\u2022 incubation period</li><li>\u2022 exposure</li><li>\u2022 primary case</li><li>\u2022 denominator</li><li>\u2022 susceptible to disease</li><li>\u2022 primary</li><li>\u2022 excluded</li><li>\u2022 numerator and denominator</li><li>\u2022 SAR calculation.</li><li>\u2022 Secondary attack rate of some important diseases are -</li><li>\u2022 Secondary attack rate of some important diseases are -</li><li>\u2022 \u200b\u200b\u200b\u200b\u200b        \u200b\u200b\u200b\u200b\u200b</li><li>\u2022 Chickenpox -</li><li>\u2022 Chickenpox -</li><li>\u2022 Period of Communicability/ infectivity - 1\u20132 days before to 4\u20135 days after appearance of rash . Incubation Period - 14-16 days Rash - Chickenpox rash - Dew drop on rose petal appearance Centripetal distribution, Pleomorphic rash</li><li>\u2022 Period of Communicability/ infectivity - 1\u20132 days before to 4\u20135 days after appearance of rash .</li><li>\u2022 Communicability/ infectivity</li><li>\u2022 1\u20132 days before</li><li>\u2022 4\u20135 days after</li><li>\u2022 rash</li><li>\u2022 Incubation Period - 14-16 days</li><li>\u2022 Incubation Period</li><li>\u2022 14-16</li><li>\u2022 Rash - Chickenpox rash - Dew drop on rose petal appearance Centripetal distribution, Pleomorphic rash</li><li>\u2022 Chickenpox rash</li><li>\u2022 Dew drop</li><li>\u2022 rose petal</li><li>\u2022 Centripetal</li><li>\u2022 Pleomorphic</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The secondary attack rate of Chickenpox is - 90%</li><li>\u27a4 secondary attack rate</li><li>\u27a4 Chickenpox</li><li>\u27a4 90%</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2bb37f98",
      "audio": ""
    },
    {
      "text": "During an obstetrics and gynecology rotation, a medical resident is learning about the complications associated with viral infections during pregnancy. A topic of particular interest is the risk of congenital varicella syndrome (CVS) in the fetus when a pregnant woman contracts the Varicella Zoster virus, especially during the first 20 weeks of gestation. The resident is asked about the likelihood of developing CVS in children born to mothers who become infected with Varicella Zoster virus during this critical period. What is the percentage risk of congenital varicella syndrome in these cases?",
      "options": [
        {
          "label": "A",
          "text": "20-40%",
          "correct": false
        },
        {
          "label": "B",
          "text": "0.4-2%",
          "correct": true
        },
        {
          "label": "C",
          "text": "2-10%",
          "correct": false
        },
        {
          "label": "D",
          "text": "14-25%",
          "correct": false
        }
      ],
      "correct_answer": "B. 0.4-2%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 0.4-2%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Infection during pregnancy presents a risk for the foetus leading to congenital varicella syndrome . It occurs in 0.4-2.0 percent of children born to mothers who become infected with VZV during the first 20 weeks of gestation.</li><li>\u2022 Infection</li><li>\u2022 pregnancy</li><li>\u2022 risk</li><li>\u2022 foetus</li><li>\u2022 congenital varicella syndrome</li><li>\u2022 0.4-2.0 percent</li><li>\u2022 children born to mothers</li><li>\u2022 infected with VZV</li><li>\u2022 first 20 weeks of gestation.</li><li>\u2022 Congenital Varicella : Most threatening if transmitted in Ist trimester of pregnancy.</li><li>\u2022 Congenital Varicella</li><li>\u2022 threatening</li><li>\u2022 Ist trimester</li><li>\u2022 pregnancy.</li><li>\u2022 Common Gestational Periods for Vertical Transmission of Diseases -</li><li>\u2022 Common Gestational Periods for Vertical Transmission of Diseases -</li><li>\u2022 Congenital Varicella: First trimester Congenital Rubella: First trimester Congenital Parvovirus: Second Trimester Congenital Syphilis: Third trimester Congenital Toxoplasmosis: Third trimester Congenital Hepatitis B: Third trimester Congenital CMV: Third trimester Congenital HIV: During delivery Congenital Hepatitis C: During delivery Congenital Herpes: During delivery</li><li>\u2022 Congenital Varicella: First trimester</li><li>\u2022 Congenital Varicella: First trimester</li><li>\u2022 Congenital Rubella: First trimester</li><li>\u2022 Congenital Rubella: First trimester</li><li>\u2022 Congenital Parvovirus: Second Trimester</li><li>\u2022 Congenital Syphilis: Third trimester</li><li>\u2022 Congenital Toxoplasmosis: Third trimester</li><li>\u2022 Congenital Hepatitis B: Third trimester</li><li>\u2022 Congenital Hepatitis B: Third trimester</li><li>\u2022 Congenital CMV: Third trimester</li><li>\u2022 Congenital HIV: During delivery</li><li>\u2022 Congenital HIV: During delivery</li><li>\u2022 Congenital Hepatitis C: During delivery</li><li>\u2022 Congenital Herpes: During delivery</li><li>\u2022 Congenital Herpes: During delivery</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 0.4 - 2% of children who acquire this condition born to mothers who become infected with Varicella Zoster virus during first 20 weeks of gestation.</li><li>\u27a4 0.4 - 2% of children</li><li>\u27a4 acquire</li><li>\u27a4 born to mothers</li><li>\u27a4 infected</li><li>\u27a4 Varicella Zoster virus</li><li>\u27a4 first 20 weeks of gestation.</li><li>\u27a4 Ref : Park 26 th edition (page 158)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 158)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "91f0dece",
      "audio": ""
    },
    {
      "text": "A medical resident treating a patient with chickenpox is discussing the case with a senior colleague. They talk about the infectious period of chickenpox, which is important for implementing appropriate isolation measures and preventing the spread of the infection. The resident is asked to identify the typical period during which a patient with chickenpox is infectious to others. When is the period of infectivity in a case of chickenpox?",
      "options": [
        {
          "label": "A",
          "text": "1 to 2 days before rash and 4 to 5 days thereafter",
          "correct": true
        },
        {
          "label": "B",
          "text": "4 to 5 days before rash and 1 to 2 days thereafter",
          "correct": false
        },
        {
          "label": "C",
          "text": "3 to 4 days before rash and 4 to 5 days thereafter",
          "correct": false
        },
        {
          "label": "D",
          "text": "1 day before rash and 2 days thereafter",
          "correct": false
        }
      ],
      "correct_answer": "A. 1 to 2 days before rash and 4 to 5 days thereafter",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. 1 to 2 days before rash and 4 to 5 days thereafter</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The period of communicability of patients with varicella is estimated to range from 1 to 2 days before the appearance of rash , and 4 to 5 days thereafter. The virus tends to die out before the pustular stage . The patient ceases to be infectious once the lesions have crusted.</li><li>\u2022 period of communicability</li><li>\u2022 varicella</li><li>\u2022 1 to 2 days</li><li>\u2022 before</li><li>\u2022 rash</li><li>\u2022 4 to 5 days</li><li>\u2022 virus</li><li>\u2022 die</li><li>\u2022 before</li><li>\u2022 pustular stage</li><li>\u2022 patient ceases</li><li>\u2022 infectious</li><li>\u2022 lesions</li><li>\u2022 crusted.</li><li>\u2022 Some important Pointers -</li><li>\u2022 Some important Pointers -</li><li>\u2022 Chicken pox rash - Dew drop on rose petal appearance; Centripetal distribution ; Pleomorphic rash False about chickenpox is - Crusts contain live virus Chickenpox Synonym : \u2018Varicella\u2019 Causative agent: Varicella zoster virus [Human (alpha) Herpes Virus\u20133 ] Incubation period: 14\u201316 days Source of infection: Case ( person-to-person contact ) Mode of transmission : Air droplets (respiratory) Secondary Attack rate : 90%MC late complication of chickenpox : Shingles (caused by reactivation of the virus decades after the initial episode of chickenpox ) Most rapid and sensitive means of diagnosis: Examination of vesicle fluid under electron microscope (shows round particles) Congenital Varicella: Most threatening if transmitted in 1 st trimester of pregnancy Live attenuated Chickenpox Monovalent Vaccine Strain - OKA strain</li><li>\u2022 Chicken pox rash - Dew drop on rose petal appearance; Centripetal distribution ; Pleomorphic rash</li><li>\u2022 Dew drop</li><li>\u2022 rose petal</li><li>\u2022 Centripetal distribution</li><li>\u2022 Pleomorphic rash</li><li>\u2022 False about chickenpox is - Crusts contain live virus</li><li>\u2022 False</li><li>\u2022 Crusts</li><li>\u2022 live virus</li><li>\u2022 Chickenpox Synonym : \u2018Varicella\u2019</li><li>\u2022 Synonym</li><li>\u2022 \u2018Varicella\u2019</li><li>\u2022 Causative agent: Varicella zoster virus [Human (alpha) Herpes Virus\u20133 ]</li><li>\u2022 Varicella zoster virus</li><li>\u2022 Herpes Virus\u20133</li><li>\u2022 Incubation period: 14\u201316 days</li><li>\u2022 14\u201316 days</li><li>\u2022 Source of infection: Case ( person-to-person contact )</li><li>\u2022 person-to-person contact</li><li>\u2022 Mode of transmission : Air droplets (respiratory)</li><li>\u2022 Mode</li><li>\u2022 transmission</li><li>\u2022 Air droplets</li><li>\u2022 Secondary Attack rate : 90%MC late complication of chickenpox : Shingles (caused by reactivation of the virus decades after the initial episode of chickenpox )</li><li>\u2022 Secondary Attack rate</li><li>\u2022 90%MC</li><li>\u2022 chickenpox</li><li>\u2022 Shingles</li><li>\u2022 reactivation</li><li>\u2022 virus decades</li><li>\u2022 initial episode of chickenpox</li><li>\u2022 Most rapid and sensitive means of diagnosis: Examination of vesicle fluid under electron microscope (shows round particles)</li><li>\u2022 rapid and sensitive</li><li>\u2022 vesicle fluid</li><li>\u2022 electron microscope</li><li>\u2022 Congenital Varicella: Most threatening if transmitted in 1 st trimester of pregnancy</li><li>\u2022 Most threatening</li><li>\u2022 1 st</li><li>\u2022 trimester</li><li>\u2022 pregnancy</li><li>\u2022 Live attenuated Chickenpox Monovalent Vaccine Strain - OKA strain</li><li>\u2022 Live attenuated Chickenpox Monovalent Vaccine Strain</li><li>\u2022 OKA</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The period of infectivity in a case of Chickenpox - 1 to 2 days before rash and 4 to 5 days thereafter.</li><li>\u27a4 period of infectivity</li><li>\u27a4 Chickenpox</li><li>\u27a4 1 to 2 days before</li><li>\u27a4 rash</li><li>\u27a4 4 to 5 days thereafter.</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c7a696ff",
      "audio": ""
    },
    {
      "text": "A pediatric resident is evaluating a child at a Community Health Center (CHC) who presents with fever and a distinctive rash. Upon examination, the resident notes the simultaneous presence of papules, vesicles, and crusts all in the same area of the skin. This combination of lesions at different stages of development in the same area is characteristic of a specific viral infection. What is the most probable diagnosis for this child?",
      "options": [
        {
          "label": "A",
          "text": "Small pox",
          "correct": false
        },
        {
          "label": "B",
          "text": "Measles",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dengue",
          "correct": false
        },
        {
          "label": "D",
          "text": "Chickenpox",
          "correct": true
        }
      ],
      "correct_answer": "D. Chickenpox",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/18/image_4PQz4JP.png"
      ],
      "explanation_images": [
        "https://my.clevelandclinic.org/-/scassets/images/org/health/articles/10855-smallpox",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image-20231128145356-1.jpeg",
        "https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcRj7uaO9jM9z0k4dHy9_lFnLS9eMRr-Nksglw&usqp=CAU",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture11_HrNvuDK.jpg"
      ],
      "explanation": "<p><strong>Ans. D. Chickenpox</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Small pox: smallpox lesions appear in the same stage of development at the same time all over the body ( non pleomorphic ), unlike chickenpox where different stages are seen in the same area.</li><li>\u2022 Option</li><li>\u2022 A. Small pox:</li><li>\u2022 smallpox lesions</li><li>\u2022 same stage of development</li><li>\u2022 same time</li><li>\u2022 non pleomorphic</li><li>\u2022 unlike chickenpox</li><li>\u2022 different stages</li><li>\u2022 seen</li><li>\u2022 same area.</li><li>\u2022 Option B. Measles: Maculopapular rash that typically begins on the face and spreads downward . It does not present with lesions at different stages (papules, vesicles, crusts) in the same area.</li><li>\u2022 Option B. Measles:</li><li>\u2022 Maculopapular rash</li><li>\u2022 begins</li><li>\u2022 face and spreads downward</li><li>\u2022 not</li><li>\u2022 lesions at different stages</li><li>\u2022 same area.</li><li>\u2022 Option C. Dengue: Dengue fever can present with a rash, but it is usually a diffuse erythematous rash , not one with papules, vesicles, and crusts in the same area.</li><li>\u2022 Option C. Dengue:</li><li>\u2022 Dengue fever</li><li>\u2022 rash,</li><li>\u2022 diffuse erythematous rash</li><li>\u2022 not</li><li>\u2022 papules, vesicles, and crusts</li><li>\u2022 same area.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chickenpox rash - Dew drop on rose petal appearance ; Centripetal distribution; Pleomorphic rash.</li><li>\u27a4 Chickenpox rash</li><li>\u27a4 Dew drop</li><li>\u27a4 rose</li><li>\u27a4 petal appearance</li><li>\u27a4 Centripetal distribution; Pleomorphic rash.</li><li>\u27a4 Difference between Chicken Pox and Small Pox rash</li><li>\u27a4 Difference between Chicken Pox and Small Pox rash</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li><li>\u27a4 Ref : Park 26 th edition (page 159)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8f8eaae5",
      "audio": ""
    },
    {
      "text": "During a clinical discussion on the epidemiology of common viral infections, a medical resident asks about the seasonality of varicella-zoster virus (VZV) infections. Understanding the seasonal trends of infectious diseases is crucial for planning public health interventions and anticipating healthcare needs. Based on epidemiological patterns, in which of the following months is a varicella-zoster virus infection (chickenpox) more likely to occur?",
      "options": [
        {
          "label": "A",
          "text": "March",
          "correct": true
        },
        {
          "label": "B",
          "text": "August",
          "correct": false
        },
        {
          "label": "C",
          "text": "October",
          "correct": false
        },
        {
          "label": "D",
          "text": "November",
          "correct": false
        }
      ],
      "correct_answer": "A. March",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. March</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 CHICKENPOX:</li><li>\u2022 CHICKENPOX:</li><li>\u2022 Also known as \u2018 Varicella \u2019 Causative agent: Varicella zoster virus [Human (alpha) Herpes Virus \u2013 3 ] Secondary attack rate: 90% Incubation period: 14\u201316 days Rash: Dew drop on rose petal appearance ; Centripetal distribution; Pleomorphic rash MC late complication of Chickenpox : Shingles (caused by reactivation of the virus decades after the initial episode of chickenpox ) Aspirin must not be given to children with chickenpox: Risk of Reye\u2019s Syndrome Strain of Live attenuated Chickenpox Vaccine : OKA strain Congenital Varicella : Most threatening if transmitted in 1 st trimester of pregnancy</li><li>\u2022 Also known as \u2018 Varicella \u2019</li><li>\u2022 Varicella</li><li>\u2022 Causative agent: Varicella zoster virus [Human (alpha) Herpes Virus \u2013 3 ]</li><li>\u2022 Varicella zoster virus</li><li>\u2022 Herpes Virus \u2013 3</li><li>\u2022 Secondary attack rate: 90%</li><li>\u2022 90%</li><li>\u2022 Incubation period: 14\u201316 days</li><li>\u2022 14\u201316 days</li><li>\u2022 Rash: Dew drop on rose petal appearance ; Centripetal distribution; Pleomorphic rash</li><li>\u2022 Dew drop</li><li>\u2022 rose petal appearance</li><li>\u2022 Centripetal distribution; Pleomorphic rash</li><li>\u2022 MC late complication of Chickenpox : Shingles (caused by reactivation of the virus decades after the initial episode of chickenpox )</li><li>\u2022 MC late complication</li><li>\u2022 Chickenpox</li><li>\u2022 Shingles</li><li>\u2022 reactivation of</li><li>\u2022 virus decades</li><li>\u2022 after</li><li>\u2022 initial episode</li><li>\u2022 chickenpox</li><li>\u2022 Aspirin must not be given to children with chickenpox: Risk of Reye\u2019s Syndrome</li><li>\u2022 Aspirin</li><li>\u2022 not</li><li>\u2022 Risk of Reye\u2019s</li><li>\u2022 Syndrome</li><li>\u2022 Strain of Live attenuated Chickenpox Vaccine : OKA strain</li><li>\u2022 Strain</li><li>\u2022 Live attenuated Chickenpox Vaccine</li><li>\u2022 OKA strain</li><li>\u2022 Congenital Varicella : Most threatening if transmitted in 1 st trimester of pregnancy</li><li>\u2022 Congenital Varicella</li><li>\u2022 Most threatening</li><li>\u2022 1 st trimester</li><li>\u2022 pregnancy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Varicella-zoster virus infections ( chickenpox ) are more likely to occur in March, late winter and early spring , which is important for healthcare planning and public health interventions .</li><li>\u27a4 Varicella-zoster virus</li><li>\u27a4 chickenpox</li><li>\u27a4 March,</li><li>\u27a4 late winter and early spring</li><li>\u27a4 healthcare planning</li><li>\u27a4 public health interventions</li><li>\u27a4 Ref : Clinical Maternal-Fetal Medicine by Winn, 1/e p263</li><li>\u27a4 Ref</li><li>\u27a4 : Clinical Maternal-Fetal Medicine by Winn, 1/e p263</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b066dfe7",
      "audio": ""
    },
    {
      "text": "A medical resident is discussing the administration of the measles vaccine with a supervising physician. The conversation focuses on contraindications to vaccination, which are critical for ensuring patient safety. The resident is asked about definitive contraindications for administering the measles vaccine. Which of the following is considered a definitive contraindication for the measles vaccine?",
      "options": [
        {
          "label": "A",
          "text": "Pregnancy",
          "correct": true
        },
        {
          "label": "B",
          "text": "HIV infection- asymptomatic",
          "correct": false
        },
        {
          "label": "C",
          "text": "Respiratory infection",
          "correct": false
        },
        {
          "label": "D",
          "text": "Malnutrition",
          "correct": false
        }
      ],
      "correct_answer": "A. Pregnancy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Pregnancy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. HIV Infection - Asymptomatic: Can be administered to HIV-infected individuals , especially if they are asymptomatic or not severely immunocompromised . Vaccination should be considered after careful evaluation of the immune status.</li><li>\u2022 Option B. HIV Infection - Asymptomatic:</li><li>\u2022 administered to HIV-infected individuals</li><li>\u2022 asymptomatic</li><li>\u2022 not severely immunocompromised</li><li>\u2022 Vaccination</li><li>\u2022 considered</li><li>\u2022 evaluation of the immune status.</li><li>\u2022 Option C. Respiratory Infection: Not a contraindication, if the illness is mild and without fever , vaccination can generally proceed .</li><li>\u2022 Option C. Respiratory Infection: Not</li><li>\u2022 contraindication,</li><li>\u2022 illness is mild</li><li>\u2022 without fever</li><li>\u2022 proceed</li><li>\u2022 Option D. Malnutrition: Malnutrition , particularly in countries where measles is endemic , is not a contraindication to measles vaccination. In fact, vaccination is crucial in malnourished individuals due to their increased risk of severe measles .</li><li>\u2022 Option D. Malnutrition:</li><li>\u2022 ,</li><li>\u2022 measles is endemic</li><li>\u2022 not</li><li>\u2022 contraindication</li><li>\u2022 measles</li><li>\u2022 vaccination</li><li>\u2022 malnourished</li><li>\u2022 increased risk</li><li>\u2022 severe measles</li><li>\u2022 Some important pointers regarding vaccine contraindications -</li><li>\u2022 Vaccines contraindicated in Pregnancy : All live vaccines EXCEPT Yellow fever vaccine Vaccines contraindicated in HIV : Asymptomatic HIV: NONE Symptomatic HIV : All live vaccines EXCEPT MMR, Varicella & Zoster may be given if required Vaccines contraindicated in Immuno-suppression: All live vaccines Vaccines contraindicated in Corticosteroid therapy: All live vaccines Vaccines contraindicated in fever : Typhoid vaccines Vaccines contraindicated in ARTI/diarrhoea: NONE Vaccines contraindicated together: Yellow fever and Cholera vaccine Vaccine contraindicated in Preterm-premature baby with birth weight < 2 kg: Hepatitis B Vaccines contraindicated in age < 1 year (infants): \u2013 Yellow fever vaccine, Meningococcal vaccine, Pneumococcal vaccine Vaccines contraindicated in age < 2 year (infants): \u2013 Meningococcal vaccine, Pneumococcal vaccine, Typhoid vaccines Vaccine contraindicated in progressive neurological disease : Pertussis vaccine (Pertussis vaccine IS NOT CONTRAINDICATED IN epilepsy controlled on medications, Cerebral palsy) Only absolute contraindication to killed vaccines : Severe local or general reaction to a previous dose</li><li>\u2022 Vaccines contraindicated in Pregnancy : All live vaccines EXCEPT Yellow fever vaccine</li><li>\u2022 contraindicated</li><li>\u2022 Pregnancy</li><li>\u2022 EXCEPT Yellow fever vaccine</li><li>\u2022 Vaccines contraindicated in HIV : Asymptomatic HIV: NONE Symptomatic HIV : All live vaccines EXCEPT MMR, Varicella & Zoster may be given if required</li><li>\u2022 contraindicated</li><li>\u2022 HIV</li><li>\u2022 Asymptomatic HIV: NONE Symptomatic HIV : All live vaccines EXCEPT MMR, Varicella & Zoster may be given if required</li><li>\u2022 Asymptomatic HIV: NONE</li><li>\u2022 Symptomatic HIV : All live vaccines EXCEPT MMR, Varicella & Zoster may be given if required</li><li>\u2022 Symptomatic HIV</li><li>\u2022 All live vaccines</li><li>\u2022 MMR, Varicella & Zoster</li><li>\u2022 Vaccines contraindicated in Immuno-suppression: All live vaccines</li><li>\u2022 Vaccines contraindicated in Corticosteroid therapy: All live vaccines</li><li>\u2022 Vaccines contraindicated in fever : Typhoid vaccines</li><li>\u2022 contraindicated</li><li>\u2022 fever</li><li>\u2022 Typhoid vaccines</li><li>\u2022 Vaccines contraindicated in ARTI/diarrhoea: NONE</li><li>\u2022 Vaccines contraindicated together: Yellow fever and Cholera vaccine</li><li>\u2022 Vaccine contraindicated in Preterm-premature baby with birth weight < 2 kg: Hepatitis B</li><li>\u2022 Preterm-premature baby</li><li>\u2022 Hepatitis B</li><li>\u2022 Vaccines contraindicated in age < 1 year (infants): \u2013 Yellow fever vaccine, Meningococcal vaccine, Pneumococcal vaccine</li><li>\u2022 Vaccines contraindicated in age < 2 year (infants): \u2013 Meningococcal vaccine, Pneumococcal vaccine, Typhoid vaccines</li><li>\u2022 Vaccine contraindicated in progressive neurological disease : Pertussis vaccine (Pertussis vaccine IS NOT CONTRAINDICATED IN epilepsy controlled on medications, Cerebral palsy)</li><li>\u2022 contraindicated</li><li>\u2022 progressive neurological disease</li><li>\u2022 Pertussis vaccine</li><li>\u2022 Only absolute contraindication to killed vaccines : Severe local or general reaction to a previous dose</li><li>\u2022 absolute contraindication</li><li>\u2022 killed vaccines</li><li>\u2022 local or general reaction</li><li>\u2022 previous dose</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Measles vaccine is definitively contraindicated in pregnancy.</li><li>\u27a4 Measles vaccine</li><li>\u27a4 definitively</li><li>\u27a4 contraindicated</li><li>\u27a4 pregnancy.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 729)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 729)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "054cedea",
      "audio": ""
    },
    {
      "text": "During a clinical discussion on the management of measles, particularly in high-risk patients or those with contraindications to the measles vaccine, the topic of passive immunization arises. A medical resident is asked about the appropriate dosing of human immunoglobulin for providing passive immunity against measles. Understanding the correct dosage is crucial for effective post-exposure prophylaxis in susceptible individuals. What is the recommended dose of human immunoglobulin for passive immunization against measles?",
      "options": [
        {
          "label": "A",
          "text": "0.15 ml per kg body weight",
          "correct": false
        },
        {
          "label": "B",
          "text": "0.25 ml per kg body weight",
          "correct": true
        },
        {
          "label": "C",
          "text": "0.35 ml per kg body weight",
          "correct": false
        },
        {
          "label": "D",
          "text": "0.45 ml per kg body weight",
          "correct": false
        }
      ],
      "correct_answer": "B. 0.25 ml per kg body weight",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 0.25 ml per kg body weight</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Measles may be prevented by administration of immunoglobulin (human) early in the incubation period . The dose recommended by WHO is 0.25 ml per kg of body weight should be given within 4 days of exposure.</li><li>\u2022 Measles</li><li>\u2022 prevented</li><li>\u2022 immunoglobulin (human)</li><li>\u2022 incubation period</li><li>\u2022 dose</li><li>\u2022 WHO</li><li>\u2022 0.25 ml</li><li>\u2022 body weight</li><li>\u2022 within 4 days</li><li>\u2022 exposure.</li><li>\u2022 The person passively immunized should be given live vaccine, 8-12 weeks later.</li><li>\u2022 passively immunized</li><li>\u2022 live vaccine, 8-12 weeks</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dose of human immunoglobulin for providing passive immunity against measles - 0.25 ml per kg of body weight.</li><li>\u27a4 Dose</li><li>\u27a4 human immunoglobulin</li><li>\u27a4 passive immunity</li><li>\u27a4 against</li><li>\u27a4 measles</li><li>\u27a4 0.25 ml</li><li>\u27a4 kg of body weight.</li><li>\u27a4 Ref : Park 26 th edition (page 165)</li><li>\u27a4 Ref : Park 26 th edition (page 165)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2979ca5d",
      "audio": ""
    },
    {
      "text": "During a pediatric infectious disease rotation, a medical student learns about the natural immunity conferred by viral infections. One topic of interest is the immunity that follows an infection with the measles virus. Understanding the duration of immunity after natural infection is important for patient counseling and future vaccination planning. After a patient recovers from an attack of measles, how long does the immunity typically last?",
      "options": [
        {
          "label": "A",
          "text": "5 years",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lifelong",
          "correct": true
        },
        {
          "label": "C",
          "text": "10 years",
          "correct": false
        },
        {
          "label": "D",
          "text": "No immunity",
          "correct": false
        }
      ],
      "correct_answer": "B. Lifelong",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. lifelong</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 No age is immune if there was no previous immunity . One attack of measles generally confers life-long immunity. Second attacks are rare .</li><li>\u2022 No age</li><li>\u2022 immune</li><li>\u2022 no previous immunity</li><li>\u2022 One</li><li>\u2022 measles</li><li>\u2022 life-long immunity.</li><li>\u2022 Second attacks</li><li>\u2022 rare</li><li>\u2022 Other diseases provide lifelong immunity with a single attack - Mumps, Rubella, Yellow fever.</li><li>\u2022 Other diseases</li><li>\u2022 lifelong immunity</li><li>\u2022 single attack</li><li>\u2022 Mumps, Rubella, Yellow fever.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In measles disease , both natural infection and vaccination confer lifelong immunity/protection from infection of measles.</li><li>\u27a4 measles disease</li><li>\u27a4 both</li><li>\u27a4 natural infection and vaccination</li><li>\u27a4 lifelong immunity/protection</li><li>\u27a4 measles.</li><li>\u27a4 Ref : Park 26 th edition (page 162)</li><li>\u27a4 Ref : Park 26 th edition (page 162)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b0ecca69",
      "audio": ""
    },
    {
      "text": "A medical resident is preparing for a public health campaign focused on maternal and child health, which includes educating about vaccine-preventable diseases such as rubella. During a team meeting, the topic of rubella's clinical course and its implications for public health is discussed. The resident is asked to explain the incubation period of rubella, also known as German measles, to help the team develop appropriate educational materials and strategies. What is the average incubation period of rubella?",
      "options": [
        {
          "label": "A",
          "text": "10 days",
          "correct": false
        },
        {
          "label": "B",
          "text": "5 days",
          "correct": false
        },
        {
          "label": "C",
          "text": "18 days",
          "correct": true
        },
        {
          "label": "D",
          "text": "28 days",
          "correct": false
        }
      ],
      "correct_answer": "C. 18 days",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture12.jpg"
      ],
      "explanation": "<p><strong>Ans. C. 18 days</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Rubella has got an average incubation period of 18 days (14-21 days).</li><li>\u2022 Rubella</li><li>\u2022 got</li><li>\u2022 average incubation period</li><li>\u2022 18 days (14-21 days).</li><li>\u2022 Rubella (German Measles) - Some Important Pointers -</li><li>\u2022 Rubella (German Measles)</li><li>\u2022 Causative agent: RNA virus of Togavirus family Source of infection: Cases or subclinical cases \u2013 \u2018 No known carrier state\u2019 for postnatally acquired rubella Mode of transmission: Air droplets (respiratory) Period of communicability: One week prior to onset of symptoms to one week after rash appears. Immunity for Rubella: \u2013 Single attack confers life long immunity (Second attacks rare) 40% of reproductive age group females are susceptible in India Infants protected till 4-6 months of age Most widely used test for diagnosis: Heme-agglutination Inhibition test (HAI) Rubella Vaccine - Type of vaccine : Live attenuated, \u2018strain RA 27/3\u2019 [Vaccine virus non-communicable] Dose and route: 0.5 ml, subcutaneous Rubella vaccine is contraindicated in pregnancy and not given to infants \u2013 If female vaccinated for rubella : Advice against pregnancy for next 3 months Priority groups for rubella vaccination in India: 1st PRIORITY: 15\u201349 years reproductive age group females 2nd priority : All children 1\u201314 years age 3rd priority : Routine universal immunization of all children aged 1</li><li>\u2022 Causative agent: RNA virus of Togavirus family</li><li>\u2022 RNA virus</li><li>\u2022 Togavirus family</li><li>\u2022 Source of infection: Cases or subclinical cases \u2013 \u2018 No known carrier state\u2019 for postnatally acquired rubella</li><li>\u2022 Cases or subclinical cases</li><li>\u2022 No known carrier state\u2019</li><li>\u2022 postnatally</li><li>\u2022 acquired rubella</li><li>\u2022 Mode of transmission: Air droplets (respiratory)</li><li>\u2022 Air droplets</li><li>\u2022 Period of communicability: One week prior to onset of symptoms to one week after rash appears.</li><li>\u2022 One week prior to onset of symptoms</li><li>\u2022 one</li><li>\u2022 week after rash appears.</li><li>\u2022 Immunity for Rubella: \u2013 Single attack confers life long immunity (Second attacks rare) 40% of reproductive age group females are susceptible in India Infants protected till 4-6 months of age</li><li>\u2022 Single attack confers life long immunity</li><li>\u2022 40% of reproductive age group females are susceptible in India Infants protected till 4-6 months of age</li><li>\u2022 40% of reproductive age group females are susceptible in India</li><li>\u2022 40%</li><li>\u2022 females are susceptible</li><li>\u2022 Infants protected till 4-6 months of age</li><li>\u2022 Infants</li><li>\u2022 protected</li><li>\u2022 4-6 months of age</li><li>\u2022 Most widely used test for diagnosis: Heme-agglutination Inhibition test (HAI)</li><li>\u2022 widely used test</li><li>\u2022 Heme-agglutination Inhibition test</li><li>\u2022 Rubella Vaccine -</li><li>\u2022 Type of vaccine : Live attenuated, \u2018strain RA 27/3\u2019 [Vaccine virus non-communicable]</li><li>\u2022 Type of vaccine</li><li>\u2022 Live attenuated, \u2018strain RA 27/3\u2019</li><li>\u2022 Dose and route: 0.5 ml, subcutaneous</li><li>\u2022 0.5 ml, subcutaneous</li><li>\u2022 Rubella vaccine is contraindicated in pregnancy and not given to infants \u2013 If female vaccinated for rubella : Advice against pregnancy for next 3 months</li><li>\u2022 Rubella vaccine</li><li>\u2022 contraindicated</li><li>\u2022 pregnancy</li><li>\u2022 not</li><li>\u2022 female vaccinated</li><li>\u2022 rubella</li><li>\u2022 against pregnancy</li><li>\u2022 next 3 months</li><li>\u2022 Priority groups for rubella vaccination in India:</li><li>\u2022 1st PRIORITY: 15\u201349 years reproductive age group females</li><li>\u2022 1st PRIORITY: 15\u201349 years reproductive age</li><li>\u2022 females</li><li>\u2022 2nd priority : All children 1\u201314 years age</li><li>\u2022 2nd priority</li><li>\u2022 1\u201314 years age</li><li>\u2022 3rd priority : Routine universal immunization of all children aged 1</li><li>\u2022 3rd priority</li><li>\u2022 Routine universal immunization</li><li>\u2022 all children aged 1</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Average incubation period for German measles (Rubella) - 18 days (14-21 days)</li><li>\u27a4 incubation period</li><li>\u27a4 German measles (Rubella)</li><li>\u27a4 18 days (14-21</li><li>\u27a4 days)</li><li>\u27a4 Incubation period of some important diseases -</li><li>\u27a4 Ref : Park 26 th edition (page 166)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 166)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6eed2316",
      "audio": ""
    },
    {
      "text": "During a public health campaign aimed at increasing vaccination rates, a 30-year-old pediatrician is discussing the rubella vaccine with his interns. He emphasizes the importance of understanding the components of vaccines, including the specific viral strains used, to effectively communicate with the community and address any concerns. He poses a question to his interns about the strain of the virus used in the current rubella vaccines. Which strain of the virus is used in the current rubella vaccines?",
      "options": [
        {
          "label": "A",
          "text": "RA 27/3 strain",
          "correct": true
        },
        {
          "label": "B",
          "text": "Jeryll lynn strain",
          "correct": false
        },
        {
          "label": "C",
          "text": "Edmonston Zagreb strain",
          "correct": false
        },
        {
          "label": "D",
          "text": "17 D strain",
          "correct": false
        }
      ],
      "correct_answer": "A. RA 27/3 strain",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture13.jpg"
      ],
      "explanation": "<p><strong>Ans. A. RA 27/3 strain</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Jeryll lynn strain - Mumps vaccine</li><li>\u2022 Option B. Jeryll lynn strain</li><li>\u2022 Option C. Edmonston Zagreb strain - Measles vaccine</li><li>\u2022 Option C. Edmonston Zagreb strain</li><li>\u2022 Option D. 17 D strain - Yellow Fever Vaccine</li><li>\u2022 Option D. 17 D strain</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rubella vaccine strain - RA 27/3</li><li>\u27a4 Rubella</li><li>\u27a4 strain -</li><li>\u27a4 RA 27/3</li><li>\u27a4 Vaccines and different strains :</li><li>\u27a4 Ref: Park 26 th edition (page 167)</li><li>\u27a4 Ref: Park 26 th edition (page 167)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3ab76612",
      "audio": ""
    },
    {
      "text": "A 5-year-old child presents to the outpatient department (OPD) with a 2-day history of bilateral tender neck swelling, accompanied by low-grade fever, myalgia, and headache. Based on the presentation, a likely diagnosis is a viral infection typically causing parotitis. The medical resident is considering potential complications of the disease and discusses this with a colleague. Which of the following is NOT a recognized complication of this disease, the condition likely affecting this child?",
      "options": [
        {
          "label": "A",
          "text": "Pancreatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Orchitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sensorineural deafness",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cholecystitis",
          "correct": true
        }
      ],
      "correct_answer": "D. Cholecystitis",
      "question_images": [
        "https://www.cdc.gov/mumps/images/people_mumps.jpg?_=95438"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Cholecystitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The complications for mumps include orchitis, ovaritis, pancreatitis, meningoencephalitis, thyroiditis, neuritis, hepatitis and myocarditis . Rarer complications include nerve deafness, polyarthritis, hydrocephalus, encephalitis, cerebellar ataxia, facial palsy and transverse myelitis .</li><li>\u2022 complications</li><li>\u2022 mumps</li><li>\u2022 orchitis, ovaritis, pancreatitis, meningoencephalitis, thyroiditis, neuritis, hepatitis</li><li>\u2022 myocarditis</li><li>\u2022 Rarer</li><li>\u2022 nerve deafness, polyarthritis, hydrocephalus, encephalitis, cerebellar ataxia, facial palsy</li><li>\u2022 transverse myelitis</li><li>\u2022 Mumps is one of the main infectious causes of sensorineural deafness , which affects approximately 5 per 100,000 mumps cases .</li><li>\u2022 Mumps</li><li>\u2022 infectious causes of sensorineural deafness</li><li>\u2022 5 per 100,000 mumps cases</li><li>\u2022 Some Important Pointers related to MUMPS</li><li>\u2022 Some Important Pointers related to MUMPS</li><li>\u2022 Causative agent: Myxovirus parotiditis ( RNA paramyxovirus) Incubation Period: 14-21 days Source of Infection: Clinical & subclinical cases Mode of transmission : Air droplets (respiratory) Period of Communicability: 4-6 days before to 7 days after onset of symptoms Mumps show lifelong immunity Secondary attack rate of Mumps: 86% Clinical features: Salivary (esp. Parotid) glands involvement MC complication: Aseptic meningitis MC complication in adolescents: Orchitis, Oophoritis Mumps is prevented by: Active immunization by Mumps vaccine \u2013 Type: Live attenuated vaccine (Strain: Jeryll Lynn strain )</li><li>\u2022 Causative agent: Myxovirus parotiditis ( RNA paramyxovirus)</li><li>\u2022 Myxovirus parotiditis</li><li>\u2022 RNA paramyxovirus)</li><li>\u2022 Incubation Period: 14-21 days</li><li>\u2022 14-21</li><li>\u2022 Source of Infection: Clinical & subclinical cases</li><li>\u2022 Mode of transmission : Air droplets (respiratory)</li><li>\u2022 Mode of transmission</li><li>\u2022 Air droplets (respiratory)</li><li>\u2022 Period of Communicability: 4-6 days before to 7 days after onset of symptoms</li><li>\u2022 Period of Communicability:</li><li>\u2022 4-6 days</li><li>\u2022 before</li><li>\u2022 7 days after</li><li>\u2022 onset</li><li>\u2022 symptoms</li><li>\u2022 Mumps show lifelong immunity</li><li>\u2022 Mumps</li><li>\u2022 lifelong immunity</li><li>\u2022 Secondary attack rate of Mumps: 86%</li><li>\u2022 Secondary attack</li><li>\u2022 86%</li><li>\u2022 Clinical features: Salivary (esp. Parotid) glands involvement MC complication: Aseptic meningitis MC complication in adolescents: Orchitis, Oophoritis</li><li>\u2022 Salivary (esp. Parotid) glands involvement MC complication: Aseptic meningitis MC complication in adolescents: Orchitis, Oophoritis</li><li>\u2022 Salivary (esp. Parotid) glands involvement</li><li>\u2022 Salivary (esp. Parotid) glands</li><li>\u2022 MC complication: Aseptic meningitis</li><li>\u2022 MC complication: Aseptic meningitis</li><li>\u2022 MC complication in adolescents: Orchitis, Oophoritis</li><li>\u2022 MC</li><li>\u2022 adolescents: Orchitis, Oophoritis</li><li>\u2022 Mumps is prevented by: Active immunization by Mumps vaccine \u2013 Type: Live attenuated vaccine (Strain: Jeryll Lynn strain )</li><li>\u2022 prevented</li><li>\u2022 Active</li><li>\u2022 Mumps vaccine</li><li>\u2022 Live attenuated vaccine</li><li>\u2022 Jeryll Lynn strain</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The complications of Mumps include Orchitis, Pancreatitis, Sensorineural deafness but not Cholecystitis.</li><li>\u27a4 complications of Mumps</li><li>\u27a4 Orchitis, Pancreatitis, Sensorineural deafness</li><li>\u27a4 not</li><li>\u27a4 Cholecystitis.</li><li>\u27a4 Ref : Park 26 th edition (page 168)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 168)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1e421e15",
      "audio": ""
    },
    {
      "text": "During an epidemiology lecture at a medical school, the professor discusses the transmission dynamics of various viral infections. Mumps, a contagious viral infection, is highlighted for its notable secondary attack rate, particularly in settings where close contact occurs, such as schools and family households. A medical student is asked about the secondary attack rate of mumps to understand its transmissibility. What is the secondary attack rate of mumps?",
      "options": [
        {
          "label": "A",
          "text": "26%",
          "correct": false
        },
        {
          "label": "B",
          "text": "66%",
          "correct": false
        },
        {
          "label": "C",
          "text": "86%",
          "correct": true
        },
        {
          "label": "D",
          "text": "100%",
          "correct": false
        }
      ],
      "correct_answer": "C. 86%",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture14.jpg"
      ],
      "explanation": "<p><strong>Ans. C. 86%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Secondary attack rate for mumps is estimated to be about 86 percent.</li><li>\u2022 Secondary Attack Rate (SAR)</li><li>\u2022 Is no. of exposed persons developing the disease within the range of incubation period (IP), following exposure to the primary case Denominator includes only those susceptible in close contact Primary case is always excluded both from numerator and denominator for SAR calculation</li><li>\u2022 Is no. of exposed persons developing the disease within the range of incubation period (IP), following exposure to the primary case</li><li>\u2022 Denominator includes only those susceptible in close contact</li><li>\u2022 Primary case is always excluded both from numerator and denominator for SAR calculation</li><li>\u2022 Secondary Attack Rate of some diseases</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Secondary attack rate of Mumps - 86% (>85%)</li><li>\u27a4 Infectivity is also termed as Secondary attack rate</li><li>\u27a4 Ref : Park 26 th edition (page 168)</li><li>\u27a4 Ref : Park 26 th edition (page 168)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "214c8e41",
      "audio": ""
    },
    {
      "text": "During an infectious disease rotation, a medical resident is tasked with developing a protocol for managing potential outbreaks of Influenza H1N1 in a hospital setting. As part of the protocol, the resident must consider options for chemoprophylaxis, especially for high-risk patients and healthcare workers who may be exposed to the virus. The resident discusses with the supervising physician about the appropriate medication for chemoprophylaxis against Influenza H1N1. Which medication is recommended for chemoprophylaxis against Influenza H1N1?",
      "options": [
        {
          "label": "A",
          "text": "45 mg OD of Oseltamivir",
          "correct": false
        },
        {
          "label": "B",
          "text": "75 mg OD of Oseltamivir",
          "correct": true
        },
        {
          "label": "C",
          "text": "45 mg OD of Zanamivir",
          "correct": false
        },
        {
          "label": "D",
          "text": "70 mg OD of Zanamivir",
          "correct": false
        }
      ],
      "correct_answer": "B. 75 mg OD of Oseltamivir",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 75 mg of Oseltamivir</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Oseltamivir (Tamiflu) is the drug of choice for chemoprophylaxis to health care personnel and close contacts of suspected, probable or confirmed case of pandemic influenza A (H1N1) 2009. It should be given till 10 days after last exposure .</li><li>\u2022 Oseltamivir (Tamiflu)</li><li>\u2022 chemoprophylaxis to health care personnel and close contacts</li><li>\u2022 probable or confirmed</li><li>\u2022 pandemic influenza A (H1N1)</li><li>\u2022 10 days after last exposure</li><li>\u2022 For adults above 40 kg the dose is 75 mg OD.</li><li>\u2022 For adults</li><li>\u2022 40 kg</li><li>\u2022 75 mg OD.</li><li>\u2022 H1N1 (Type A) \u2013 Cause of Swine flu</li><li>\u2022 H1N1 (Type A)</li><li>\u2022 Swine flu</li><li>\u2022 Antiviral therapy for H1N1 :</li><li>\u2022 Antiviral</li><li>\u2022 H1N1</li><li>\u2022 Severe/progressive clinical illness: Oseltamivir (if not available or resistant , use Zanamivir ) High risk of severe/complicated illness : Oseltamivir OR Zanamivir Not high risk OR Uncomplicated confirmed/suspected illness: No need of treatment Dosage: Oseltamivir - 75 mg BD \u00d7 5 days (DOC) Zanamivir - 2 inhalations ( 2 \u00d7 5 mg) BD \u00d7 5 days</li><li>\u2022 Severe/progressive clinical illness: Oseltamivir (if not available or resistant , use Zanamivir )</li><li>\u2022 Severe/progressive</li><li>\u2022 Oseltamivir</li><li>\u2022 not available</li><li>\u2022 resistant</li><li>\u2022 Zanamivir</li><li>\u2022 High risk of severe/complicated illness : Oseltamivir OR Zanamivir</li><li>\u2022 High risk</li><li>\u2022 severe/complicated</li><li>\u2022 : Oseltamivir OR Zanamivir</li><li>\u2022 Not high risk OR Uncomplicated confirmed/suspected illness: No need of treatment</li><li>\u2022 Not</li><li>\u2022 Uncomplicated</li><li>\u2022 No</li><li>\u2022 treatment</li><li>\u2022 Dosage: Oseltamivir - 75 mg BD \u00d7 5 days (DOC) Zanamivir - 2 inhalations ( 2 \u00d7 5 mg) BD \u00d7 5 days</li><li>\u2022 Oseltamivir - 75 mg BD \u00d7 5 days (DOC) Zanamivir - 2 inhalations ( 2 \u00d7 5 mg) BD \u00d7 5 days</li><li>\u2022 Oseltamivir - 75 mg BD \u00d7 5 days (DOC)</li><li>\u2022 Oseltamivir</li><li>\u2022 75 mg BD</li><li>\u2022 5 days</li><li>\u2022 Zanamivir - 2 inhalations ( 2 \u00d7 5 mg) BD \u00d7 5 days</li><li>\u2022 Zanamivir</li><li>\u2022 2 inhalations</li><li>\u2022 2 \u00d7 5</li><li>\u2022 BD</li><li>\u2022 5 days</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chemoprophylaxis against H1N1 - Oseltamivir 75 mg OD till 10 days after last exposure.</li><li>\u27a4 Chemoprophylaxis</li><li>\u27a4 H1N1 - Oseltamivir 75 mg OD</li><li>\u27a4 10 days</li><li>\u27a4 last exposure.</li></ul>\n<p><strong>References:</strong></p><ul><li>\u21b3 Reference: Park 26 th edition (page 175)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "43caa11d",
      "audio": ""
    },
    {
      "text": "A medical resident in an internal medicine ward is managing a patient suspected of having Influenza H1N1. As part of the management plan, the resident needs to advise the patient and their family about isolation practices to prevent the spread of the virus. Understanding the communicability period of Influenza H1N1 is crucial for implementing effective infection control measures. When does a case of Influenza H1N1 typically become communicable with others?",
      "options": [
        {
          "label": "A",
          "text": "5 days before onset of symptoms",
          "correct": false
        },
        {
          "label": "B",
          "text": "3 days before onset of symptoms",
          "correct": false
        },
        {
          "label": "C",
          "text": "1 day before onset of symptoms",
          "correct": true
        },
        {
          "label": "D",
          "text": "From the day of onset of symptoms",
          "correct": false
        }
      ],
      "correct_answer": "C. 1 day before onset of symptoms",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 1 day before onset of symptoms</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Virus is present in the nasopharynx from 1 to 2 days before and 1 to 2 days after onset of symptoms.</li><li>\u2022 Virus</li><li>\u2022 nasopharynx</li><li>\u2022 1 to 2 days before</li><li>\u2022 1 to 2 days after onset of symptoms.</li><li>\u2022 Period of Communicability : Is the time during which an infectious agent may be transferred directly/indirectly from an infected</li><li>\u2022 Period of Communicability</li><li>\u2022 time during</li><li>\u2022 infectious agent</li><li>\u2022 transferred</li><li>\u2022 infected</li><li>\u2022 person to another person , from infected animal to man or from an infected person to animal , including arthropods .</li><li>\u2022 person to another person</li><li>\u2022 infected animal to man</li><li>\u2022 infected person to animal</li><li>\u2022 arthropods</li><li>\u2022 An important measure of communicability is secondary attack rate.</li><li>\u2022 measure of communicability</li><li>\u2022 secondary attack rate.</li><li>\u2022 Period of Communicability/ Infectivity of some important diseases -</li><li>\u2022 Communicability/ Infectivity</li><li>\u2022 important diseases</li><li>\u2022 Chickenpox : 1\u20132 days before to 4\u20135 days after appearance of rash Measles : 4 days before to 5 days after appearance of rash Rubella: 7 days before symptoms to 7 days after appearance of rash Mumps: 4\u20136 days before symptoms to 7 days thereafter Influenza : 1\u20132 days before to 1\u20132 days after onset of symptoms Diphtheria : 14\u201328 days from disease onset Pertussis: 7 days after exposure to 3 weeks after paroxysmal stage Meningococccus: Until absent from nasal and throat discharges Tuberculosis: As long as not treated Poliomyelitis: 7\u201310 days before and after onset of symptoms Hepatitis A: 2 weeks before to 1 week after onset of jaundice Hepatitis B: Till disappearance of HBsAg & appearance of anti-HBs Tetanus: None</li><li>\u2022 Chickenpox : 1\u20132 days before to 4\u20135 days after appearance of rash</li><li>\u2022 Chickenpox</li><li>\u2022 1\u20132 days before</li><li>\u2022 4\u20135 days after</li><li>\u2022 rash</li><li>\u2022 Measles : 4 days before to 5 days after appearance of rash</li><li>\u2022 Measles</li><li>\u2022 4 days before</li><li>\u2022 5 days after</li><li>\u2022 rash</li><li>\u2022 Rubella: 7 days before symptoms to 7 days after appearance of rash</li><li>\u2022 Mumps: 4\u20136 days before symptoms to 7 days thereafter</li><li>\u2022 Influenza : 1\u20132 days before to 1\u20132 days after onset of symptoms</li><li>\u2022 Influenza</li><li>\u2022 1\u20132 days before</li><li>\u2022 1\u20132 days</li><li>\u2022 onset of symptoms</li><li>\u2022 Diphtheria : 14\u201328 days from disease onset</li><li>\u2022 Diphtheria</li><li>\u2022 14\u201328 days</li><li>\u2022 disease onset</li><li>\u2022 Pertussis: 7 days after exposure to 3 weeks after paroxysmal stage</li><li>\u2022 Meningococccus: Until absent from nasal and throat discharges</li><li>\u2022 Tuberculosis: As long as not treated</li><li>\u2022 Poliomyelitis: 7\u201310 days before and after onset of symptoms</li><li>\u2022 Hepatitis A: 2 weeks before to 1 week after onset of jaundice</li><li>\u2022 Hepatitis B: Till disappearance of HBsAg & appearance of anti-HBs</li><li>\u2022 Tetanus: None</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Influenza Period of Communicability/ Infectivity - 1\u20132 days before to 1\u20132 days after onset of symptoms.</li><li>\u27a4 Influenza</li><li>\u27a4 Communicability/ Infectivity</li><li>\u27a4 1\u20132 days before</li><li>\u27a4 1\u20132 days after</li><li>\u27a4 Ref : Park 26 th edition (page 170)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 170)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aa0398bb",
      "audio": ""
    },
    {
      "text": "In an infectious disease lecture, a medical resident is learning about Corynebacterium diphtheriae, the bacterium responsible for diphtheria. The discussion focuses on the factors that contribute to the virulence of this pathogen. Understanding the virulence factors of Corynebacterium diphtheriae is crucial for comprehending the pathogenesis of diphtheria and for developing effective treatment and prevention strategies. Which is the most important factor for determining the virulence of Corynebacterium diphtheriae?",
      "options": [
        {
          "label": "A",
          "text": "Endotoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "O antigens",
          "correct": false
        },
        {
          "label": "C",
          "text": "Exotoxin",
          "correct": true
        },
        {
          "label": "D",
          "text": "K antigen",
          "correct": false
        }
      ],
      "correct_answer": "C. Exotoxin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Exotoxin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Endotoxin: Endotoxins are associated with the outer membrane of Gram-negative bacteria . Corynebacterium diphtheriae is a Gram-positive bacterium and does not produce endotoxin.</li><li>\u2022 Option A. Endotoxin:</li><li>\u2022 outer membrane</li><li>\u2022 Gram-negative bacteria</li><li>\u2022 Corynebacterium diphtheriae</li><li>\u2022 Gram-positive</li><li>\u2022 bacterium</li><li>\u2022 not</li><li>\u2022 endotoxin.</li><li>\u2022 Option B. O Antigen: It is a cell-wall component and important in the pathogenesis of the disease but not responsible for the major disease signs and symptoms.</li><li>\u2022 Option B. O Antigen:</li><li>\u2022 cell-wall component</li><li>\u2022 pathogenesis</li><li>\u2022 disease</li><li>\u2022 not</li><li>\u2022 major disease signs</li><li>\u2022 symptoms.</li><li>\u2022 Option D. K Antigen: It is a cell-wall component (capsular polysaccharides) and important in the pathogenesis of the disease but not responsible for the major disease signs and symptoms.</li><li>\u2022 Option D. K Antigen:</li><li>\u2022 cell-wall component</li><li>\u2022 pathogenesis</li><li>\u2022 disease</li><li>\u2022 not</li><li>\u2022 major disease signs</li><li>\u2022 symptoms.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Most important factor for determining virulence of Corynebacterium diphtheria \u2013 Exotoxin.</li><li>\u27a4 important factor</li><li>\u27a4 determining virulence</li><li>\u27a4 Corynebacterium diphtheria \u2013 Exotoxin.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 749) and WHO Health topics - Diphtheria</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 749) and WHO Health topics - Diphtheria</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e1a16ea8",
      "audio": ""
    },
    {
      "text": "A medical resident working in a community health center is reviewing the epidemiology and clinical aspects of diphtheria as part of a public health initiative. The resident is presented with a series of statements about diphtheria and is asked to identify which one is NOT true. This exercise is important for ensuring accurate understanding and effective communication about the disease to the public. Which of the following statements about diphtheria is NOT true?",
      "options": [
        {
          "label": "A",
          "text": "Carriers are more common sources of infection than cases",
          "correct": false
        },
        {
          "label": "B",
          "text": "Incubation period is 2-6 days",
          "correct": false
        },
        {
          "label": "C",
          "text": "25 Lf of diphtheria toxoid are present per ml in DPT vaccine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diphtheria is an endemic disease in India",
          "correct": false
        }
      ],
      "correct_answer": "C. 25 Lf of diphtheria toxoid are present per ml in DPT vaccine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-093455.png"
      ],
      "explanation": "<p><strong>Ans. C. 25 Lf of diphtheria toxoid are present per ml in DPT vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Carriers are more common sources of infection than cases : TRUE . 95% of total disease transmission is due to carriers</li><li>\u2022 Option A</li><li>\u2022 Carriers are more common sources of infection than cases</li><li>\u2022 TRUE</li><li>\u2022 95%</li><li>\u2022 transmission</li><li>\u2022 carriers</li><li>\u2022 Nasal carriers are more dangerous than throat carriers Incidence of carriers in a community: 0.5-1% Immunization does not prevent carrier state</li><li>\u2022 Nasal carriers are more dangerous than throat carriers</li><li>\u2022 Nasal carriers</li><li>\u2022 more dangerous</li><li>\u2022 throat carriers</li><li>\u2022 Incidence of carriers in a community: 0.5-1%</li><li>\u2022 Incidence of carriers</li><li>\u2022 0.5-1%</li><li>\u2022 Immunization does not prevent carrier state</li><li>\u2022 does not</li><li>\u2022 carrier state</li><li>\u2022 Note - Source of infection : Case or carrier</li><li>\u2022 Source of infection</li><li>\u2022 Case or carrier</li><li>\u2022 Option B. Incubation period is 2-6 days : TRUE</li><li>\u2022 Option B. Incubation period is 2-6 days</li><li>\u2022 TRUE</li><li>\u2022 Mode of transmission : droplet infection (main mode), directly from cutaneous lesions and fomites Period of Infectivity : 14-28 days from onset of disease ; longer for carriers. A case/carrier may be considered non-communicable when at least 2 cultures from nose and throat , 24 hrs apart , are negative. MC Subtype: Faucial ( Tonsillar + Pharyngeal )</li><li>\u2022 Mode of transmission : droplet infection (main mode), directly from cutaneous lesions and fomites</li><li>\u2022 Mode</li><li>\u2022 transmission</li><li>\u2022 droplet infection</li><li>\u2022 cutaneous lesions and fomites</li><li>\u2022 Period of Infectivity : 14-28 days from onset of disease ; longer for carriers. A case/carrier may be considered non-communicable when at least 2 cultures from nose and throat , 24 hrs apart , are negative.</li><li>\u2022 Period of Infectivity</li><li>\u2022 14-28 days</li><li>\u2022 onset of disease</li><li>\u2022 A case/carrier may be considered non-communicable when at least 2 cultures from nose and throat , 24 hrs apart , are negative.</li><li>\u2022 A case/carrier may be considered non-communicable when at least 2 cultures from nose and throat , 24 hrs apart , are negative.</li><li>\u2022 case/carrier</li><li>\u2022 non-communicable</li><li>\u2022 2 cultures</li><li>\u2022 nose and throat</li><li>\u2022 24 hrs apart</li><li>\u2022 negative.</li><li>\u2022 MC Subtype: Faucial ( Tonsillar + Pharyngeal )</li><li>\u2022 MC</li><li>\u2022 Faucial</li><li>\u2022 Tonsillar + Pharyngeal</li><li>\u2022 Option D. Diphtheria is an endemic disease in India : TRUE</li><li>\u2022 Option D. Diphtheria is an endemic disease in India</li><li>\u2022 TRUE</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 DPT vaccine - 25 Lf of diphtheria toxoid are present per 0.5 ml i.e. per dose.</li><li>\u27a4 DPT</li><li>\u27a4 25 Lf</li><li>\u27a4 diphtheria toxoid</li><li>\u27a4 0.5 ml</li><li>\u27a4 per dose.</li><li>\u27a4 DT Vaccine - Contains up to 2 Lf of diphtheria toxoid per dose.</li><li>\u27a4 DT</li><li>\u27a4 2 Lf</li><li>\u27a4 diphtheria toxoid</li><li>\u27a4 dose.</li><li>\u27a4 Ref : Park 27 th edition (page 180)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 27 th edition (page 180)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dcb37f9f",
      "audio": ""
    },
    {
      "text": "A medical resident working in a pediatric clinic is reviewing the National Immunization Schedule as part of a public health initiative to improve vaccination rates in the community. Recently, there have been updates to the schedule, particularly regarding the measles vaccine. The resident is discussing these changes with a senior pediatrician to ensure accurate information is provided to patients and their families. In the National Immunization Schedule, the measles vaccine has been replaced by which of the following vaccines?",
      "options": [
        {
          "label": "A",
          "text": "MR vaccine",
          "correct": true
        },
        {
          "label": "B",
          "text": "MMR vaccine",
          "correct": false
        },
        {
          "label": "C",
          "text": "MMRV vaccine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hexavalent vaccine",
          "correct": false
        }
      ],
      "correct_answer": "A. MR vaccine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017_KHN9A8u.png"
      ],
      "explanation": "<p><strong>Ans. A. MR vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B.  MMR :  Is a type of live attenuated vaccine , recommended at the age of 15\u201318 months.</li><li>\u2022 Option B.  MMR</li><li>\u2022 live attenuated vaccine</li><li>\u2022 15\u201318 months.</li><li>\u2022 NOTE - In Delhi\u2019s Immunization Schedule , there are 2 additional vaccines \u2013 MMR ( single dose at 15 months of age) and Typhoid ( single dose between 2-5 years of age)</li><li>\u2022 Delhi\u2019s Immunization Schedule</li><li>\u2022 2 additional vaccines</li><li>\u2022 MMR</li><li>\u2022 single</li><li>\u2022 15 months</li><li>\u2022 Typhoid</li><li>\u2022 single dose</li><li>\u2022 2-5</li><li>\u2022 years</li><li>\u2022 Option C.  MMRV Combination Vaccine:</li><li>\u2022 Option C.  MMRV Combination Vaccine:</li><li>\u2022 Given at age group of 9 months\u201312 years Minimum interval between 2 doses : 4 weeks Preferable schedule: 2nd dose 6 weeks-3 months later or at 4-6 years age.</li><li>\u2022 Given at age group of 9 months\u201312 years</li><li>\u2022 Given</li><li>\u2022 9 months\u201312 years</li><li>\u2022 Minimum interval between 2 doses : 4 weeks</li><li>\u2022 Minimum</li><li>\u2022 2 doses</li><li>\u2022 4 weeks</li><li>\u2022 Preferable schedule: 2nd dose 6 weeks-3 months later or at 4-6 years age.</li><li>\u2022 2nd dose</li><li>\u2022 6 weeks-3 months later</li><li>\u2022 4-6 years age.</li><li>\u2022 The maximum age for administration of MMRV is 12 years . It should not be administered to anyone 13 years of age or older .</li><li>\u2022 The maximum</li><li>\u2022 MMRV</li><li>\u2022 12 years</li><li>\u2022 not</li><li>\u2022 anyone 13 years of age or older</li><li>\u2022 Option D.  Hexavalent Vaccine:</li><li>\u2022 Option D.  Hexavalent Vaccine:</li><li>\u2022 There is no hexavalent vaccine available in India that contains MMR in combination.</li><li>\u2022 no hexavalent vaccine</li><li>\u2022 India</li><li>\u2022 MMR</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In National Immunisation Schedule , Measles vaccine has been replaced by Measles Rubella (MR) vaccine .</li><li>\u27a4 National Immunisation Schedule</li><li>\u27a4 Measles vaccine</li><li>\u27a4 replaced by</li><li>\u27a4 Measles Rubella (MR) vaccine</li><li>\u27a4 NEW National Immunization Schedule (NIS) 2023-24</li><li>\u27a4 National Immunization Schedule</li><li>\u27a4 2023-24</li><li>\u27a4 NOTE -</li><li>\u27a4 JE vaccine only in Endemic districts HiB Vaccine introduced as Pentavalent vaccine \u2013 DPT + HepB + HiB vaccine in 16 states. fIPV is fractionated intradermal at 6 weeks & 14 weeks or IPV Intramuscular only at 14 weeks Rotaviral vaccine introduced in 9 States \u2013 Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura. Measles-Rubella/ MR vaccine started from 5 States/UTs - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry. Pneumococcal conjugate PCV vaccine introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar Adult JE Vaccine introduced in 31 high burden districts from Assam , Uttar Pradesh and West Bengal for adult . JE vaccination in the age-group of 15-65 years. MoHFW-GOI ( August 2018 ) - TT be replaced by Td ; Replacement for TT booster doses given at 10 years, 16 years age and Pregnant women (incl . booster dose ).</li><li>\u27a4 JE vaccine only in Endemic districts</li><li>\u27a4 JE vaccine</li><li>\u27a4 Endemic districts</li><li>\u27a4 HiB Vaccine introduced as Pentavalent vaccine \u2013 DPT + HepB + HiB vaccine in 16 states.</li><li>\u27a4 HiB Vaccine</li><li>\u27a4 Pentavalent vaccine</li><li>\u27a4 DPT + HepB + HiB</li><li>\u27a4 16 states.</li><li>\u27a4 fIPV is fractionated intradermal at 6 weeks & 14 weeks or IPV Intramuscular only at 14 weeks</li><li>\u27a4 fIPV</li><li>\u27a4 intradermal at 6 weeks</li><li>\u27a4 14 weeks</li><li>\u27a4 IPV Intramuscular</li><li>\u27a4 14 weeks</li><li>\u27a4 Rotaviral vaccine introduced in 9 States \u2013 Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura.</li><li>\u27a4 Rotaviral vaccine</li><li>\u27a4 9 States</li><li>\u27a4 Measles-Rubella/ MR vaccine started from 5 States/UTs - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry.</li><li>\u27a4 Measles-Rubella/ MR vaccine</li><li>\u27a4 5 States/UTs</li><li>\u27a4 Pneumococcal conjugate PCV vaccine introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar</li><li>\u27a4 Pneumococcal conjugate</li><li>\u27a4 Adult JE Vaccine introduced in 31 high burden districts from Assam , Uttar Pradesh and West Bengal for adult . JE vaccination in the age-group of 15-65 years.</li><li>\u27a4 Adult JE Vaccine</li><li>\u27a4 31 high burden districts</li><li>\u27a4 Assam</li><li>\u27a4 Uttar Pradesh and West Bengal</li><li>\u27a4 adult</li><li>\u27a4 JE vaccination</li><li>\u27a4 15-65 years.</li><li>\u27a4 MoHFW-GOI ( August 2018 ) - TT be replaced by Td ; Replacement for TT booster doses given at 10 years, 16 years age and Pregnant women (incl . booster dose ).</li><li>\u27a4 MoHFW-GOI</li><li>\u27a4 August 2018</li><li>\u27a4 TT</li><li>\u27a4 replaced</li><li>\u27a4 Td</li><li>\u27a4 TT booster</li><li>\u27a4 at 10 years, 16 years</li><li>\u27a4 Pregnant women</li><li>\u27a4 . booster dose</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 732)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 732)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e887aa14",
      "audio": ""
    },
    {
      "text": "A medical resident working in a community health center is involved in planning a measles immunization program. As part of the program, various strategies are being considered to effectively increase measles immunity in the community. The resident is tasked with identifying key components of the immunization strategy, particularly activities that are unique and not regularly repeated. In the context of a measles immunization program, which of the following activities is considered a \u2018one-time activity\u2019 aimed at rapidly increasing community immunity levels?",
      "options": [
        {
          "label": "A",
          "text": "Catch up",
          "correct": true
        },
        {
          "label": "B",
          "text": "Follow up",
          "correct": false
        },
        {
          "label": "C",
          "text": "Outreach vaccination",
          "correct": false
        },
        {
          "label": "D",
          "text": "High risk immunisation",
          "correct": false
        }
      ],
      "correct_answer": "A. Catch up",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Catch up</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Follow up: Subsequent nationwide vaccination campaigns conducted every 2\u20134 years (not one-time event) targeting usually all children born after the catch-up campaign . (Part of WHO Measles Elimination Strategy: \u2018Catch up, keep up, Follow up\u2019)</li><li>\u2022 Option B. Follow up:</li><li>\u2022 Subsequent nationwide vaccination campaigns</li><li>\u2022 2\u20134 years</li><li>\u2022 children born</li><li>\u2022 after</li><li>\u2022 catch-up campaign</li><li>\u2022 Option C. Outreach vaccination :  While outreach vaccination is important for reaching underserved or hard-to-reach populations , it is generally an ongoing activity rather than a one-time event.</li><li>\u2022 Option C. Outreach vaccination</li><li>\u2022 reaching underserved</li><li>\u2022 hard-to-reach populations</li><li>\u2022 ongoing activity</li><li>\u2022 Option D. High risk immunization: Immunization of high-risk groups is an important part of any immunization strategy but is typically an ongoing effort rather than a one-time activity.</li><li>\u2022 Option D. High risk immunization:</li><li>\u2022 part</li><li>\u2022 any immunization strategy</li><li>\u2022 ongoing effort</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Measles Catch-up campaigns - One time Nationwide , vaccination campaign targeting all children 9 months to 14 years of age , irrespective of history of Measles disease or vaccination status.</li><li>\u27a4 Measles Catch-up campaigns</li><li>\u27a4 One time Nationwide</li><li>\u27a4 vaccination campaign</li><li>\u27a4 9 months to 14 years of age</li><li>\u27a4 irrespective</li><li>\u27a4 Measles disease or vaccination status.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 730)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 730)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "345c1a47",
      "audio": ""
    },
    {
      "text": "A medical resident in a family practice clinic is discussing influenza vaccination with patients as part of an annual public health campaign. One of the patients, a 45-year-old woman, asks about the effectiveness of the inactivated influenza vaccine. The resident recalls recent studies and guidelines to provide an informed answer, emphasizing the importance of vaccination in preventing influenza and its complications, especially in adults younger than 65 years of age. What is the effectiveness of the inactivated influenza vaccine in adults younger than 65 years of age?",
      "options": [
        {
          "label": "A",
          "text": "60%",
          "correct": true
        },
        {
          "label": "B",
          "text": "70%",
          "correct": false
        },
        {
          "label": "C",
          "text": "80%",
          "correct": false
        },
        {
          "label": "D",
          "text": "90%",
          "correct": false
        }
      ],
      "correct_answer": "A. 60%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. 60%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Inactivated influenza vaccine : The vaccine is about 60 percent effective among healthy persons younger than 65 years of age. On vaccination, the vaccine becomes effective after 14 days . The immunity lasts from 6-12 months . The vaccine is 50-60 percent effective in preventing hospitalization and 80 percent effective in preventing death among elderly persons.</li><li>\u2022 Inactivated influenza vaccine</li><li>\u2022 60 percent effective</li><li>\u2022 healthy</li><li>\u2022 younger than 65 years</li><li>\u2022 vaccine</li><li>\u2022 effective</li><li>\u2022 14 days</li><li>\u2022 immunity lasts</li><li>\u2022 6-12 months</li><li>\u2022 50-60 percent effective</li><li>\u2022 preventing hospitalization</li><li>\u2022 80 percent</li><li>\u2022 effective</li><li>\u2022 preventing death</li><li>\u2022 Inactivated Influenza vaccine - Trivalent Flu Vaccine</li><li>\u2022 Inactivated Influenza vaccine</li><li>\u2022 Trivalent Flu Vaccine</li><li>\u2022 \u2022 Protection: \u2013 Two influenza A viruses (an H1N1 and an H3N2 ) \u2013 An influenza B virus</li><li>\u2022 Two</li><li>\u2022 influenza A viruses</li><li>\u2022 H1N1</li><li>\u2022 H3N2</li><li>\u2022 influenza B virus</li><li>\u2022 \u2022 Types of Trivalent vaccine : \u2013 Standard-dose trivalent shots: Approved for people of different ages. \u2013 High-dose trivalent shot : Approved for people 65 and older. \u2013 Trivalent shot : Approved for people 18 and older. \u2013 Recombinant trivalent shot : Approved for people 18 years and older.</li><li>\u2022 Trivalent vaccine</li><li>\u2022 Standard-dose</li><li>\u2022 different ages.</li><li>\u2022 High-dose trivalent shot</li><li>\u2022 65 and older.</li><li>\u2022 Trivalent shot</li><li>\u2022 18 and older.</li><li>\u2022 Recombinant trivalent shot</li><li>\u2022 18 years</li><li>\u2022 and older.</li><li>\u2022 Contraindications to Inactivated Influenza vaccines - Severe allergy to chicken eggs. History of hypersensitivity/anaphylactic reactions previously. Development of Guillain-Barr\u00e9 Syndrome (GBS) within 6 weeks of vaccine. Infants less than 6 month\u2019s age. Moderate-to-severe illness with fever .</li><li>\u2022 Contraindications to Inactivated Influenza vaccines - Severe allergy to chicken eggs. History of hypersensitivity/anaphylactic reactions previously. Development of Guillain-Barr\u00e9 Syndrome (GBS) within 6 weeks of vaccine. Infants less than 6 month\u2019s age. Moderate-to-severe illness with fever .</li><li>\u2022 Contraindications</li><li>\u2022 Inactivated Influenza vaccines -</li><li>\u2022 Severe allergy to chicken eggs. History of hypersensitivity/anaphylactic reactions previously. Development of Guillain-Barr\u00e9 Syndrome (GBS) within 6 weeks of vaccine. Infants less than 6 month\u2019s age. Moderate-to-severe illness with fever .</li><li>\u2022 Severe allergy to chicken eggs.</li><li>\u2022 allergy</li><li>\u2022 chicken eggs.</li><li>\u2022 History of hypersensitivity/anaphylactic reactions previously.</li><li>\u2022 hypersensitivity/anaphylactic reactions</li><li>\u2022 Development of Guillain-Barr\u00e9 Syndrome (GBS) within 6 weeks of vaccine.</li><li>\u2022 Guillain-Barr\u00e9 Syndrome</li><li>\u2022 6 weeks</li><li>\u2022 Infants less than 6 month\u2019s age.</li><li>\u2022 Infants less</li><li>\u2022 6 month\u2019s age.</li><li>\u2022 Moderate-to-severe illness with fever .</li><li>\u2022 Moderate-to-severe illness</li><li>\u2022 fever</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The effectiveness of the inactivated influenza vaccine in adults younger than 65 years of age is typically around - 50-60%.</li><li>\u27a4 effectiveness</li><li>\u27a4 inactivated influenza vaccine</li><li>\u27a4 adults younger</li><li>\u27a4 65 years of age</li><li>\u27a4 - 50-60%.</li><li>\u27a4 Ref : Park 26 th edition (page 173)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 173)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2117c233",
      "audio": ""
    },
    {
      "text": "During an infectious disease rotation, a medical resident is consulted about a patient who is identified as a carrier of Corynebacterium diphtheriae, the bacterium responsible for diphtheria. While the patient is asymptomatic, the resident understands the importance of treating carriers to prevent the spread of the infection. The resident discusses with the supervising physician about the appropriate pharmacological intervention for carriers of diphtheria. What is the recommended drug for treating carriers of diphtheria?",
      "options": [
        {
          "label": "A",
          "text": "Penicillin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Erythromycin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Doxycycline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rifampicin",
          "correct": false
        }
      ],
      "correct_answer": "B. Erythromycin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155339.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155111.png"
      ],
      "explanation": "<p><strong>Ans. B. Erythromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Penicillin: can be used as DOC for treating Diphtheria Cases not carriers.</li><li>\u2022 Option A. Penicillin:</li><li>\u2022 DOC</li><li>\u2022 Diphtheria</li><li>\u2022 Cases</li><li>\u2022 Option C. Doxycycline: Drug of choice for chemoprophylaxis for Malaria , if needed for <6 weeks (not for diphtheria)</li><li>\u2022 Option C. Doxycycline:</li><li>\u2022 Drug of choice</li><li>\u2022 chemoprophylaxis</li><li>\u2022 Malaria</li><li>\u2022 <6 weeks</li><li>\u2022 Option D. Rifampicin: Drug of choice for chemoprophylaxis for Meningococcal meningitis (not for diphtheria)</li><li>\u2022 Option D. Rifampicin:</li><li>\u2022 Drug of choice</li><li>\u2022 chemoprophylaxis</li><li>\u2022 Meningococcal</li><li>\u2022 meningitis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drug of Choice in Diphtheria:-</li><li>\u27a4 Drug of Choice</li><li>\u27a4 Diphtheria:-</li><li>\u27a4 Drugs for Chemoprophylaxis:</li><li>\u27a4 Drugs for Chemoprophylaxis:</li><li>\u27a4 Ref : Park 26 th edition (page 177)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 177)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d1e69e79",
      "audio": ""
    },
    {
      "text": "During a public health seminar focusing on vaccine-preventable diseases, a discussion arises about the global efforts to eliminate measles. A medical resident is reviewing various factors that support the potential elimination of measles in the near future. The resident considers the key elements that contribute to the successful control and eventual elimination of measles but also recognizes challenges that might impede these efforts. Which of the following points is NOT in favor of the elimination of measles in the near future?",
      "options": [
        {
          "label": "A",
          "text": "Human and animals are the reservoirs of infection",
          "correct": true
        },
        {
          "label": "B",
          "text": "There are no subclinical cases.",
          "correct": false
        },
        {
          "label": "C",
          "text": "The incubation period is fairly fixed at ten days.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Effective vaccine is available.",
          "correct": false
        }
      ],
      "correct_answer": "A. Human and animals are the reservoirs of infection",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Human and animals are the reservoirs of infection</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. There are no subclinical cases: Correct.</li><li>\u2022 Option B. There are no subclinical cases:</li><li>\u2022 Option C. The incubation period is fairly fixed at ten days: Correct</li><li>\u2022 Option C. The incubation period is fairly fixed at ten days:</li><li>\u2022 Option D. Effective vaccine is available: Correct. Very effective vaccine is available.</li><li>\u2022 Option D. Effective vaccine is available:</li><li>\u2022 Eradication of Measles : Requires a vaccination coverage >96%. Epidemic of measles occur: If the proportion of susceptible children is >40%. If Measles is introduced in a virgin community : it infects >90% children.</li><li>\u2022 Eradication of Measles : Requires a vaccination coverage >96%.</li><li>\u2022 Eradication</li><li>\u2022 Measles</li><li>\u2022 vaccination coverage >96%.</li><li>\u2022 Epidemic of measles occur: If the proportion of susceptible children is >40%.</li><li>\u2022 Epidemic</li><li>\u2022 measles</li><li>\u2022 susceptible children is >40%.</li><li>\u2022 If Measles is introduced in a virgin community : it infects >90% children.</li><li>\u2022 Measles</li><li>\u2022 introduced</li><li>\u2022 virgin community</li><li>\u2022 infects >90%</li><li>\u2022 The experience of eradicating polio and small pox using similar strategies of vaccination combined with surveillance and contamination already exist.</li><li>\u2022 eradicating polio</li><li>\u2022 small pox</li><li>\u2022 similar strategies</li><li>\u2022 vaccination</li><li>\u2022 surveillance and contamination</li><li>\u2022 Other reasons for the elimination of measles in the future:</li><li>\u2022 Other reasons</li><li>\u2022 elimination of measles</li><li>\u2022 future:</li><li>\u2022 Source of Infection are only cases (carriers are not known to occur) Measles has no second attacks ( lifelong immunity seen) Manifestations of disease are well known to the community .</li><li>\u2022 Source of Infection are only cases (carriers are not known to occur)</li><li>\u2022 Source</li><li>\u2022 only cases</li><li>\u2022 Measles has no second attacks ( lifelong immunity seen)</li><li>\u2022 Measles</li><li>\u2022 no second attacks</li><li>\u2022 lifelong immunity</li><li>\u2022 Manifestations of disease are well known to the community .</li><li>\u2022 Manifestations</li><li>\u2022 well known</li><li>\u2022 community</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Reasons for the elimination of measles in the future:</li><li>\u27a4 Reasons</li><li>\u27a4 elimination of measles</li><li>\u27a4 future:</li><li>\u27a4 Human beings are the only reservoir of infection. Man is Obligate Host. Source of Infection are ONLY CASES (carriers are not known to occur). There are no subclinical cases. Manifestations of disease are well known to the community. Measles has no second attacks (lifelong immunity seen). The incubation period is fairly fixed at ten days . Very effective vaccine is available.</li><li>\u27a4 Human beings are the only reservoir of infection. Man is Obligate Host.</li><li>\u27a4 Human beings</li><li>\u27a4 only reservoir</li><li>\u27a4 Man</li><li>\u27a4 Obligate Host.</li><li>\u27a4 Source of Infection are ONLY CASES (carriers are not known to occur).</li><li>\u27a4 Source of Infection</li><li>\u27a4 ONLY CASES</li><li>\u27a4 There are no subclinical cases.</li><li>\u27a4 no subclinical cases.</li><li>\u27a4 Manifestations of disease are well known to the community.</li><li>\u27a4 Manifestations</li><li>\u27a4 well known</li><li>\u27a4 Measles has no second attacks (lifelong immunity seen).</li><li>\u27a4 no second attacks</li><li>\u27a4 The incubation period is fairly fixed at ten days .</li><li>\u27a4 incubation period</li><li>\u27a4 fairly fixed at ten days</li><li>\u27a4 Very effective vaccine is available.</li><li>\u27a4 Very effective</li><li>\u27a4 available.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 731)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 731)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1200b9d0",
      "audio": ""
    },
    {
      "text": "While attending a lecture on respiratory illnesses in children, a medical student learns about various infectious diseases that present with prolonged coughing. The lecturer emphasizes the importance of recognizing specific clinical patterns in diagnosis. One disease, known for its characteristic and protracted cough, is highlighted for being notoriously referred to as the \"Hundred-day cough.\" The student is asked to identify this disease based on its distinctive clinical presentation. Which respiratory illness is commonly known as the \"Hundred-day cough\" due to its prolonged and characteristic coughing episodes?",
      "options": [
        {
          "label": "A",
          "text": "Pertussis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tuberculosis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Plague",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diphtheria",
          "correct": false
        }
      ],
      "correct_answer": "A. Pertussis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Pertussis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B.  Tuberculosis: Incorrect. Serious respiratory illness caused by Mycobacterium tuberculosis . TB symptoms include a persistent cough , but the disease is known for its systemic symptoms and potential for severe lung damage rather than the duration of coughing episodes .</li><li>\u2022 Option B.  Tuberculosis: Incorrect.</li><li>\u2022 respiratory illness</li><li>\u2022 Mycobacterium tuberculosis</li><li>\u2022 persistent cough</li><li>\u2022 its systemic symptoms</li><li>\u2022 severe lung damage</li><li>\u2022 duration of coughing episodes</li><li>\u2022 Option C. Plague: Incorrect. Caused by Yersinia pestis , can have a respiratory form known as pneumonic plague .</li><li>\u2022 Option C. Plague:</li><li>\u2022 Incorrect.</li><li>\u2022 Yersinia pestis</li><li>\u2022 pneumonic plague</li><li>\u2022 Option D. Diphtheria: Incorrect . Bacterial infection caused by Corynebacterium diphtheriae . While it affects the respiratory system, it is not associated with the prolonged cough , as characteristic of pertussis .</li><li>\u2022 Option D. Diphtheria: Incorrect</li><li>\u2022 Corynebacterium diphtheriae</li><li>\u2022 not</li><li>\u2022 prolonged cough</li><li>\u2022 pertussis</li><li>\u2022 Some Important Pointers related to Pertussis/Whooping Cough -</li><li>\u2022 \u2022 Causative agent: Bordetella pertussis ( 5% cases by B. parapertussis ) \u2022 Also known as \u2018 Whooping Cough\u2019 or \u2018 100 Day Cough\u2019 \u2013 Paroxysms of cough are followed by an inspiratory whoop (high pitch) \u2022 Incubation period : 7\u201314 days \u2022 Source of Infection: Case There is no subclinical or chronic carrier state. Neither vaccination nor infection confers long-term immunity. \u2022 Secondary Attack rate: > 90% \u2022 Incidence and fatality: Females > Males. \u2022 Leukocytosis does not correlates with the severity of cough. \u2022 Chief complications: Bronchitis, bronchopneumonia, bronchiectasis, subconjunctival hemorrhages , epistaxis, hemoptysis , punctuate cerebral hemorrhages, convulsions and coma . \u2022 Laboratory diagnosis: Culturing of nasopharyngeal swabs on Bordet-Gengou medium, polymerase chain reaction ( PCR ), immunofluorescence (DFA), and serological methods \u2022 Drug of choice: Erythromycin (40 mg/kg QID \u00d7 10 days)</li><li>\u2022 Bordetella pertussis</li><li>\u2022 5%</li><li>\u2022 B. parapertussis</li><li>\u2022 Whooping Cough\u2019</li><li>\u2022 100 Day Cough\u2019</li><li>\u2022 Paroxysms</li><li>\u2022 inspiratory whoop</li><li>\u2022 : 7\u201314 days</li><li>\u2022 Case</li><li>\u2022 no subclinical or chronic carrier state.</li><li>\u2022 Neither</li><li>\u2022 vaccination nor infection</li><li>\u2022 confers long-term immunity.</li><li>\u2022 Secondary Attack rate: > 90%</li><li>\u2022 Leukocytosis</li><li>\u2022 not</li><li>\u2022 severity of cough.</li><li>\u2022 bronchopneumonia,</li><li>\u2022 subconjunctival hemorrhages</li><li>\u2022 hemoptysis</li><li>\u2022 convulsions and coma</li><li>\u2022 nasopharyngeal swabs</li><li>\u2022 Bordet-Gengou medium,</li><li>\u2022 PCR</li><li>\u2022 immunofluorescence (DFA),</li><li>\u2022 serological methods</li><li>\u2022 Erythromycin (40 mg/kg QID \u00d7 10 days)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hundred Day Cough is - Pertussis (Whooping Cough ) - caused by Bordetella pertussis).</li><li>\u27a4 Hundred Day Cough</li><li>\u27a4 Pertussis (Whooping Cough</li><li>\u27a4 Bordetella</li><li>\u27a4 pertussis).</li><li>\u27a4 Ref : Park 26 th edition (page 179)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 179)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ff9be60",
      "audio": ""
    },
    {
      "text": "A medical resident in a pediatric clinic is reviewing epidemiological data on pertussis (whooping cough) as part of his research project. Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease. While vaccination has significantly reduced its incidence, there are concerns about increasing cases in certain populations. The resident is analyzing trends in the incidence and fatality of pertussis, particularly in vulnerable groups, to better understand the current challenges in managing and preventing this disease. Which statement accurately reflects the current trends in the incidence and fatality of pertussis?",
      "options": [
        {
          "label": "A",
          "text": "More in Males",
          "correct": false
        },
        {
          "label": "B",
          "text": "More in Females",
          "correct": true
        },
        {
          "label": "C",
          "text": "Equal in Males and females",
          "correct": false
        },
        {
          "label": "D",
          "text": "Differs in Males and Females in different states",
          "correct": false
        }
      ],
      "correct_answer": "B. More in Females",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. More in females</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Incidence and fatality of Pertussis are observed to be more among female than male children.</li><li>\u2022 Incidence and fatality</li><li>\u2022 Pertussis</li><li>\u2022 more</li><li>\u2022 female</li><li>\u2022 Some Important Pointers related to Pertussis/Whooping Cough -</li><li>\u2022 Important</li><li>\u2022 Pertussis/Whooping Cough</li><li>\u2022 Causative agent: Bordetella pertussis (5% cases by B. parapertussis) Also known as \u2018 Whooping Cough\u2019 or \u2018100 Day Cough\u2019 \u2013 Paroxysms of cough are followed by an inspiratory whoop (high pitch) . Incubation period: 7\u201314 days Source of Infection : Case There is no subclinical or chronic carrier state Neither vaccination nor infection confers long-term immunity. Secondary Attack rate: > 90% Incidence and fatality: Females > Males Leukocytosis does not correlates with the severity of cough . Chief complications: Bronchitis, bronchopneumonia , bronchiectasis, subconjunctival hemorrhages , epistaxis, hemoptysis, punctuate cerebral hemorrhages, convulsions and coma. Laboratory diagnosis: Culturing of nasopharyngeal swabs on Bordet-Gengou medium , polymerase chain reaction ( PCR) , immunofluorescence ( DFA ), and serological methods . Drug of choice: Erythromycin (40 mg/kg QID \u00d7 10 days)</li><li>\u2022 Causative agent: Bordetella pertussis (5% cases by B. parapertussis)</li><li>\u2022 Bordetella pertussis</li><li>\u2022 Also known as \u2018 Whooping Cough\u2019 or \u2018100 Day Cough\u2019 \u2013 Paroxysms of cough are followed by an inspiratory whoop (high pitch) .</li><li>\u2022 Whooping Cough\u2019 or \u2018100 Day Cough\u2019</li><li>\u2022 Paroxysms</li><li>\u2022 cough</li><li>\u2022 inspiratory whoop (high pitch)</li><li>\u2022 Incubation period: 7\u201314 days</li><li>\u2022 7\u201314 days</li><li>\u2022 Source of Infection : Case There is no subclinical or chronic carrier state Neither vaccination nor infection confers long-term immunity.</li><li>\u2022 Source of Infection</li><li>\u2022 Case</li><li>\u2022 There is no subclinical or chronic carrier state Neither vaccination nor infection confers long-term immunity.</li><li>\u2022 There is no subclinical or chronic carrier state</li><li>\u2022 no subclinical or chronic carrier state</li><li>\u2022 Neither vaccination nor infection confers long-term immunity.</li><li>\u2022 Neither vaccination nor infection</li><li>\u2022 long-term immunity.</li><li>\u2022 Secondary Attack rate: > 90%</li><li>\u2022 Secondary</li><li>\u2022 90%</li><li>\u2022 Incidence and fatality: Females > Males</li><li>\u2022 Females</li><li>\u2022 Leukocytosis does not correlates with the severity of cough .</li><li>\u2022 Leukocytosis</li><li>\u2022 not</li><li>\u2022 severity of cough</li><li>\u2022 Chief complications: Bronchitis, bronchopneumonia , bronchiectasis, subconjunctival hemorrhages , epistaxis, hemoptysis, punctuate cerebral hemorrhages, convulsions and coma.</li><li>\u2022 bronchopneumonia</li><li>\u2022 subconjunctival hemorrhages</li><li>\u2022 hemoptysis,</li><li>\u2022 punctuate cerebral</li><li>\u2022 Laboratory diagnosis: Culturing of nasopharyngeal swabs on Bordet-Gengou medium , polymerase chain reaction ( PCR) , immunofluorescence ( DFA ), and serological methods .</li><li>\u2022 Culturing</li><li>\u2022 nasopharyngeal swabs</li><li>\u2022 Bordet-Gengou</li><li>\u2022 medium</li><li>\u2022 PCR)</li><li>\u2022 DFA</li><li>\u2022 serological methods</li><li>\u2022 Drug of choice: Erythromycin (40 mg/kg QID \u00d7 10 days)</li><li>\u2022 Erythromycin (40 mg/kg QID \u00d7 10 days)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Incidence and fatality of Pertussis are observed to be more among female than male children.</li><li>\u27a4 Incidence and fatality of Pertussis</li><li>\u27a4 more</li><li>\u27a4 female than</li><li>\u27a4 male</li><li>\u27a4 Ref : Park 26 th edition (page 179)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 179)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "70f3ce9e",
      "audio": ""
    },
    {
      "text": "In a primary care setting, a family medicine physician encounters a family where one child has been diagnosed with pertussis. Recognizing the contagious nature of the disease, the physician considers the appropriate treatment protocol not only for the affected child but also for the family members who have been in close contact. The physician reviews the latest treatment guidelines to ensure the recommended first-line therapy is provided to both the patient and the contacts to effectively control the spread of the disease. What is the recommended first-line therapy for treating individuals diagnosed with pertussis and their close contacts?",
      "options": [
        {
          "label": "A",
          "text": "Cotrimoxazole",
          "correct": false
        },
        {
          "label": "B",
          "text": "Doxycycline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Erythromycin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ciprofloxacin",
          "correct": false
        }
      ],
      "correct_answer": "C. Erythromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Erythromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cotrimoxazole: Incorrect. Not the first-line treatment for pertussis.</li><li>\u2022 Option A. Cotrimoxazole:</li><li>\u2022 Not</li><li>\u2022 first-line</li><li>\u2022 pertussis.</li><li>\u2022 Option B.  Doxycycline: Incorrect. Doxycycline can be used in certain cases, especially in older children and adults , but it is not typically the first-line treatment for pertussis.</li><li>\u2022 Option B.  Doxycycline:</li><li>\u2022 used</li><li>\u2022 certain cases,</li><li>\u2022 older children and adults</li><li>\u2022 not</li><li>\u2022 first-line</li><li>\u2022 pertussis.</li><li>\u2022 Option D. Ciprofloxacin : Incorrect. Not used as the first-line treatment for pertussis.</li><li>\u2022 Option D. Ciprofloxacin</li><li>\u2022 Not</li><li>\u2022 first-line treatment</li><li>\u2022 pertussis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Drug of choice for Pertussis Case and Contact : Erythromycin (40 mg/kg QID X 10 days)</li><li>\u27a4 Drug of choice</li><li>\u27a4 Pertussis Case</li><li>\u27a4 Contact</li><li>\u27a4 Erythromycin (40 mg/kg QID X 10 days)</li><li>\u27a4 Ref: Park 26 th edition (page 180)</li><li>\u27a4 Ref:</li><li>\u27a4 Park 26 th edition (page 180)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be6924a4",
      "audio": ""
    },
    {
      "text": "A medical resident in a public health clinic is advising parents about pertussis (whooping cough) as part of an educational initiative. Bordetella pertussis, the bacterium responsible for pertussis, has a specific period during which it is infectious. The resident needs to be well-informed about this infective period to provide accurate advice on prevention and control measures, such as isolation and treatment. However, there are some misconceptions about the infective period of B. pertussis. Which of the following statements is NOT true regarding the infective period of Bordetella pertussis?",
      "options": [
        {
          "label": "A",
          "text": "Whooping cough is more infectious during catarrhal stage",
          "correct": false
        },
        {
          "label": "B",
          "text": "Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage",
          "correct": false
        },
        {
          "label": "C",
          "text": "Asymptomatic chronic carriers of B. pertussis are common",
          "correct": true
        },
        {
          "label": "D",
          "text": "Secondary attack rate is 90%",
          "correct": false
        }
      ],
      "correct_answer": "C. Asymptomatic chronic carriers of B. pertussis are common",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture17.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Asymptomatic chronic carriers of B. pertussis are common</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Whooping cough is more infectious during the catarrhal stage: True . The catarrhal stage , which is the early phase of whooping cough , is characterized by symptoms similar to a common cold . During this stage, the disease is highly infectious. Catarrhal stage ( 1 week after exposure to 3 weeks after onset of paroxysmal stage , although communicability diminishes rapidly after the catarrhal stage ).</li><li>\u2022 Option A. Whooping cough is more infectious during the catarrhal stage:</li><li>\u2022 True</li><li>\u2022 catarrhal stage</li><li>\u2022 early</li><li>\u2022 whooping cough</li><li>\u2022 symptoms</li><li>\u2022 common cold</li><li>\u2022 disease</li><li>\u2022 highly infectious.</li><li>\u2022 Catarrhal stage</li><li>\u2022 1 week after exposure</li><li>\u2022 3 weeks after</li><li>\u2022 onset of paroxysmal stage</li><li>\u2022 diminishes</li><li>\u2022 rapidly after the catarrhal stage</li><li>\u2022 Option B. Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage: True . The infective period for whooping cough can last from the initial exposure through the paroxysmal stage , during which severe coughing fits occur.</li><li>\u2022 Option B. Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage:</li><li>\u2022 True</li><li>\u2022 infective period</li><li>\u2022 whooping</li><li>\u2022 last</li><li>\u2022 initial exposure</li><li>\u2022 paroxysmal stage</li><li>\u2022 severe coughing</li><li>\u2022 Option D. Secondary attack rate is 90%: True . The secondary attack rate for whooping cough is very high , meaning that the disease is highly contagious within households or close-contact settings.</li><li>\u2022 Option D. Secondary attack rate is 90%: True</li><li>\u2022 whooping cough</li><li>\u2022 very high</li><li>\u2022 highly contagious</li><li>\u2022 households or close-contact settings.</li><li>\u2022 Some Important Pointers related to PERTUSSIS -</li><li>\u2022 Drug of choice : Erythromycin (40 mg/kg in 4 divided doses X 10 days) Complications: Bronchitis, bronchopneumonia , bronchiectasis, convulsions, coma</li><li>\u2022 Drug of choice : Erythromycin (40 mg/kg in 4 divided doses X 10 days)</li><li>\u2022 Drug of choice</li><li>\u2022 Erythromycin (40 mg/kg in 4 divided doses X 10 days)</li><li>\u2022 Complications: Bronchitis, bronchopneumonia , bronchiectasis, convulsions, coma</li><li>\u2022 bronchopneumonia</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While whooping cough is highly contagious during the catarrhal stage and has a high secondary attack rate, the asymptomatic chronic carriers of B. pertussis are uncommon .</li><li>\u27a4 whooping</li><li>\u27a4 highly contagious</li><li>\u27a4 catarrhal stage</li><li>\u27a4 high secondary attack</li><li>\u27a4 asymptomatic chronic carriers</li><li>\u27a4 B. pertussis</li><li>\u27a4 uncommon</li><li>\u27a4 SAR of some diseases are:</li><li>\u27a4 Ref : Park 26 th edition (page 179)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 179)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "931a2c20",
      "audio": ""
    },
    {
      "text": "An intern, as part of their pediatric clinic rotation, is focusing on the safety profiles of childhood vaccines. This review is crucial to enhance their understanding of vaccine safety and to better counsel parents effectively. In particular, the intern is examining the rare but serious side effects that can occur post-vaccination. The topic of discussion shifts to convulsions, a serious complication that can be associated with certain vaccines, albeit rarely. The intern is tasked with identifying the specific vaccine linked to this adverse effect. Which vaccine is known to have a rare association with convulsions as a serious post-immunization complication?",
      "options": [
        {
          "label": "A",
          "text": "DPT",
          "correct": true
        },
        {
          "label": "B",
          "text": "BCG",
          "correct": false
        },
        {
          "label": "C",
          "text": "Meningococcal vaccine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Measles Rubella (MR)",
          "correct": false
        }
      ],
      "correct_answer": "A. DPT",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154619.png"
      ],
      "explanation": "<p><strong>Ans. A. DPT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. BCG (Bacillus Calmette\u2013Gu\u00e9rin): Incorrect . The complications associated with BCG vaccine are Prolonged severe ulceration at site of vaccination , Suppurative lymphadenitis , Osteomyelitis , Disseminated BCG infection and Death .</li><li>\u2022 Option B. BCG (Bacillus Calmette\u2013Gu\u00e9rin):</li><li>\u2022 Incorrect</li><li>\u2022 Prolonged severe ulceration</li><li>\u2022 site</li><li>\u2022 vaccination</li><li>\u2022 lymphadenitis</li><li>\u2022 Osteomyelitis</li><li>\u2022 Disseminated BCG infection</li><li>\u2022 Death</li><li>\u2022 Option C. Meningococcal vaccine: Incorrect . In rare cases, a meningococcal vaccine may cause a severe allergic reaction (Hypersensitivity).</li><li>\u2022 Option C. Meningococcal vaccine:</li><li>\u2022 Incorrect</li><li>\u2022 severe allergic reaction</li><li>\u2022 Option D. MR (Measles and Rubella): Incorrect . Although febrile convulsions can occur following the MR vaccine due to fever , the association is less prominent compared to the DPT vaccine . Measles (& MMR) vaccine can lead to Toxic Shock Syndrome.</li><li>\u2022 Option D. MR (Measles and Rubella):</li><li>\u2022 Incorrect</li><li>\u2022 febrile convulsions</li><li>\u2022 MR vaccine</li><li>\u2022 fever</li><li>\u2022 less prominent</li><li>\u2022 DPT vaccine</li><li>\u2022 Measles (& MMR)</li><li>\u2022 Toxic Shock Syndrome.</li><li>\u2022 Some Specific side effects of important vaccines are:</li><li>\u2022 Specific side effects</li><li>\u2022 \u2022 Guillian Barre Syndrome: Killed influenza vaccine</li><li>\u2022 Guillian Barre Syndrome: Killed influenza vaccine</li><li>\u2022 \u2022 Vaccine associated paralysis: OPV (Sabin)</li><li>\u2022 \u2022 Vaccine associated paralysis: OPV (Sabin)</li><li>\u2022 \u2022 Shock: DPT, Pertussis vaccine</li><li>\u2022 \u2022 Hypersensitivity: Hep-B, Meningococcal vaccine, DPT, dT</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The rare vaccine reactions post DPT vaccination are persistent (more than 3 hours ) inconsolable screaming, seizures, hypotonic hypo-responsive episodes, anaphylactic reaction, and very rarely encephalopathy.</li><li>\u27a4 rare</li><li>\u27a4 post DPT vaccination</li><li>\u27a4 persistent</li><li>\u27a4 3 hours</li><li>\u27a4 screaming, seizures, hypotonic hypo-responsive episodes, anaphylactic reaction,</li><li>\u27a4 encephalopathy.</li><li>\u27a4 Some important Rare vaccine reactions:</li><li>\u27a4 Ref : Park 26 th edition (page 180)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 180)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "05646e77",
      "audio": ""
    },
    {
      "text": "During an epidemiology lecture at a medical school, the topic of Neisseria meningitidis (the causative agent of meningococcal meningitis) is being discussed. The professor explains that various serotypes of N. meningitidis are responsible for the disease's epidemiology, including both endemic cases and outbreaks. A medical student, interested in infectious diseases, is asked to identify the serotype of N. meningitidis that is less commonly associated with causing both endemic disease and outbreaks. Which serotype of Neisseria meningitidis is typically NOT associated with causing both endemic disease and outbreaks?",
      "options": [
        {
          "label": "A",
          "text": "X",
          "correct": false
        },
        {
          "label": "B",
          "text": "Y",
          "correct": false
        },
        {
          "label": "C",
          "text": "Z",
          "correct": true
        },
        {
          "label": "D",
          "text": "W135",
          "correct": false
        }
      ],
      "correct_answer": "C. Z",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Z</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 12 serotypes have been identified , viz. Groups A, B, C, 29E, H, I, K, L, W135, X, Y, Z based on the structure of the polysaccharide capsule.</li><li>\u2022 12 serotypes</li><li>\u2022 identified</li><li>\u2022 Groups</li><li>\u2022 A, B, C, 29E, H, I, K, L, W135, X, Y, Z</li><li>\u2022 polysaccharide capsule.</li><li>\u2022 The majority of invasive meningococcal infections are caused by organisms of serogroups A, B, C, X, W135 and Y . Meningococci of these serogroups have the potential to cause both endemic disease and outbreaks .</li><li>\u2022 meningococcal infections</li><li>\u2022 serogroups A, B, C, X, W135</li><li>\u2022 Y</li><li>\u2022 Meningococci</li><li>\u2022 serogroups</li><li>\u2022 both endemic disease and outbreaks</li><li>\u2022 Most lethal form is B</li><li>\u2022 lethal</li><li>\u2022 B</li><li>\u2022 Epidemics - A, C > B > W-135, Y</li><li>\u2022 In African meningitis belt , subgroup A has been the most important cause of disease .</li><li>\u2022 African meningitis belt</li><li>\u2022 subgroup A</li><li>\u2022 important</li><li>\u2022 disease</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Neisseria meningitides Serotype not associated with endemics and outbreaks - Serotype Z.</li><li>\u27a4 Neisseria meningitides</li><li>\u27a4 not</li><li>\u27a4 endemics and outbreaks - Serotype Z.</li><li>\u27a4 MC serotype of Meningococcus causing epidemics worldwide is A and the most lethal form is B.</li><li>\u27a4 MC serotype</li><li>\u27a4 Meningococcus</li><li>\u27a4 epidemics</li><li>\u27a4 worldwide</li><li>\u27a4 A</li><li>\u27a4 lethal form</li><li>\u27a4 B.</li><li>\u27a4 Ref : Park 26 th edition (page 181)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 181)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a60aa9c9",
      "audio": ""
    },
    {
      "text": "In a paediatric immunization clinic, a nurse practitioner is educating a group of new parents about the vaccination schedule for their infants. One of the vaccines discussed is the quadrivalent meningococcal vaccine, which offers protection against four strains of Neisseria meningitidis. A parent inquires about the appropriate age to start this vaccination for their child. The nurse practitioner knows that the vaccine's efficacy and safety are age-dependent and prepares to explain the age guidelines. At what minimum age is the quadrivalent meningococcal vaccine typically not recommended in children?",
      "options": [
        {
          "label": "A",
          "text": "15 year",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 years",
          "correct": true
        },
        {
          "label": "C",
          "text": "5 years",
          "correct": false
        },
        {
          "label": "D",
          "text": "10 years",
          "correct": false
        }
      ],
      "correct_answer": "B. 2 years",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. 2 years</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Quadrivalent vaccines are administered as a single dose to individuals aged > 2 years .</li><li>\u2022 Quadrivalent vaccines</li><li>\u2022 single dose</li><li>\u2022 > 2 years</li><li>\u2022 Important pointers regarding Meningococcal Vaccine -</li><li>\u2022 Meningococcal Vaccine</li><li>\u2022 Type of Vaccine: killed vaccine, cellular fraction Dose: 0.5 ml Route: Subcutaneous Site: Antero-lateral thigh (Middle one-third) Booster every 3 years Available for group A, C, W135 and Y meningococci Vaccine is not available for Group B meningococcus : Group B polysaccharide is non-immunogenic. Contraindications: Pregnancy Infants and children < 2 years of age (due to development of immunologic tolerance )</li><li>\u2022 Type of Vaccine: killed vaccine, cellular fraction</li><li>\u2022 killed vaccine, cellular fraction</li><li>\u2022 Dose: 0.5 ml</li><li>\u2022 Dose: 0.5 ml</li><li>\u2022 Route: Subcutaneous</li><li>\u2022 Subcutaneous</li><li>\u2022 Site: Antero-lateral thigh (Middle one-third)</li><li>\u2022 Site: Antero-lateral thigh (Middle one-third)</li><li>\u2022 Booster every 3 years</li><li>\u2022 3 years</li><li>\u2022 Available for group A, C, W135 and Y meningococci Vaccine is not available for Group B meningococcus : Group B polysaccharide is non-immunogenic.</li><li>\u2022 group A, C, W135 and Y meningococci</li><li>\u2022 Vaccine is not available for Group B meningococcus : Group B polysaccharide is non-immunogenic.</li><li>\u2022 Vaccine is not available for Group B meningococcus : Group B polysaccharide is non-immunogenic.</li><li>\u2022 not</li><li>\u2022 Group B meningococcus</li><li>\u2022 non-immunogenic.</li><li>\u2022 Contraindications: Pregnancy Infants and children < 2 years of age (due to development of immunologic tolerance )</li><li>\u2022 Pregnancy Infants and children < 2 years of age (due to development of immunologic tolerance )</li><li>\u2022 Pregnancy</li><li>\u2022 Pregnancy</li><li>\u2022 Infants and children < 2 years of age (due to development of immunologic tolerance )</li><li>\u2022 Infants and children < 2 years</li><li>\u2022 immunologic tolerance</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Meningococcal Vaccine - Contraindications - Pregnant women, Infants and children <2 years of age.</li><li>\u27a4 Meningococcal Vaccine</li><li>\u27a4 Contraindications</li><li>\u27a4 Pregnant women, Infants</li><li>\u27a4 <2 years</li><li>\u27a4 Ref : Park 26 th edition (page 182)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 182)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6327d66e",
      "audio": ""
    },
    {
      "text": "During a public health department meeting, a medical officer is discussing strategies for controlling an outbreak of meningococcal meningitis in a community. Various measures are considered, including vaccination and antibiotic prophylaxis. However, certain interventions are not recommended in the control of meningococcal meningitis epidemics. The medical officer is reviewing these strategies to ensure that the response is evidence-based and effective. In the control of an epidemic of meningococcal meningitis, which of the following interventions is NOT recommended?",
      "options": [
        {
          "label": "A",
          "text": "Mass vaccination",
          "correct": false
        },
        {
          "label": "B",
          "text": "Health education",
          "correct": false
        },
        {
          "label": "C",
          "text": "Isolation of cases",
          "correct": true
        },
        {
          "label": "D",
          "text": "Mass chemoprophylaxis",
          "correct": false
        }
      ],
      "correct_answer": "C. Isolation of cases",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Isolation of Cases</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mass vaccination: This is a recommended intervention in the control of a meningococcal meningitis epidemic . Vaccination is effective in preventing the spread of the disease , especially in areas with high incidence rates .</li><li>\u2022 Option A. Mass vaccination:</li><li>\u2022 meningococcal meningitis epidemic</li><li>\u2022 effective</li><li>\u2022 preventing</li><li>\u2022 spread</li><li>\u2022 disease</li><li>\u2022 areas</li><li>\u2022 high incidence rates</li><li>\u2022 Option B. Health education:  HE is an important component of epidemic control . Educating the public about the symptoms of meningococcal meningitis and the importance of seeking timely medical care can help in early detection and treatment of cases .</li><li>\u2022 Option B. Health education:  HE</li><li>\u2022 component</li><li>\u2022 epidemic control</li><li>\u2022 symptoms</li><li>\u2022 meningococcal meningitis</li><li>\u2022 medical care</li><li>\u2022 early detection</li><li>\u2022 treatment of cases</li><li>\u2022 Option D. Mass chemoprophylaxis: Mass chemoprophylaxis, using antibiotics like rifampicin, ciprofloxacin, or ceftriaxone , can be recommended in certain situations during a meningococcal meningitis epidemic . It is particularly used for close contacts of infected individuals to prevent the spread of the disease .</li><li>\u2022 Option D. Mass chemoprophylaxis:</li><li>\u2022 antibiotics</li><li>\u2022 rifampicin, ciprofloxacin, or ceftriaxone</li><li>\u2022 meningococcal meningitis epidemic</li><li>\u2022 close contacts of infected individuals</li><li>\u2022 prevent</li><li>\u2022 spread</li><li>\u2022 disease</li><li>\u2022 Some Important Pointers</li><li>\u2022 DOC for Chemoprophylaxis of Meningococcal Meningitis - Rifampicin (600 mg BD \u00d7 2 days). Meningococcal disease is endemic in India. Treatment with Penicillin doesn\u2019t eradicate the carrier state in meningococcal meningitis. Meningococcal Meningitis Prevention & Control</li><li>\u2022 DOC for Chemoprophylaxis of Meningococcal Meningitis - Rifampicin (600 mg BD \u00d7 2 days).</li><li>\u2022 DOC</li><li>\u2022 Chemoprophylaxis</li><li>\u2022 Meningococcal Meningitis</li><li>\u2022 Rifampicin (600 mg BD \u00d7 2 days).</li><li>\u2022 Meningococcal disease is endemic in India.</li><li>\u2022 Meningococcal disease</li><li>\u2022 endemic</li><li>\u2022 Treatment with Penicillin doesn\u2019t eradicate the carrier state in meningococcal meningitis.</li><li>\u2022 Penicillin doesn\u2019t eradicate</li><li>\u2022 carrier state</li><li>\u2022 meningococcal meningitis.</li><li>\u2022 Meningococcal Meningitis Prevention & Control</li><li>\u2022 Treatment of cases:</li><li>\u2022 Treatment of cases:</li><li>\u2022 Antibiotics started < 48 hours of illness save 95% lives. Drug of choice: Penicillin (Ceftriaxone if allergic to Penicillin) Epidemics : Single dose Long-acting Chloramphenicol or Ceftriaxone Treatment of carriers: Rifampici</li><li>\u2022 Antibiotics started < 48 hours of illness save 95% lives.</li><li>\u2022 Antibiotics</li><li>\u2022 started < 48 hours</li><li>\u2022 95% lives.</li><li>\u2022 Drug of choice: Penicillin (Ceftriaxone if allergic to Penicillin)</li><li>\u2022 Penicillin</li><li>\u2022 Epidemics : Single dose Long-acting Chloramphenicol or Ceftriaxone</li><li>\u2022 Epidemics</li><li>\u2022 Single dose</li><li>\u2022 Chloramphenicol or Ceftriaxone</li><li>\u2022 Treatment of carriers: Rifampici</li><li>\u2022 Treatment of carriers: Rifampici</li><li>\u2022 Treatment of contacts:</li><li>\u2022 Treatment of contacts:</li><li>\u2022 Start treatment < 24 hours of identification of index case Drugs used: Rifampicin, Ciprofloxacin, Ceftriaxone, Azithromycin</li><li>\u2022 Start treatment < 24 hours of identification of index case</li><li>\u2022 Start treatment < 24 hours</li><li>\u2022 index case</li><li>\u2022 Drugs used: Rifampicin, Ciprofloxacin, Ceftriaxone, Azithromycin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the control of a meningococcal meningitis epidemic , isolation of individual cases is not a typically recommended intervention. Mass vaccination and chemoprophylaxis , along with health education , are key strategies in controlling and preventing the spread of the disease.</li><li>\u27a4 meningococcal meningitis epidemic</li><li>\u27a4 isolation</li><li>\u27a4 not</li><li>\u27a4 Mass vaccination</li><li>\u27a4 chemoprophylaxis</li><li>\u27a4 health education</li><li>\u27a4 controlling and preventing</li><li>\u27a4 spread of the disease.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 757)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 757)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0a5097ab",
      "audio": ""
    },
    {
      "text": "A pediatric resident is evaluating a 6-month-old infant in a community health center. The infant presents with high fever, rapid breathing, and a convulsion. The resident refers to the IMNCI (Integrated Management of Neonatal and Childhood Illnesses) chart for guidance on management. According to the IMNCI chart, what does the pink color indicate regarding the necessary action for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Outpatient treatment",
          "correct": false
        },
        {
          "label": "B",
          "text": "Give injection/ oral drops",
          "correct": false
        },
        {
          "label": "C",
          "text": "Home management",
          "correct": false
        },
        {
          "label": "D",
          "text": "Urgent referral",
          "correct": true
        }
      ],
      "correct_answer": "D. Urgent referral",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Urgent referral</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Outpatient treatment: Yellow color</li><li>\u2022 Option A. Outpatient treatment:</li><li>\u2022 Option B. Give injection/ oral drops - yellow color</li><li>\u2022 Option B. Give injection/ oral drops -</li><li>\u2022 Option C. Home management - green color</li><li>\u2022 Option C. Home management -</li><li>\u2022 Integrated Management of Neonatal and Childness illness (IMNCI)</li><li>\u2022 Integrated Management of Neonatal and Childness illness (IMNCI)</li><li>\u2022 IMNCI is a strategy for reducing morbidity and mortality associated with major causes of childhood illness.</li><li>\u2022 IMNCI</li><li>\u2022 reducing morbidity and mortality</li><li>\u2022 major</li><li>\u2022 childhood illness.</li><li>\u2022 Curative component includes management of:</li><li>\u2022 Curative component</li><li>\u2022 1. Diarrhoea</li><li>\u2022 2. Measles</li><li>\u2022 3. Pneumonia</li><li>\u2022 4. Malaria</li><li>\u2022 5. Severe malnutrition and nutritional counseling</li><li>\u2022 Case management process : Is presented in a series of charts (Mnemonic: A Case Is Treated & Care Given ).</li><li>\u2022 Case management process</li><li>\u2022 A Case Is Treated & Care Given</li><li>\u2022 Assess the young infant or child Classify the illness Identify the treatment Treat the infant or child Counsel the mother Give follow-up care</li><li>\u2022 Assess the young infant or child</li><li>\u2022 Classify the illness</li><li>\u2022 Identify the treatment</li><li>\u2022 Treat the infant or child</li><li>\u2022 Counsel the mother</li><li>\u2022 Give follow-up care</li><li>\u2022 Example - IMNCI guidelines for Pneumonia</li><li>\u2022 IMNCI</li><li>\u2022 Pneumonia</li><li>\u2022 Ref : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 428)</li><li>\u2022 Ref</li><li>\u2022 : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 428)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "036f0d9e",
      "audio": ""
    },
    {
      "text": "In a pediatric clinic, a medical resident is evaluating a series of infants under 2 months old as part of an initiative to enhance early disease detection and management. The resident is utilizing the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines to classify the severity of illnesses in these young patients. While discussing the cases with a senior pediatrician, the resident is asked to identify which classification is not typically used in the IMNCI guidelines for infants less than 2 months old. Which of the following is NOT a classification under the IMNCI for this age group?",
      "options": [
        {
          "label": "A",
          "text": "Very severe disease",
          "correct": false
        },
        {
          "label": "B",
          "text": "Severe pneumonia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pneumonia",
          "correct": true
        },
        {
          "label": "D",
          "text": "No pneumonia- cough or cold",
          "correct": false
        }
      ],
      "correct_answer": "C. Pneumonia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image_bI6qll7.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154152.png"
      ],
      "explanation": "<p><strong>Ans. C. Pneumonia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Very severe disease : Incorrect . This includes critical signs like Stopped feeding well , convulsions , abnormally sleepy or difficult to wake , stridor in calm child, wheezing</li><li>\u2022 Option A. Very severe disease</li><li>\u2022 Incorrect</li><li>\u2022 critical signs</li><li>\u2022 Stopped feeding well</li><li>\u2022 convulsions</li><li>\u2022 difficult</li><li>\u2022 wake</li><li>\u2022 stridor</li><li>\u2022 calm</li><li>\u2022 child, wheezing</li><li>\u2022 Option B. Severe pneumonia: Incorrect . 'Severe pneumonia' characterized by symptoms like chest indrawing and fast breathing ( 60 per minute or more )</li><li>\u2022 Option B. Severe pneumonia: Incorrect</li><li>\u2022 chest indrawing</li><li>\u2022 fast breathing</li><li>\u2022 60 per minute or more</li><li>\u2022 Option D. No pneumonia-cough or cold: Incorrect . This term is used when an infant presents with a cough or cold but does not show signs of pneumonia or very severe disease i.e. No severe chest indrawing and no fast breathing.</li><li>\u2022 Option D. No pneumonia-cough or cold:</li><li>\u2022 Incorrect</li><li>\u2022 used</li><li>\u2022 infant</li><li>\u2022 cough or cold</li><li>\u2022 does not</li><li>\u2022 signs of pneumonia</li><li>\u2022 very severe disease</li><li>\u2022 No</li><li>\u2022 chest indrawing</li><li>\u2022 no fast breathing.</li><li>\u2022 IMNCI guidelines for pneumonia (NEW, 2017 Guideline)</li><li>\u2022 IMNCI</li><li>\u2022 pneumonia</li><li>\u2022 If 0-2 months old Young Infant</li><li>\u2022 0-2 months</li><li>\u2022 Young Infant</li><li>\u2022 \u2022 Count the breaths (recount, if >60/min ) \u2022 Look for severe chest indrawing .</li><li>\u2022 breaths</li><li>\u2022 >60/min</li><li>\u2022 severe</li><li>\u2022 chest indrawing</li><li>\u2022 2 month - 5 year child</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the IMNCI classification for infants less than 2 months old, the specific category of ' Pneumonia ' is not used. Instead, respiratory conditions are classified as 'Severe pneumonia' or 'Very severe disease.</li><li>\u27a4 IMNCI</li><li>\u27a4 infants less than 2 months</li><li>\u27a4 Pneumonia</li><li>\u27a4 not used.</li><li>\u27a4 respiratory conditions</li><li>\u27a4 classified</li><li>\u27a4 'Severe pneumonia' or 'Very severe disease.</li><li>\u27a4 Ref : Park 26 th edition (page 187)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 187)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d476805",
      "audio": ""
    },
    {
      "text": "A group of medical residents participating in a public health initiative are tasked with developing a protocol for the administration of cotrimoxazole in pediatric patients. They are focusing on standardizing treatment according to the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines. The residents are reviewing the dosing guidelines for different age groups and weights. According to the IMNCI guidelines, what is the recommended dosage of pediatric cotrimoxazole tablets for children aged 1 to 5 years with a body weight of 10-19 kg?",
      "options": [
        {
          "label": "A",
          "text": "One tablet twice a day",
          "correct": false
        },
        {
          "label": "B",
          "text": "Two tablets twice a day",
          "correct": false
        },
        {
          "label": "C",
          "text": "Three tablets twice a day",
          "correct": true
        },
        {
          "label": "D",
          "text": "Four tablets twice a day",
          "correct": false
        }
      ],
      "correct_answer": "C. Three tablets twice a day",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture20_RImCV8I.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Three tablets twice a day</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 1 tablet twice a day: Incorrect. This dosage is appropriate for infants <2 months , weight 3-5 kg.</li><li>\u2022 Option A. 1 tablet twice a day:</li><li>\u2022 Incorrect.</li><li>\u2022 dosage</li><li>\u2022 infants <2 months</li><li>\u2022 3-5 kg.</li><li>\u2022 Option B. 2 tablets twice a day: Incorrect . This dosage is less than the recommended amount for an infant 2-12 months , weighing between 6 and 9 kg as per IMNCI guidelines .</li><li>\u2022 Option B. 2 tablets twice a day:</li><li>\u2022 Incorrect</li><li>\u2022 dosage</li><li>\u2022 less</li><li>\u2022 infant 2-12 months</li><li>\u2022 weighing</li><li>\u2022 6 and 9</li><li>\u2022 kg</li><li>\u2022 IMNCI guidelines</li><li>\u2022 Option D. 4 tablets twice a day: Incorrect . This dosage exceeds the recommended amount for a child in the specified weight range according to IMNCI guidelines .</li><li>\u2022 Option D. 4 tablets twice a day:</li><li>\u2022 Incorrect</li><li>\u2022 dosage exceeds</li><li>\u2022 recommended</li><li>\u2022 child</li><li>\u2022 specified weight</li><li>\u2022 IMNCI guidelines</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pediatric Cotrimoxazole Dosage - (as per age and weight)</li><li>\u27a4 Pediatric Cotrimoxazole Dosage</li><li>\u27a4 Ref: Park 26 th edition (page 187)</li><li>\u27a4 Ref:</li><li>\u27a4 Park 26 th edition (page 187)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d13eab23",
      "audio": ""
    },
    {
      "text": "A team of medical residents is participating in a global health challenge competition, where they are tasked with developing innovative strategies to achieve the targets set by the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea by 2025. As part of the challenge, they are given a quiz to test their knowledge of the plan's objectives. The team needs to identify which of the following objectives for 2025 is not included in the plan. Which goal is NOT a part of the Integrated Global Plan for the Prevention and Control of Pneumonia and Diarrhoea?",
      "options": [
        {
          "label": "A",
          "text": "Reduce pneumonia mortality in under 5 children to < 3 per 1000 live births",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reduce diarrhoea mortality in under 5 children to < 3 per 1000 live births",
          "correct": true
        },
        {
          "label": "C",
          "text": "Reduce incidence of severe pneumonia by 75% as compared to 2010 levels",
          "correct": false
        },
        {
          "label": "D",
          "text": "Reduce incidence of severe diarrhoea by 75% as compared to 2010 levels",
          "correct": false
        }
      ],
      "correct_answer": "B. Reduce diarrhoea mortality in under 5 children to < 3 per 1000 live births",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125739.png"
      ],
      "explanation": "<p><strong>Ans. B. Reduce diarrhoea mortality in under 5 children to < 3 per 1000 live births</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduce Pneumonia mortality in Under-five < 3 per 1000 LB , Reduce Diarrhoea mortality in Infants < 1 per 1000 LB</li><li>\u2022 Option A. Reduce Pneumonia mortality</li><li>\u2022 in Under-five < 3 per 1000 LB</li><li>\u2022 Reduce Diarrhoea mortality</li><li>\u2022 < 1 per 1000 LB</li><li>\u2022 Option C. Reduce Incidence of Severe Pneumonia in Under- fives by 75% (2010 baseline)</li><li>\u2022 Option C. Reduce Incidence of Severe Pneumonia in Under-</li><li>\u2022 75%</li><li>\u2022 Option D. Reduce Incidence of Severe Diarrhoea in Under -fives by 75% (2010 baseline)</li><li>\u2022 Option D. Reduce Incidence of Severe Diarrhoea in Under</li><li>\u2022 75%</li><li>\u2022 Reduce Global no. of Stunted Under-fives by 40% (2010 baseline)</li><li>\u2022 Reduce</li><li>\u2022 Stunted Under-fives</li><li>\u2022 40%</li><li>\u2022 \u2022 Coverage targets:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Integrated Global Action Plan for Prevention and Control of Pneumonia & Diarrhoea (GAPPD) Specific Goals for 2025 are</li><li>\u27a4 Integrated Global Action Plan</li><li>\u27a4 Prevention</li><li>\u27a4 Control of Pneumonia</li><li>\u27a4 Diarrhoea</li><li>\u27a4 2025</li><li>\u27a4 Reduce Pneumonia mortality in Under-five < 3 per 1000 LB Reduce Diarrhoea mortality in Infants < 1 per 1000 LB Reduce Incidence of Severe Diarrhoea in Under-fives by 75% (2010 baseline) Reduce Incidence of Severe Pneumonia in Under-fives by 75% (2010 baseline) Reduce Global no. of Stunted Under-fives by 40% (2010 baseline)</li><li>\u27a4 Reduce Pneumonia mortality in Under-five < 3 per 1000 LB</li><li>\u27a4 Pneumonia</li><li>\u27a4 < 3 per 1000 LB</li><li>\u27a4 Reduce Diarrhoea mortality in Infants < 1 per 1000 LB</li><li>\u27a4 Diarrhoea</li><li>\u27a4 < 1 per 1000 LB</li><li>\u27a4 Reduce Incidence of Severe Diarrhoea in Under-fives by 75% (2010 baseline)</li><li>\u27a4 Severe Diarrhoea</li><li>\u27a4 75%</li><li>\u27a4 Reduce Incidence of Severe Pneumonia in Under-fives by 75% (2010 baseline)</li><li>\u27a4 Severe Pneumonia</li><li>\u27a4 75%</li><li>\u27a4 Reduce Global no. of Stunted Under-fives by 40% (2010 baseline)</li><li>\u27a4 Global no. of Stunted</li><li>\u27a4 40%</li><li>\u27a4 Ref : Park 26 th edition (page 189)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 189)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "75a6aa7c",
      "audio": ""
    },
    {
      "text": "In a seminar on the recent advancements in COVID-19 vaccine technology. One of the topics discussed is the variety of vaccine platforms used to combat the pandemic. A particular focus is given to a vaccine developed using a recombinant chimpanzee adenovirus vector. Which COVID-19 vaccine is developed using a recombinant chimpanzee adenovirus vector?",
      "options": [
        {
          "label": "A",
          "text": "Covishield vaccine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Covaxin vaccine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pfizer BioNtech vaccine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Moderna COVID 19 vaccine",
          "correct": false
        }
      ],
      "correct_answer": "A. Covishield vaccine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125437.png"
      ],
      "explanation": "<p><strong>Ans. A. Covishield vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Covaxin vaccine: Whole Virion Inactivated vaccine, strain is \" Niv-2020-770 \".  Manufactured by Bharat Biotech BSL-3 facility & ICMR & NIV ( 100 % Indigenous vaccine of India). This is for Individuals \u226518 years old, given in 2 doses ( 0.5 mL each) 4-6 weeks apart (Route - ONLY Intramuscular, at Deltoid muscle ). Protective efficacy is 86-96%.</li><li>\u2022 Option B. Covaxin vaccine:</li><li>\u2022 Virion</li><li>\u2022 Niv-2020-770</li><li>\u2022 Bharat Biotech BSL-3 facility</li><li>\u2022 ICMR</li><li>\u2022 NIV</li><li>\u2022 100</li><li>\u2022 \u226518</li><li>\u2022 2 doses</li><li>\u2022 0.5</li><li>\u2022 4-6</li><li>\u2022 Deltoid muscle</li><li>\u2022 86-96%.</li><li>\u2022 Option C. Pfizer BioNTech vaccine: mRNA vaccine. It uses messenger RNA to instruct cells to produce the spike protein of the virus, triggering an immune response .</li><li>\u2022 Option C. Pfizer BioNTech vaccine:</li><li>\u2022 mRNA</li><li>\u2022 messenger RNA</li><li>\u2022 spike protein</li><li>\u2022 triggering</li><li>\u2022 immune response</li><li>\u2022 Option D. Moderna COVID-19 vaccine: Similar to the Pfizer BioNTech vaccine, this is also an mRNA vaccine and operates on the same principle.</li><li>\u2022 Option D. Moderna COVID-19 vaccine:</li><li>\u2022 Pfizer BioNTech vaccine,</li><li>\u2022 mRNA vaccine</li><li>\u2022 operates</li><li>\u2022 same principle.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Covishield vaccine is a recombinant chimpanzee adenovirus vector vaccine</li><li>\u27a4 Covishield vaccine</li><li>\u27a4 recombinant</li><li>\u27a4 adenovirus</li><li>\u27a4 Comparison of some important COVID vaccines</li><li>\u27a4 Ref : Park 26 th edition (page 203)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 203)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c2f13166",
      "audio": ""
    },
    {
      "text": "During a global health seminar, a medical student is learning about the timeline of significant events in the COVID-19 pandemic. One of the key moments in the pandemic was when the World Health Organization (WHO) officially declared COVID-19 as a pandemic. This declaration had substantial implications for public health responses worldwide. The student is asked to recall the specific date on which WHO made this declaration. On what date did the World Health Organization (WHO) declare COVID-19 as a pandemic?",
      "options": [
        {
          "label": "A",
          "text": "11 February 2020",
          "correct": false
        },
        {
          "label": "B",
          "text": "21 February 2020",
          "correct": false
        },
        {
          "label": "C",
          "text": "11 March 2020",
          "correct": true
        },
        {
          "label": "D",
          "text": "21 March 2020",
          "correct": false
        }
      ],
      "correct_answer": "C. 11 March 2020",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 11 March 2020</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 COVID-19 since its first detection in China, spread to over 200 countries /territories. COVID-19. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This declaration was a response to the rapid global spread and severe impact of the virus , signaling a heightened level of concern and the need for countries worldwide to take urgent and aggressive action to control the spread of the virus .</li><li>\u2022 COVID-19</li><li>\u2022 first detection</li><li>\u2022 China,</li><li>\u2022 200 countries</li><li>\u2022 World Health Organization</li><li>\u2022 COVID-19</li><li>\u2022 pandemic</li><li>\u2022 March 11, 2020.</li><li>\u2022 rapid global spread</li><li>\u2022 , signaling</li><li>\u2022 heightened level</li><li>\u2022 concern</li><li>\u2022 worldwide</li><li>\u2022 take urgent and aggressive action</li><li>\u2022 control the spread of the virus</li><li>\u2022 January 30, 2020 - WHO declared COVID-19 a Public Health Emergency of International Concern , not a pandemic.</li><li>\u2022 January 30, 2020</li><li>\u2022 WHO</li><li>\u2022 COVID-19</li><li>\u2022 Public Health Emergency</li><li>\u2022 International Concern</li><li>\u2022 February 11, 2020 - The disease caused by the novel coronavirus was officially named COVID-19 by WHO.</li><li>\u2022 February 11, 2020</li><li>\u2022 novel coronavirus</li><li>\u2022 COVID-19</li><li>\u2022 WHO.</li><li>\u2022 December 08, 2020 : First dose of Covid vaccine administered globally (in United Kingdom)</li><li>\u2022 December 08, 2020</li><li>\u2022 First dose</li><li>\u2022 Covid vaccine</li><li>\u2022 globally</li><li>\u2022 Indian</li><li>\u2022 Indian</li><li>\u2022 30 January 2020 : India reports its First cases of COVID-19 from Thrissur, Kerala</li><li>\u2022 30 January 2020</li><li>\u2022 First cases of COVID-19</li><li>\u2022 Thrissur, Kerala</li><li>\u2022 25 March 2020 : Nation-wide lockdown imposed</li><li>\u2022 25 March 2020</li><li>\u2022 Nation-wide lockdown</li><li>\u2022 16 January 2021 : First dose of Covid vaccine administered in India ; India begins one of the world\u2019s biggest COVID-19 vaccination programs</li><li>\u2022 16 January 2021</li><li>\u2022 First</li><li>\u2022 Covid vaccine</li><li>\u2022 India</li><li>\u2022 India</li><li>\u2022 world\u2019s biggest COVID-19 vaccination</li><li>\u2022 December 2021 : DGCI approves Covaxin for use in 12-18 years old children</li><li>\u2022 December 2021</li><li>\u2022 Covaxin</li><li>\u2022 12-18 years old children</li><li>\u2022 December 2021 : Booster drive , 15-18 years old children vaccination drive announced</li><li>\u2022 December 2021</li><li>\u2022 Booster drive</li><li>\u2022 15-18 years old children</li><li>\u2022 According to CDC ( Centre for Disease Control ) \u201c Pandemic is an epidemic spread over several countries or continents , usually affecting a large number of people .</li><li>\u2022 Centre for Disease Control</li><li>\u2022 Pandemic</li><li>\u2022 epidemic spread</li><li>\u2022 several countries</li><li>\u2022 continents</li><li>\u2022 affecting</li><li>\u2022 large number of people</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020.</li><li>\u27a4 World Health Organization</li><li>\u27a4 COVID-19</li><li>\u27a4 a pandemic</li><li>\u27a4 March 11, 2020.</li><li>\u27a4 Ref : Park 26 th edition (page 191)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 191)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f2660024",
      "audio": ""
    },
    {
      "text": "A medical student, studying for a public health exam, is reviewing the National Immunisation Schedule. While familiarizing themselves with the various vaccines included in the schedule, the student is also trying to identify vaccines that are not typically part of this standard schedule but may be recommended in certain specific situations or risk groups. Understanding what is and isn't included in the national schedule is essential for future clinical practice, especially in pediatrics and family medicine. Which of the following vaccines is NOT typically included in the National Immunisation Schedule?",
      "options": [
        {
          "label": "A",
          "text": "Rota virus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rubella",
          "correct": false
        },
        {
          "label": "C",
          "text": "Meningococcal meningitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hepatitis B",
          "correct": false
        }
      ],
      "correct_answer": "C. Meningococcal meningitis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017_3PDctN8.png"
      ],
      "explanation": "<p><strong>Ans. C. Meningococcal meningitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Rota virus: 3 doses at 6, 10 and 14 weeks under NIS.</li><li>\u2022 Option A. Rota virus:</li><li>\u2022 3 doses</li><li>\u2022 6, 10 and 14 weeks</li><li>\u2022 Option B. Rubella : ( MR vaccine) 2 doses at 9 months and 16-24 months under NIS.</li><li>\u2022 Option B. Rubella</li><li>\u2022 MR</li><li>\u2022 2 doses</li><li>\u2022 9 months</li><li>\u2022 16-24 months</li><li>\u2022 Option D. Hepatitis B : 4 doses at Birth, 6, 10 and 14 weeks under NIS.</li><li>\u2022 Option D. Hepatitis B</li><li>\u2022 4 doses</li><li>\u2022 Birth, 6, 10 and 14 weeks</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 NEW National Immunization Schedule (NIS) 2023-24</li><li>\u27a4 JE vaccine only in Endemic districts. HiB Vaccine introduced as Pentavalent vaccine \u2013 DPT + HepB + HiB vaccine in 16 states fIPV is fractionated intradermal at 6 weeks & 14 weeks or IPV Intramuscular only at 14 weeks. Rotaviral vaccine introduced in 9 States \u2013 Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura. Measles-Rubella (MR) vaccine started from 5 States/UTs - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry. Pneumococcal conjugate vaccine PCV introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar. Adult JE Vaccine introduced in 31 high burden districts from Assam, Uttar Pradesh and West Bengal for adult JE vaccination in the age-group of 15-65 years.</li><li>\u27a4 JE vaccine only in Endemic districts.</li><li>\u27a4 JE vaccine</li><li>\u27a4 Endemic districts.</li><li>\u27a4 HiB Vaccine introduced as Pentavalent vaccine \u2013 DPT + HepB + HiB vaccine in 16 states</li><li>\u27a4 HiB Vaccine</li><li>\u27a4 Pentavalent vaccine</li><li>\u27a4 fIPV is fractionated intradermal at 6 weeks & 14 weeks or IPV Intramuscular only at 14 weeks.</li><li>\u27a4 fIPV</li><li>\u27a4 fractionated intradermal</li><li>\u27a4 6 weeks & 14 weeks</li><li>\u27a4 IPV Intramuscular</li><li>\u27a4 14 weeks.</li><li>\u27a4 Rotaviral vaccine introduced in 9 States \u2013 Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura.</li><li>\u27a4 Rotaviral vaccine</li><li>\u27a4 9 States</li><li>\u27a4 Measles-Rubella (MR) vaccine started from 5 States/UTs - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry.</li><li>\u27a4 Measles-Rubella</li><li>\u27a4 Pneumococcal conjugate vaccine PCV introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar.</li><li>\u27a4 Pneumococcal conjugate vaccine</li><li>\u27a4 Adult JE Vaccine introduced in 31 high burden districts from Assam, Uttar Pradesh and West Bengal for adult JE vaccination in the age-group of 15-65 years.</li><li>\u27a4 Adult JE Vaccine</li><li>\u27a4 31 high burden districts</li><li>\u27a4 adult JE vaccination</li><li>\u27a4 15-65 years.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 756)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 756)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar (4 th edition) (page 756)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4c6c872f",
      "audio": ""
    },
    {
      "text": "A medical resident, specializing in cardiology, is attending a seminar on the changing trends in coronary heart disease (CHD) over the years. The seminar highlights how shifts in socio-economic status and advancements in science and technology have impacted the patterns and prevalence of CHD globally. One of the key points of discussion is a significant project carried out by the World Health Organization (WHO) to study these changing trends in CHD. The resident is interested in knowing the specific project initiated by WHO for this purpose. Which project was carried out by the World Health Organization (WHO) to elucidate the changing trends in coronary heart disease (CHD) in light of evolving socio-economic conditions and technological advancements?",
      "options": [
        {
          "label": "A",
          "text": "North Kerelia project",
          "correct": false
        },
        {
          "label": "B",
          "text": "MONICA",
          "correct": true
        },
        {
          "label": "C",
          "text": "Oslow",
          "correct": false
        },
        {
          "label": "D",
          "text": "MRFIT",
          "correct": false
        }
      ],
      "correct_answer": "B. MONICA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. MONICA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. North Kerelia project: Risk factor intervention trial aimed to reduce cardiovascular risk factor levels and to promote early diagnosis, treatment and rehabilitation of patients . The result showed the reduction of CHD deaths in 10 years.</li><li>\u2022 Option A. North Kerelia project:</li><li>\u2022 Risk factor</li><li>\u2022 intervention</li><li>\u2022 reduce cardiovascular risk</li><li>\u2022 promote early diagnosis, treatment</li><li>\u2022 rehabilitation of patients</li><li>\u2022 reduction of CHD deaths</li><li>\u2022 10 years.</li><li>\u2022 Option C. Oslow : Oslow diet/smoking intervention study aimed to determine if serum lipids lowering and smoking-cessation would reduce incidence of first attack of CHD in 40-50 yrs males . The result showed that there is reduction of MI by 47%. With this study, primary prevention of CHD entered practical field of preventive medicine in an impressive manner.</li><li>\u2022 Option C. Oslow</li><li>\u2022 Oslow diet/smoking intervention</li><li>\u2022 determine</li><li>\u2022 serum lipids lowering</li><li>\u2022 smoking-cessation</li><li>\u2022 reduce incidence</li><li>\u2022 CHD</li><li>\u2022 40-50 yrs males</li><li>\u2022 reduction</li><li>\u2022 MI by 47%.</li><li>\u2022 primary prevention of CHD</li><li>\u2022 practical field</li><li>\u2022 preventive medicine</li><li>\u2022 impressive manner.</li><li>\u2022 Option D. MRFIT: Multiple risk factor intervention trial , The study aim was to reduce cardiovascular risk factor levels ( smoking, high BP, hypercholesterolemia ). The study showed the non-significant reduction seen in CHD deaths in 10 years. \u2013 Interpretation : Control group was not properly chosen ( changed habits and lifestyle to an extent not anticipated by designers of trial )</li><li>\u2022 Option D. MRFIT:</li><li>\u2022 Multiple risk factor intervention trial</li><li>\u2022 study aim</li><li>\u2022 reduce cardiovascular risk factor levels</li><li>\u2022 smoking, high BP,</li><li>\u2022 hypercholesterolemia</li><li>\u2022 non-significant reduction</li><li>\u2022 CHD</li><li>\u2022 deaths</li><li>\u2022 10</li><li>\u2022 years.</li><li>\u2022 Interpretation</li><li>\u2022 not</li><li>\u2022 changed habits</li><li>\u2022 lifestyle</li><li>\u2022 not anticipated</li><li>\u2022 designers of trial</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Project that was carried out by the World Health Organization (WHO) to elucidate the changing trends in coronary heart disease (CHD) in light of evolving socio-economic conditions and technological advancements - MONICA</li><li>\u27a4 Project</li><li>\u27a4 carried</li><li>\u27a4 World Health Organization (WHO)</li><li>\u27a4 elucidate</li><li>\u27a4 coronary heart disease (CHD)</li><li>\u27a4 socio-economic conditions</li><li>\u27a4 technological advancements</li><li>\u27a4 MONICA</li><li>\u27a4 Ref : Park 26 th ed pg 413.</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th ed pg 413.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95a1a04d",
      "audio": ""
    },
    {
      "text": "During a public health policy meeting, a medical resident reviewed various initiatives and campaigns launched to combat significant health issues in children. One of the initiatives discussed is the SAANS campaign, launched in November 2019. The resident is tasked with identifying the specific disease targeted by the SAANS initiative, as understanding these campaigns is crucial for effective public health planning and patient education. The SAANS initiative, launched in November 2019, was aimed at combating which disease?",
      "options": [
        {
          "label": "A",
          "text": "Pneumonia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Diarrhoea",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dengue",
          "correct": false
        },
        {
          "label": "D",
          "text": "Meningitis",
          "correct": false
        }
      ],
      "correct_answer": "A. Pneumonia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture22.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/19/image_4j10Igd.png"
      ],
      "explanation": "<p><strong>Ans. A. Pneumonia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 SAANS Campaign 2019 (Launched on 16th November 2019 )</li><li>\u2022 SAANS</li><li>\u2022 2019</li><li>\u2022 16th November 2019</li><li>\u2022 SAANS : Social Awareness and Action plan to Neutralise pneumonia Successfully Target: To reduce Childhood mortality due to Pneumonia to less than 3 per 1000 Live Birth by 2025 Objectives: Awareness in community Awareness of care gives to identify early Dispels myths and notions and trigger behaviour change Target beneficiaries: Primary beneficiaries: All care givers, Mothers, Fathers Secondary beneficiaries: Key Opinion Leaders (Gram Panchayat Leaders, Local Administration, Religious Leaders, Village Health Sanitation and Nutrition Committee Members, ICDS, Private practitioners)</li><li>\u2022 SAANS : Social Awareness and Action plan to Neutralise pneumonia Successfully</li><li>\u2022 SAANS</li><li>\u2022 Social Awareness and Action plan to Neutralise pneumonia Successfully</li><li>\u2022 Target: To reduce Childhood mortality due to Pneumonia to less than 3 per 1000 Live Birth by 2025</li><li>\u2022 reduce Childhood mortality</li><li>\u2022 Pneumonia</li><li>\u2022 less</li><li>\u2022 3 per</li><li>\u2022 1000 Live Birth by 2025</li><li>\u2022 Objectives: Awareness in community Awareness of care gives to identify early Dispels myths and notions and trigger behaviour change</li><li>\u2022 Awareness in community Awareness of care gives to identify early Dispels myths and notions and trigger behaviour change</li><li>\u2022 Awareness in community</li><li>\u2022 Awareness in community</li><li>\u2022 Awareness of care gives to identify early</li><li>\u2022 Awareness of care</li><li>\u2022 identify early</li><li>\u2022 Dispels myths and notions and trigger behaviour change</li><li>\u2022 Dispels myths</li><li>\u2022 notions and trigger</li><li>\u2022 Target beneficiaries:</li><li>\u2022 Primary beneficiaries: All care givers, Mothers, Fathers</li><li>\u2022 Secondary beneficiaries: Key Opinion Leaders (Gram Panchayat Leaders, Local Administration, Religious Leaders, Village Health Sanitation and Nutrition Committee Members, ICDS, Private practitioners)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SAANS Campaign 2019 - for Childhood Pneumonia.</li><li>\u27a4 SAANS</li><li>\u27a4 2019</li><li>\u27a4 Childhood Pneumonia.</li><li>\u27a4 Ref :https://nhm.gov.in/index1.php?lang=1&level=4&sublinkid=1336&lid=716</li><li>\u27a4 Ref :https://nhm.gov.in/index1.php?lang=1&level=4&sublinkid=1336&lid=716</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b46e065",
      "audio": ""
    },
    {
      "text": "A medical student, preparing for a presentation on public health achievements, is researching significant milestones in the eradication of infectious diseases. One of the notable successes discussed is India's achievement in polio eradication. The student needs to pinpoint the year when India was officially certified as polio-free, which represents a major public health triumph. In which year was India officially certified as polio-free?",
      "options": [
        {
          "label": "A",
          "text": "27 January 2014",
          "correct": false
        },
        {
          "label": "B",
          "text": "27 February 2014",
          "correct": false
        },
        {
          "label": "C",
          "text": "27 March 2014",
          "correct": true
        },
        {
          "label": "D",
          "text": "27 April 2014",
          "correct": false
        }
      ],
      "correct_answer": "C. 27 March 2014",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 27 March 2014</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 India was declared \u2018 POLIO-FREE\u2019 on 27 March 2014 by WHO</li><li>\u2022 India</li><li>\u2022 POLIO-FREE\u2019</li><li>\u2022 27 March 2014</li><li>\u2022 WHO</li><li>\u2022 Poliomyelitis 2023 [No case has been reported in India from 13 January 2011 onwards] -</li><li>\u2022 Poliomyelitis 2023</li><li>\u2022 No. of Polio cases: ZERO No. of Vaccine derived Polio virus (VDPV) cases: Zero No. of AFP cases: 9150 Non-polio AFP rate: 5.79</li><li>\u2022 No. of Polio cases: ZERO</li><li>\u2022 No. of Vaccine derived Polio virus (VDPV) cases: Zero</li><li>\u2022 No. of AFP cases: 9150</li><li>\u2022 Non-polio AFP rate: 5.79</li><li>\u2022 Some Important Pointers related to Poliomyelitis \u2013</li><li>\u2022 Causative agent : Poliovirus (serotypes 1, 2 and 3) P1 is MCC of epidemics P2 is most antigenic and most easily eradicable P3 is MCC of VAPP (Vaccine associated paralytic poliomyelitis) \u2013 1 per 2.7 million chance Reservoir: Man ( No chronic carriers ) MC clinical occurrence: Subclinical cases For every 1 clinical case of polio : there are 1000 subclinical cases in children and 75 subclinical cases in adults Infectious material : Faeces and oro-pharyngeal secretions</li><li>\u2022 Causative agent : Poliovirus (serotypes 1, 2 and 3) P1 is MCC of epidemics P2 is most antigenic and most easily eradicable P3 is MCC of VAPP (Vaccine associated paralytic poliomyelitis) \u2013 1 per 2.7 million chance</li><li>\u2022 Causative agent</li><li>\u2022 Poliovirus</li><li>\u2022 P1 is MCC of epidemics P2 is most antigenic and most easily eradicable P3 is MCC of VAPP (Vaccine associated paralytic poliomyelitis) \u2013 1 per 2.7 million chance</li><li>\u2022 P1 is MCC of epidemics</li><li>\u2022 P1</li><li>\u2022 MCC</li><li>\u2022 epidemics</li><li>\u2022 P2 is most antigenic and most easily eradicable</li><li>\u2022 P2</li><li>\u2022 most antigenic</li><li>\u2022 easily eradicable</li><li>\u2022 P3 is MCC of VAPP (Vaccine associated paralytic poliomyelitis) \u2013 1 per 2.7 million chance</li><li>\u2022 P3</li><li>\u2022 MCC</li><li>\u2022 VAPP</li><li>\u2022 1 per 2.7 million chance</li><li>\u2022 Reservoir: Man ( No chronic carriers )</li><li>\u2022 Reservoir: Man</li><li>\u2022 No chronic carriers</li><li>\u2022 MC clinical occurrence: Subclinical cases For every 1 clinical case of polio : there are 1000 subclinical cases in children and 75 subclinical cases in adults</li><li>\u2022 Subclinical cases</li><li>\u2022 For every 1 clinical case of polio : there are 1000 subclinical cases in children and 75 subclinical cases in adults</li><li>\u2022 For every 1 clinical case of polio : there are 1000 subclinical cases in children and 75 subclinical cases in adults</li><li>\u2022 1 clinical case</li><li>\u2022 polio</li><li>\u2022 1000 subclinical cases</li><li>\u2022 children</li><li>\u2022 75 subclinical</li><li>\u2022 adults</li><li>\u2022 Infectious material : Faeces and oro-pharyngeal secretions</li><li>\u2022 Infectious material</li><li>\u2022 Faeces and oro-pharyngeal secretions</li><li>\u2022 (Polio diagnosis : Isolation of wild poliovirus from stool is the recommended method). Virus usually can be found in the feces from onset to up to < 8 weeks after paralysis , with the highest probability of detection during the first 2 weeks from onset of Paralysis .</li><li>\u2022 : Isolation</li><li>\u2022 wild poliovirus</li><li>\u2022 stool</li><li>\u2022 Virus</li><li>\u2022 found</li><li>\u2022 feces</li><li>\u2022 onset to up to < 8 weeks</li><li>\u2022 paralysis</li><li>\u2022 highest probability</li><li>\u2022 first 2 weeks</li><li>\u2022 onset of Paralysis</li><li>\u2022 Period of communicability: 7-10 days before and after onset of symptoms Risk factors for precipitation of an attack: Fatigue Trauma Intramuscular injections Operative procedures ( Tonsillectomy ) esp. in epidemics of polio Administration of Alum containing DPT vaccine Incubation period : 3 \u2013 35 days (usually 7 \u2013 14 days )</li><li>\u2022 Period of communicability: 7-10 days before and after onset of symptoms</li><li>\u2022 communicability:</li><li>\u2022 7-10 days before and after</li><li>\u2022 Risk factors for precipitation of an attack: Fatigue Trauma Intramuscular injections Operative procedures ( Tonsillectomy ) esp. in epidemics of polio Administration of Alum containing DPT vaccine</li><li>\u2022 precipitation</li><li>\u2022 Fatigue Trauma Intramuscular injections Operative procedures ( Tonsillectomy ) esp. in epidemics of polio Administration of Alum containing DPT vaccine</li><li>\u2022 Fatigue</li><li>\u2022 Trauma</li><li>\u2022 Intramuscular injections</li><li>\u2022 Operative procedures ( Tonsillectomy ) esp. in epidemics of polio</li><li>\u2022 Tonsillectomy</li><li>\u2022 epidemics of polio</li><li>\u2022 Administration of Alum containing DPT vaccine</li><li>\u2022 Alum</li><li>\u2022 DPT vaccine</li><li>\u2022 Incubation period : 3 \u2013 35 days (usually 7 \u2013 14 days )</li><li>\u2022 Incubation period</li><li>\u2022 3 \u2013 35 days</li><li>\u2022 7 \u2013 14 days</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 India was declared \u2018POLIO-FREE\u2019 on 27 March 2014</li><li>\u27a4 India</li><li>\u27a4 \u2018POLIO-FREE\u2019</li><li>\u27a4 27 March 2014</li><li>\u27a4 Ref : Park 26 th edition (page 236)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 236)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cdaeaac4",
      "audio": ""
    },
    {
      "text": "A medical consultant working with a non-governmental organization (NGO) is involved in a project focused on assessing the surveillance capacity for poliomyelitis (polio) in various regions. A critical aspect of this project is the analysis of the reporting rate of acute flaccid paralysis (AFP) cases, which serves as a key surveillance indicator for polio. Accurate detection and reporting of AFP cases are essential for monitoring potential polio outbreaks and guiding eradication efforts. The consultant is tasked with reviewing and understanding the established guidelines for AFP case detection to ensure the efficacy of the surveillance program. What are the established guidelines for detecting AFP cases as part of polio surveillance?",
      "options": [
        {
          "label": "A",
          "text": "1 AFP case for every 100000 children under 15 years of age.",
          "correct": true
        },
        {
          "label": "B",
          "text": "1 AFP case for every 1000 children under 15 years of age.",
          "correct": false
        },
        {
          "label": "C",
          "text": "1 AFP case for every 200000 children under 15 years of age.",
          "correct": false
        },
        {
          "label": "D",
          "text": "1 AFP case for every 10000 children under 15 years of age.",
          "correct": false
        }
      ],
      "correct_answer": "A. 1 AFP case for every 100000 children under 15 years of age.",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-113435.png"
      ],
      "explanation": "<p><strong>Ans. A. 1 AFP case for every 100000 children under 15 years of age.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The number of AFP cases reported each year is used as an indicator of a country's ability to detect polio - even in countries where the disease no longer occurs . A country's surveillance system needs to be sensitive enough to detect at least one case of AFP for every 100,000 children under 15, even in the absence of polio.</li><li>\u2022 AFP cases</li><li>\u2022 each year</li><li>\u2022 indicator</li><li>\u2022 country's ability</li><li>\u2022 detect polio</li><li>\u2022 disease no longer occurs</li><li>\u2022 country's surveillance system</li><li>\u2022 sensitive</li><li>\u2022 detect at least</li><li>\u2022 one</li><li>\u2022 AFP</li><li>\u2022 100,000 children</li><li>\u2022 15,</li><li>\u2022 polio.</li><li>\u2022 Surveillance Indicators -</li><li>\u2022 Surveillance Indicators -</li><li>\u2022 Acute Flaccid Paralysis (AFP) Surveillance</li><li>\u2022 Acute Flaccid Paralysis (AFP) Surveillance</li><li>\u2022 Nationwide AFP (acute flaccid paralysis) surveillance is the gold standard for detecting cases of poliomyelitis . The four steps of surveillance are:</li><li>\u2022 Nationwide AFP</li><li>\u2022 gold standard</li><li>\u2022 poliomyelitis</li><li>\u2022 four steps</li><li>\u2022 Finding and reporting children with acute flaccid paralysis (AFP) Transporting stool samples for analysis Isolating and identifying poliovirus in the laboratory Mapping the virus to determine the origin of the virus strain.</li><li>\u2022 Finding and reporting children with acute flaccid paralysis (AFP)</li><li>\u2022 Finding and reporting children</li><li>\u2022 acute flaccid paralysis (AFP)</li><li>\u2022 Transporting stool samples for analysis</li><li>\u2022 stool samples</li><li>\u2022 analysis</li><li>\u2022 Isolating and identifying poliovirus in the laboratory</li><li>\u2022 Isolating and identifying</li><li>\u2022 poliovirus</li><li>\u2022 laboratory</li><li>\u2022 Mapping the virus to determine the origin of the virus strain.</li><li>\u2022 Mapping</li><li>\u2022 virus strain.</li><li>\u2022 (All reported cases of AFP should be investigated by DIO \u2018within 48 hours\u2019 after notification )</li><li>\u2022 AFP</li><li>\u2022 DIO</li><li>\u2022 48 hours\u2019</li><li>\u2022 notification</li><li>\u2022 Available diagnostic tests for Poliomyelitis \u2013</li><li>\u2022 diagnostic</li><li>\u2022 tests</li><li>\u2022 Poliomyelitis</li><li>\u2022 Stool examination (recommended in every case of AFP) CSF examination Throat examination Blood examination</li><li>\u2022 Stool examination (recommended in every case of AFP)</li><li>\u2022 CSF examination</li><li>\u2022 Throat examination</li><li>\u2022 Blood examination</li><li>\u2022 Acute Flaccid Paralysis (AFP): Acute onset ( < 4 weeks ) in a child aged <15 years , or any case of paralytic illness in a person of any age when polio is suspected.</li><li>\u2022 Acute Flaccid Paralysis</li><li>\u2022 Acute onset</li><li>\u2022 < 4 weeks</li><li>\u2022 <15 years</li><li>\u2022 paralytic illness</li><li>\u2022 polio is suspected.</li><li>\u2022 Acute : rapid progression of from onset to maximum paralysis. Flaccid : loss of muscle tone , \u2018 floppy\u2019 as opposed to spastic or rigid. Paralysis : weakness , loss of voluntary movement. Differential diagnosis of AFP: Descending asymmetric flaccid LMN paralysis Guillain Barre Syndrome (Cytologico-albuminic dissociation). Transverse myelitis (Normal CSF, sensory loss +, bladder dysfunction +). Traumatic neuritis (any age, only one leg involved). Other Non-polio enteric viruses : Coxsackie-B , ECHO, Enterovirus type 70 and 71, Mumps.</li><li>\u2022 Acute : rapid progression of from onset to maximum paralysis.</li><li>\u2022 Acute</li><li>\u2022 rapid progression</li><li>\u2022 onset to maximum paralysis.</li><li>\u2022 Flaccid : loss of muscle tone , \u2018 floppy\u2019 as opposed to spastic or rigid.</li><li>\u2022 Flaccid</li><li>\u2022 loss of muscle tone</li><li>\u2022 floppy\u2019</li><li>\u2022 spastic or rigid.</li><li>\u2022 Paralysis : weakness , loss of voluntary movement.</li><li>\u2022 Paralysis</li><li>\u2022 weakness</li><li>\u2022 loss of voluntary movement.</li><li>\u2022 Differential diagnosis of AFP: Descending asymmetric flaccid LMN paralysis Guillain Barre Syndrome (Cytologico-albuminic dissociation). Transverse myelitis (Normal CSF, sensory loss +, bladder dysfunction +). Traumatic neuritis (any age, only one leg involved). Other Non-polio enteric viruses : Coxsackie-B , ECHO, Enterovirus type 70 and 71, Mumps.</li><li>\u2022 Differential diagnosis</li><li>\u2022 Descending</li><li>\u2022 asymmetric flaccid LMN paralysis</li><li>\u2022 Guillain Barre Syndrome (Cytologico-albuminic dissociation). Transverse myelitis (Normal CSF, sensory loss +, bladder dysfunction +). Traumatic neuritis (any age, only one leg involved). Other Non-polio enteric viruses : Coxsackie-B , ECHO, Enterovirus type 70 and 71, Mumps.</li><li>\u2022 Guillain Barre Syndrome (Cytologico-albuminic dissociation).</li><li>\u2022 Guillain Barre Syndrome</li><li>\u2022 Transverse myelitis (Normal CSF, sensory loss +, bladder dysfunction +).</li><li>\u2022 Transverse myelitis</li><li>\u2022 Traumatic neuritis (any age, only one leg involved).</li><li>\u2022 Traumatic neuritis</li><li>\u2022 Other Non-polio enteric viruses : Coxsackie-B , ECHO, Enterovirus type 70 and 71, Mumps.</li><li>\u2022 Non-polio enteric viruses</li><li>\u2022 Coxsackie-B</li><li>\u2022 ECHO, Enterovirus type 70 and 71, Mumps.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A country's surveillance system needs to be sensitive enough to detect at least one case of AFP for every 100,000 children under 15 , even in the absence of polio .</li><li>\u27a4 country's surveillance</li><li>\u27a4 sensitive</li><li>\u27a4 detect</li><li>\u27a4 least</li><li>\u27a4 one case of AFP</li><li>\u27a4 100,000 children</li><li>\u27a4 15</li><li>\u27a4 absence</li><li>\u27a4 polio</li><li>\u27a4 Ref : Park 26 th edition (page 237)</li><li>\u27a4 Ref : Park 26 th edition (page 237)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "21f8de4b",
      "audio": ""
    },
    {
      "text": "In a postgraduate teaching seminar focused on infectious diseases, a junior resident is presenting on the various strategies employed in the global initiative to eradicate polio. A significant portion of the presentation is dedicated to discussing 'the switch' \u2013 a pivotal moment in the history of polio eradication efforts. This strategy has played an essential role in the worldwide campaign to halt the transmission of all poliovirus types. The resident aims to explain the specifics of 'the switch' to the attendees, emphasizing its impact on the global fight against polio. In the global efforts to eradicate polio, what specifically does 'the switch' refer to?",
      "options": [
        {
          "label": "A",
          "text": "Replacement of tOPV with bOPV.",
          "correct": true
        },
        {
          "label": "B",
          "text": "Replacement of OPV with IPV.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Replacement of tOPV with bOPV.",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture23.jpg"
      ],
      "explanation": "<p><strong>Ans. A. Replacement of tOPV with bOPV.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The first stage of OPV withdrawal involved a global synchronized cessation of tOPV use between 18th April and 1st May 2016 , replacing tOPV with bOPV containing only type 1 and 3 polioviruses and withdrawing OPV type 2 from all immunization activities called \u201c the Switch \u201d. Once switch is made, tOPV will no longer be used anywhere in the world and manufacturers will no longer supply tOPV.</li><li>\u2022 first stage of OPV</li><li>\u2022 withdrawal</li><li>\u2022 global synchronized cessation</li><li>\u2022 tOPV</li><li>\u2022 18th April and 1st May 2016</li><li>\u2022 replacing tOPV with bOPV</li><li>\u2022 type 1 and 3 polioviruses</li><li>\u2022 withdrawing OPV type 2</li><li>\u2022 all immunization</li><li>\u2022 the Switch</li><li>\u2022 Once switch</li><li>\u2022 tOPV</li><li>\u2022 no</li><li>\u2022 used</li><li>\u2022 world</li><li>\u2022 manufacturers</li><li>\u2022 no</li><li>\u2022 longer</li><li>\u2022 tOPV.</li><li>\u2022 \u201cSWITCH\u201d - Replacing Trivalent OPV with Bivalent OPV.</li><li>\u2022 \u201cSWITCH\u201d</li><li>\u2022 Replacing Trivalent OPV</li><li>\u2022 Bivalent OPV.</li><li>\u2022 Concept: An important transition in the vaccines used to eradicate polio requires removal of all OPVs in the long\u2011term to eliminate rare risks of VAPP and cVDPV Strategy: Withdrawal of OPVs must occur in a globally synchronized manner, starting in April 2016 with a switch from trivalent OPV (tOPV) to bivalent OPV (bOPV), removing the type 2 component (OPV2) from immunization programs of countries. Preparation for the removal of OPVs also includes the introduction of at least one dose of IPV in routine immunization programs in all countries by end of 2015. Indian \u201cSwitch\u201d: National Switch Date : April 25, 2016 National Validation Day : May 09, 2016 (India to be declared free of tOPV) Destroy all tOPV on/after 25th April 2016 IPV in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): One Intramuscular dose given along with 3rd dose of DTP at 14 weeks IPV in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): Fractional dose ( 0.1 mL instead of 0.5 mL) by intradermal route at 6 and 14 weeks from April, 2016 (Right deltoid upper arm)</li><li>\u2022 Concept: An important transition in the vaccines used to eradicate polio requires removal of all OPVs in the long\u2011term to eliminate rare risks of VAPP and cVDPV</li><li>\u2022 vaccines</li><li>\u2022 eradicate polio</li><li>\u2022 all OPVs</li><li>\u2022 long\u2011term</li><li>\u2022 eliminate rare risks</li><li>\u2022 VAPP</li><li>\u2022 cVDPV</li><li>\u2022 Strategy: Withdrawal of OPVs must occur in a globally synchronized manner, starting in April 2016 with a switch from trivalent OPV (tOPV) to bivalent OPV (bOPV), removing the type 2 component (OPV2) from immunization programs of countries. Preparation for the removal of OPVs also includes the introduction of at least one dose of IPV in routine immunization programs in all countries by end of 2015.</li><li>\u2022 Withdrawal of OPVs must occur in a globally synchronized manner, starting in April 2016 with a switch from trivalent OPV (tOPV) to bivalent OPV (bOPV), removing the type 2 component (OPV2) from immunization programs of countries. Preparation for the removal of OPVs also includes the introduction of at least one dose of IPV in routine immunization programs in all countries by end of 2015.</li><li>\u2022 Withdrawal of OPVs must occur in a globally synchronized manner, starting in April 2016 with a switch from trivalent OPV (tOPV) to bivalent OPV (bOPV), removing the type 2 component (OPV2) from immunization programs of countries.</li><li>\u2022 Withdrawal</li><li>\u2022 OPVs</li><li>\u2022 globally synchronized</li><li>\u2022 starting</li><li>\u2022 April 2016</li><li>\u2022 switch from trivalent OPV</li><li>\u2022 bivalent OPV</li><li>\u2022 removing</li><li>\u2022 type 2</li><li>\u2022 from immunization</li><li>\u2022 Preparation for the removal of OPVs also includes the introduction of at least one dose of IPV in routine immunization programs in all countries by end of 2015.</li><li>\u2022 removal of OPVs</li><li>\u2022 introduction</li><li>\u2022 one dose of IPV</li><li>\u2022 routine immunization programs</li><li>\u2022 all countries</li><li>\u2022 2015.</li><li>\u2022 Indian \u201cSwitch\u201d: National Switch Date : April 25, 2016 National Validation Day : May 09, 2016 (India to be declared free of tOPV) Destroy all tOPV on/after 25th April 2016 IPV in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): One Intramuscular dose given along with 3rd dose of DTP at 14 weeks IPV in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): Fractional dose ( 0.1 mL instead of 0.5 mL) by intradermal route at 6 and 14 weeks from April, 2016 (Right deltoid upper arm)</li><li>\u2022 National Switch Date : April 25, 2016 National Validation Day : May 09, 2016 (India to be declared free of tOPV) Destroy all tOPV on/after 25th April 2016 IPV in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): One Intramuscular dose given along with 3rd dose of DTP at 14 weeks IPV in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): Fractional dose ( 0.1 mL instead of 0.5 mL) by intradermal route at 6 and 14 weeks from April, 2016 (Right deltoid upper arm)</li><li>\u2022 National Switch Date : April 25, 2016</li><li>\u2022 National Switch Date</li><li>\u2022 April 25, 2016</li><li>\u2022 National Validation Day : May 09, 2016 (India to be declared free of tOPV)</li><li>\u2022 National Validation Day</li><li>\u2022 May 09, 2016</li><li>\u2022 Destroy all tOPV on/after 25th April 2016</li><li>\u2022 Destroy</li><li>\u2022 tOPV</li><li>\u2022 25th April 2016</li><li>\u2022 IPV in 6 states (UP, Bihar, Madhya Pradesh, Gujarat, Punjab, Assam): One Intramuscular dose given along with 3rd dose of DTP at 14 weeks</li><li>\u2022 IPV</li><li>\u2022 One Intramuscular</li><li>\u2022 with 3rd dose</li><li>\u2022 DTP at 14 weeks</li><li>\u2022 IPV in other states (Orissa, Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, Puducherry): Fractional dose ( 0.1 mL instead of 0.5 mL) by intradermal route at 6 and 14 weeks from April, 2016 (Right deltoid upper arm)</li><li>\u2022 IPV</li><li>\u2022 Fractional dose</li><li>\u2022 0.1 mL</li><li>\u2022 by intradermal</li><li>\u2022 at 6 and 14 weeks</li><li>\u2022 April, 2016</li><li>\u2022 (Right deltoid upper arm)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A critical step in eradication of Polio , is \u2018the switch\u2019 which refers to - Replacement of tOPV with bOPV.</li><li>\u27a4 eradication of Polio</li><li>\u27a4 \u2018the switch\u2019</li><li>\u27a4 Replacement of tOPV</li><li>\u27a4 bOPV.</li><li>\u27a4 Ref : Park 26 th edition (page 236)</li><li>\u27a4 Ref : Park 26 th edition (page 236)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "42f61087",
      "audio": ""
    },
    {
      "text": "In an immunization clinic, a junior resident in community medicine is preparing for a training session with interns. The focus is on educating them about the National Immunisation Schedule, specifically the correct administration routes and techniques for various vaccines. An important part of this session is the fractional Inactivated Polio Vaccine (fIPV), a key vaccine in polio eradication efforts. The resident needs to ensure that the interns understand the specific route of administration for fIPV as per the National Immunisation Schedule, as this knowledge is crucial for effective vaccine delivery and patient care. According to the NIS, what is the recommended route of administration for fractional Inactivated Polio Vaccine (fIPV)?",
      "options": [
        {
          "label": "A",
          "text": "Intramuscular",
          "correct": false
        },
        {
          "label": "B",
          "text": "\u200b Intradermal",
          "correct": true
        },
        {
          "label": "C",
          "text": "Subcutaneous",
          "correct": false
        },
        {
          "label": "D",
          "text": "Oral",
          "correct": false
        }
      ],
      "correct_answer": "B. \u200b Intradermal",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-124535.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017.png"
      ],
      "explanation": "<p><strong>Ans. B. Intradermal</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 IPV Vs Fractionated IPV (fIPV)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fractionated inactivated Polio Vaccine (fIPV) is administered intradermally according to the National Immunisation Schedule.</li><li>\u27a4 Fractionated inactivated Polio Vaccine</li><li>\u27a4 intradermally</li><li>\u27a4 National Immunisation Schedule.</li><li>\u27a4 NEW National Immunization Schedule (NIS) 2023-24</li><li>\u27a4 Note - Age Limits for Delayed Immunization in NIS, India for fIPV is 1 year.</li><li>\u27a4 Age Limits</li><li>\u27a4 Delayed Immunization</li><li>\u27a4 NIS, India</li><li>\u27a4 fIPV is 1 year.</li><li>\u27a4 fIPV is fractionated intradermal at 6 weeks, 14 weeks & 9 months ( 3 doses ).</li><li>\u27a4 fIPV</li><li>\u27a4 fractionated intradermal</li><li>\u27a4 6 weeks, 14 weeks & 9 months</li><li>\u27a4 3 doses</li><li>\u27a4 Ref : Park 26 th edition (page 237)</li><li>\u27a4 Ref : Park 26 th edition (page 237)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ee0453b3",
      "audio": ""
    },
    {
      "text": "A medical resident specializing in infectious diseases is preparing a presentation on cholera, focusing on the differences between the El Tor and classical biotypes of Vibrio cholerae. Understanding these differences is important for epidemiology, clinical presentation, and public health response. The resident aims to clarify common misconceptions and highlight key characteristics that are similar or different between these two biotypes. Which of the following characteristics is NOT a difference between cases of cholera caused by the El Tor biotype and the classical biotype of Vibrio cholerae?",
      "options": [
        {
          "label": "A",
          "text": "Classical signs of cholera is absent",
          "correct": false
        },
        {
          "label": "B",
          "text": "Higher rates of carriers",
          "correct": false
        },
        {
          "label": "C",
          "text": "More number of secondary cases",
          "correct": true
        },
        {
          "label": "D",
          "text": "Chick erythrocyte agglutination is positive",
          "correct": false
        }
      ],
      "correct_answer": "C. More number of secondary cases",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. More number of secondary cases</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In El tor type:</li><li>\u2022 El tor</li><li>\u2022 Higher incidence of mild and asymptomatic infections. Classical picture of cholera may not be seen often. Fewer secondary cases in affected families. Chronic carriers are common. More resistant than classical cholera.</li><li>\u2022 Higher incidence of mild and asymptomatic infections.</li><li>\u2022 Higher incidence</li><li>\u2022 mild and asymptomatic infections.</li><li>\u2022 Classical picture of cholera may not be seen often.</li><li>\u2022 Classical</li><li>\u2022 of cholera</li><li>\u2022 not</li><li>\u2022 Fewer secondary cases in affected families.</li><li>\u2022 Fewer</li><li>\u2022 affected families.</li><li>\u2022 Chronic carriers are common.</li><li>\u2022 Chronic carriers</li><li>\u2022 common.</li><li>\u2022 More resistant than classical cholera.</li><li>\u2022 More resistant</li><li>\u2022 Some important Pointers related to Cholera -</li><li>\u2022 Cholera is an acute diarrhoel disease caused by Vibrio cholera. Vibrio cholerae : \u2018 Gram-negative bacterium\u2019 that produces cholera toxin (enterotoxin), which act on c-AMP system of mucosal cells of epithelium lining of the small intestine (to cause massive diarrhea - Rice-watery diarrhoea ) Classical biotype El Tor biotype [Serotypes: Ogawa (Earlier MC in India ), Inaba and Hikojima ] Recently El Tor Hybrid subtype has become MC in India Incubation period: 1\u20132 days (Few hours\u20135 days) Reservoir: Human beings only Essentials for treatment of cholera : Water and electrolyte replacement ( ORS ) Father of Public Health: Cholera (although some regard John Snow as the same) Most susceptible blood group to cholera : Blood group O (>B > A > AB) History of cholera : \u2013 John Snow (1813-1858): Found the link between cholera and contaminated drinking water (1854 using Spot maps) Robert Koch identified V. cholerae with a microscope as the bacillus causing the disease ( 1885 ). Cholera morbus : Used in 19th and early 20th centuries for both non-epidemic cholera and other gastrointestinal diseases (sometimes epidemic) that resembled cholera.</li><li>\u2022 Cholera is an acute diarrhoel disease caused by Vibrio cholera.</li><li>\u2022 Cholera</li><li>\u2022 acute diarrhoel disease</li><li>\u2022 Vibrio cholera.</li><li>\u2022 Vibrio cholerae : \u2018 Gram-negative bacterium\u2019 that produces cholera toxin (enterotoxin), which act on c-AMP system of mucosal cells of epithelium lining of the small intestine (to cause massive diarrhea - Rice-watery diarrhoea ) Classical biotype El Tor biotype [Serotypes: Ogawa (Earlier MC in India ), Inaba and Hikojima ] Recently El Tor Hybrid subtype has become MC in India</li><li>\u2022 Vibrio cholerae</li><li>\u2022 Gram-negative bacterium\u2019</li><li>\u2022 cholera toxin</li><li>\u2022 c-AMP system</li><li>\u2022 mucosal cells</li><li>\u2022 small intestine</li><li>\u2022 massive diarrhea -</li><li>\u2022 Rice-watery diarrhoea</li><li>\u2022 Classical biotype El Tor biotype [Serotypes: Ogawa (Earlier MC in India ), Inaba and Hikojima ] Recently El Tor Hybrid subtype has become MC in India</li><li>\u2022 Classical biotype</li><li>\u2022 Classical biotype</li><li>\u2022 El Tor biotype [Serotypes: Ogawa (Earlier MC in India ), Inaba and Hikojima ]</li><li>\u2022 El Tor biotype</li><li>\u2022 Ogawa</li><li>\u2022 India</li><li>\u2022 Inaba</li><li>\u2022 Hikojima</li><li>\u2022 Recently El Tor Hybrid subtype has become MC in India</li><li>\u2022 El Tor Hybrid</li><li>\u2022 MC in India</li><li>\u2022 Incubation period: 1\u20132 days (Few hours\u20135 days)</li><li>\u2022 1\u20132 days</li><li>\u2022 Reservoir: Human beings only</li><li>\u2022 Human beings only</li><li>\u2022 Essentials for treatment of cholera : Water and electrolyte replacement ( ORS )</li><li>\u2022 treatment of cholera</li><li>\u2022 Water and electrolyte replacement</li><li>\u2022 ORS</li><li>\u2022 Father of Public Health: Cholera (although some regard John Snow as the same)</li><li>\u2022 Father of Public Health: Cholera</li><li>\u2022 Most susceptible blood group to cholera : Blood group O (>B > A > AB)</li><li>\u2022 blood group to cholera</li><li>\u2022 Blood group O</li><li>\u2022 History of cholera : \u2013 John Snow (1813-1858): Found the link between cholera and contaminated drinking water (1854 using Spot maps)</li><li>\u2022 History of cholera</li><li>\u2022 John Snow</li><li>\u2022 link</li><li>\u2022 cholera and contaminated drinking water</li><li>\u2022 Robert Koch identified V. cholerae with a microscope as the bacillus causing the disease ( 1885 ).</li><li>\u2022 Robert Koch</li><li>\u2022 V. cholerae</li><li>\u2022 microscope</li><li>\u2022 bacillus</li><li>\u2022 disease</li><li>\u2022 1885</li><li>\u2022 Cholera morbus : Used in 19th and early 20th centuries for both non-epidemic cholera and other gastrointestinal diseases (sometimes epidemic) that resembled cholera.</li><li>\u2022 Cholera morbus</li><li>\u2022 19th</li><li>\u2022 early 20th centuries</li><li>\u2022 non-epidemic cholera</li><li>\u2022 gastrointestinal diseases</li><li>\u2022 resembled cholera.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Important Pointers related to El tor type Cholera</li><li>\u27a4 Higher incidence of mild and asymptomatic infections. Classical picture of cholera may not be seen often. Fewer secondary cases in affected families . Chronic carriers are common. More resistant than classical cholera.</li><li>\u27a4 Higher incidence of mild and asymptomatic infections.</li><li>\u27a4 Higher incidence</li><li>\u27a4 mild and asymptomatic infections.</li><li>\u27a4 Classical picture of cholera may not be seen often.</li><li>\u27a4 Classical picture of cholera</li><li>\u27a4 not</li><li>\u27a4 Fewer secondary cases in affected families .</li><li>\u27a4 Fewer secondary cases</li><li>\u27a4 affected families</li><li>\u27a4 Chronic carriers are common.</li><li>\u27a4 Chronic carriers</li><li>\u27a4 common.</li><li>\u27a4 More resistant than classical cholera.</li><li>\u27a4 More resistant</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 680)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e0c2b995",
      "audio": ""
    },
    {
      "text": "A public health officer is working on a cholera outbreak response in a region. One of the key aspects of managing the outbreak is determining when the area can be declared free of cholera. This involves understanding the criteria based on the time elapsed since the last confirmed case. The officer is reviewing these criteria to ensure that the declaration of cholera freedom in the area is based on sound epidemiological principles and to plan for post-outbreak surveillance. When can an area be declared free of cholera after the death or isolation of the last confirmed case?",
      "options": [
        {
          "label": "A",
          "text": "5 days",
          "correct": false
        },
        {
          "label": "B",
          "text": "15 days",
          "correct": false
        },
        {
          "label": "C",
          "text": "10 days",
          "correct": true
        },
        {
          "label": "D",
          "text": "28 days",
          "correct": false
        }
      ],
      "correct_answer": "C. 10 days",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-114333.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0C. 10 days</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 An area is declared free of cholera when twice the incubation period (i.e., 10 days ) has elapsed since the death, recovery or isolation of the last case</li><li>\u2022 An area</li><li>\u2022 free of cholera</li><li>\u2022 twice</li><li>\u2022 incubation period</li><li>\u2022 10 days</li><li>\u2022 elapsed</li><li>\u2022 death, recovery or isolation</li><li>\u2022 last case</li><li>\u2022 Incubation period of Cholera - 1\u20132 days (Few hours\u20135 days)</li><li>\u2022 Incubation period</li><li>\u2022 Cholera</li><li>\u2022 1\u20132 days</li><li>\u2022 Guidelines for Cholera Control (WHO)</li><li>\u2022 Guidelines for Cholera Control (WHO)</li><li>\u2022 Verification of diagnosis : Identifying Vibrio cholerae 01 in stools of few patients is sufficient It is \u2018not necessary to culture stools of all cases or contacts\u2019 Notification: Cholera is a notifiable disease locally, nationally and internationally Under International Health Regulations, Cholera is notifiable to WHO by national govt within 24 hours ( no. of cases & deaths to be reported daily and weekly) An area is declared free of Cholera when twice the IP has elapsed since last case. Early case finding: through aggressive case search Establishment of treatment centres Rehydration therapy: through ORS Adjuncts to therapy: Only antibiotics may be used when vomiting stops</li><li>\u2022 Verification of diagnosis : Identifying Vibrio cholerae 01 in stools of few patients is sufficient It is \u2018not necessary to culture stools of all cases or contacts\u2019</li><li>\u2022 Verification of diagnosis</li><li>\u2022 Identifying Vibrio cholerae 01 in stools of few patients is sufficient It is \u2018not necessary to culture stools of all cases or contacts\u2019</li><li>\u2022 Identifying Vibrio cholerae 01 in stools of few patients is sufficient</li><li>\u2022 Vibrio cholerae 01 in stools</li><li>\u2022 few patients</li><li>\u2022 sufficient</li><li>\u2022 It is \u2018not necessary to culture stools of all cases or contacts\u2019</li><li>\u2022 \u2018not</li><li>\u2022 culture stools</li><li>\u2022 all cases or contacts\u2019</li><li>\u2022 Notification: Cholera is a notifiable disease locally, nationally and internationally Under International Health Regulations, Cholera is notifiable to WHO by national govt within 24 hours ( no. of cases & deaths to be reported daily and weekly) An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 Notification:</li><li>\u2022 Cholera is a notifiable disease locally, nationally and internationally Under International Health Regulations, Cholera is notifiable to WHO by national govt within 24 hours ( no. of cases & deaths to be reported daily and weekly) An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 Cholera is a notifiable disease locally, nationally and internationally</li><li>\u2022 Cholera</li><li>\u2022 locally, nationally and internationally</li><li>\u2022 Under International Health Regulations, Cholera is notifiable to WHO by national govt within 24 hours ( no. of cases & deaths to be reported daily and weekly)</li><li>\u2022 International Health Regulations, Cholera</li><li>\u2022 WHO</li><li>\u2022 national govt</li><li>\u2022 24 hours</li><li>\u2022 no. of cases & deaths</li><li>\u2022 daily and weekly)</li><li>\u2022 An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 area</li><li>\u2022 declared free of Cholera</li><li>\u2022 twice</li><li>\u2022 IP</li><li>\u2022 elapsed since last case.</li><li>\u2022 Early case finding: through aggressive case search</li><li>\u2022 Early case</li><li>\u2022 aggressive case</li><li>\u2022 Establishment of treatment centres</li><li>\u2022 Establishment</li><li>\u2022 treatment centres</li><li>\u2022 Rehydration therapy: through ORS</li><li>\u2022 Rehydration</li><li>\u2022 ORS</li><li>\u2022 Adjuncts to therapy: Only antibiotics may be used when vomiting stops</li><li>\u2022 Adjuncts</li><li>\u2022 antibiotics</li><li>\u2022 vomiting stops</li><li>\u2022 Epidemiological investigations : General sanitation measures, epidemiological studies Sanitation measures: Water control, excreta disposal, food sanitation, disinfection Chemoprophylaxis: Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community . Drug of choice for chemoprophylaxis: Tetracycline To prevent one case of cholera, 10,000 persons need to be given chemoprophylaxis. Vaccination Health education : Most effective prophylactic measure</li><li>\u2022 Epidemiological investigations : General sanitation measures, epidemiological studies</li><li>\u2022 Epidemiological investigations</li><li>\u2022 sanitation</li><li>\u2022 Sanitation measures: Water control, excreta disposal, food sanitation, disinfection</li><li>\u2022 Water control, excreta disposal, food sanitation, disinfection</li><li>\u2022 Chemoprophylaxis: Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community . Drug of choice for chemoprophylaxis: Tetracycline To prevent one case of cholera, 10,000 persons need to be given chemoprophylaxis.</li><li>\u2022 Chemoprophylaxis:</li><li>\u2022 Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community . Drug of choice for chemoprophylaxis: Tetracycline To prevent one case of cholera, 10,000 persons need to be given chemoprophylaxis.</li><li>\u2022 Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community .</li><li>\u2022 Mass</li><li>\u2022 not advised</li><li>\u2022 total community</li><li>\u2022 household contacts</li><li>\u2022 closed community</li><li>\u2022 Drug of choice for chemoprophylaxis: Tetracycline</li><li>\u2022 Drug of choice</li><li>\u2022 Tetracycline</li><li>\u2022 To prevent one case of cholera, 10,000 persons need to be given chemoprophylaxis.</li><li>\u2022 To prevent</li><li>\u2022 10,000</li><li>\u2022 chemoprophylaxis.</li><li>\u2022 Vaccination</li><li>\u2022 Vaccination</li><li>\u2022 Health education : Most effective prophylactic measure</li><li>\u2022 Health education</li><li>\u2022 Most effective</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 An area is declared free of Cholera when twice the IP has elapsed since last case (i.e . 10 days )</li><li>\u27a4 declared free of Cholera</li><li>\u27a4 twice</li><li>\u27a4 IP</li><li>\u27a4 elapsed since last</li><li>\u27a4 case</li><li>\u27a4 . 10 days</li><li>\u27a4 Ref : Park 26 th edition (page 270)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 270)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bc3575d0",
      "audio": ""
    },
    {
      "text": "An epidemiologist working with a global health organization is developing a training module on outbreak response strategies for various infectious diseases. One of the diseases being focused on is cholera, known for its potential to cause rapid and severe outbreaks, especially in areas with poor water and sanitation facilities. The training module aims to outline the key steps and interventions necessary for an effective response to a cholera outbreak. However, it is also important to clarify common misconceptions about what should not be included in these response strategies. The epidemiologist is preparing a question to test the trainees' understanding of these concepts. In the context of an effective response strategy for a cholera outbreak, which of the following steps is NOT typically recommended?",
      "options": [
        {
          "label": "A",
          "text": "Food safety",
          "correct": false
        },
        {
          "label": "B",
          "text": "Immunisation with whole cell killed parenteral vaccine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Proper excreta disposal",
          "correct": false
        },
        {
          "label": "D",
          "text": "Super chlorination of water",
          "correct": false
        }
      ],
      "correct_answer": "B. Immunisation with whole cell killed parenteral vaccine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-114613.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0B. Immunisation with whole cell killed parenteral vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Mass vaccination is not recommended in an outbreak of cholera.</li><li>\u2022 Mass vaccination</li><li>\u2022 not</li><li>\u2022 outbreak of cholera.</li><li>\u2022 Guidelines for Cholera Control (WHO):</li><li>\u2022 Cholera Control (WHO):</li><li>\u2022 Verification of diagnosis: Identifying Vibrio cholerae 01 in stools of few patients is sufficient. It is \u2018 not necessary to culture stools of all cases or contacts\u2019. Notification: Cholera is a notifiable disease locally, nationally and internationally. Under International Health Regulations , Cholera is notifiable to WHO by National Govt within 24 hours (no. of cases & deaths to be reported daily and weekly). An area is declared free of Cholera when twice the IP has elapsed since last case. Early case finding: through aggressive case search Establishment of treatment centres Rehydration therapy: through ORS Adjuncts to therapy: Only antibiotics may be used when vomiting stops.</li><li>\u2022 Verification of diagnosis: Identifying Vibrio cholerae 01 in stools of few patients is sufficient. It is \u2018 not necessary to culture stools of all cases or contacts\u2019.</li><li>\u2022 Identifying Vibrio cholerae 01 in stools of few patients is sufficient. It is \u2018 not necessary to culture stools of all cases or contacts\u2019.</li><li>\u2022 Identifying Vibrio cholerae 01 in stools of few patients is sufficient.</li><li>\u2022 Vibrio cholerae 01</li><li>\u2022 stools</li><li>\u2022 few patients</li><li>\u2022 It is \u2018 not necessary to culture stools of all cases or contacts\u2019.</li><li>\u2022 not necessary</li><li>\u2022 culture</li><li>\u2022 all cases or contacts\u2019.</li><li>\u2022 Notification: Cholera is a notifiable disease locally, nationally and internationally. Under International Health Regulations , Cholera is notifiable to WHO by National Govt within 24 hours (no. of cases & deaths to be reported daily and weekly). An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 Notification:</li><li>\u2022 Cholera is a notifiable disease locally, nationally and internationally. Under International Health Regulations , Cholera is notifiable to WHO by National Govt within 24 hours (no. of cases & deaths to be reported daily and weekly). An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 Cholera is a notifiable disease locally, nationally and internationally.</li><li>\u2022 Cholera is a notifiable disease locally, nationally and internationally.</li><li>\u2022 Cholera</li><li>\u2022 disease locally, nationally and internationally.</li><li>\u2022 Under International Health Regulations , Cholera is notifiable to WHO by National Govt within 24 hours (no. of cases & deaths to be reported daily and weekly).</li><li>\u2022 Under International Health Regulations , Cholera is notifiable to WHO by National Govt within 24 hours (no. of cases & deaths to be reported daily and weekly).</li><li>\u2022 International Health Regulations</li><li>\u2022 Cholera</li><li>\u2022 National Govt</li><li>\u2022 24 hours</li><li>\u2022 An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 An area is declared free of Cholera when twice the IP has elapsed since last case.</li><li>\u2022 free of Cholera</li><li>\u2022 twice</li><li>\u2022 IP</li><li>\u2022 elapsed</li><li>\u2022 last case.</li><li>\u2022 Early case finding: through aggressive case search</li><li>\u2022 Establishment of treatment centres</li><li>\u2022 Rehydration therapy: through ORS</li><li>\u2022 ORS</li><li>\u2022 Adjuncts to therapy: Only antibiotics may be used when vomiting stops.</li><li>\u2022 antibiotics</li><li>\u2022 vomiting stops.</li><li>\u2022 Epidemiological investigations : General sanitation measures, epidemiological studies . Sanitation measures: Water control, excreta disposal , food sanitation, disinfection Chemoprophylaxis: Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community. Drug of choice for chemoprophylaxis: Tetracycline To prevent one case of cholera , 10,000 persons need to be given chemoprophylaxis. Health education : most effective prophylactic measure Vaccination - Mass vaccination is not recommended</li><li>\u2022 Epidemiological investigations : General sanitation measures, epidemiological studies .</li><li>\u2022 Epidemiological investigations</li><li>\u2022 General sanitation</li><li>\u2022 epidemiological studies</li><li>\u2022 Sanitation measures: Water control, excreta disposal , food sanitation, disinfection Chemoprophylaxis: Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community. Drug of choice for chemoprophylaxis: Tetracycline</li><li>\u2022 Sanitation</li><li>\u2022 Water control, excreta disposal</li><li>\u2022 Chemoprophylaxis: Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community. Drug of choice for chemoprophylaxis: Tetracycline</li><li>\u2022 Chemoprophylaxis:</li><li>\u2022 Chemoprophylaxis:</li><li>\u2022 Mass chemoprophylaxis is not advised for total community ; is only advisable for household contacts or a closed community.</li><li>\u2022 not advised</li><li>\u2022 total community</li><li>\u2022 household contacts</li><li>\u2022 closed community.</li><li>\u2022 Drug of choice for chemoprophylaxis: Tetracycline</li><li>\u2022 Drug of choice</li><li>\u2022 Tetracycline</li><li>\u2022 To prevent one case of cholera , 10,000 persons need to be given chemoprophylaxis.</li><li>\u2022 prevent one case of cholera</li><li>\u2022 10,000 persons</li><li>\u2022 chemoprophylaxis.</li><li>\u2022 Health education : most effective prophylactic measure</li><li>\u2022 Health education</li><li>\u2022 most effective</li><li>\u2022 Vaccination - Mass vaccination is not recommended</li><li>\u2022 Mass vaccination</li><li>\u2022 not</li><li>\u2022 CHOLERA ORAL VACCINES</li><li>\u2022 Dukoral * (WC-rBS): Monovalent , V cholera O1 plus Recombinant toxin B subunit Sanchol : Bivalent, Serogroups O1 & O139 , No toxin B subunit, No buffer required mORCVAX : Bivalent, Serogroups O1 & O139 , No toxin B subunit, No buffer required CVD103-HgR : Live attenuated, single dose , not produced now</li><li>\u2022 Dukoral * (WC-rBS): Monovalent , V cholera O1 plus Recombinant toxin B subunit</li><li>\u2022 Dukoral</li><li>\u2022 Monovalent</li><li>\u2022 V cholera O1</li><li>\u2022 toxin B</li><li>\u2022 Sanchol : Bivalent, Serogroups O1 & O139 , No toxin B subunit, No buffer required</li><li>\u2022 Sanchol</li><li>\u2022 Bivalent,</li><li>\u2022 Serogroups O1 & O139</li><li>\u2022 mORCVAX : Bivalent, Serogroups O1 & O139 , No toxin B subunit, No buffer required</li><li>\u2022 mORCVAX</li><li>\u2022 Bivalent, Serogroups O1 & O139</li><li>\u2022 CVD103-HgR : Live attenuated, single dose , not produced now</li><li>\u2022 CVD103-HgR</li><li>\u2022 Live attenuated, single dose</li><li>\u2022 not</li><li>\u2022 * Dukoral \u00ae is mainly used for travellers . Two doses of Dukoral\u00ae provide protection against cholera for 2 years.</li><li>\u2022 Dukoral</li><li>\u2022 travellers</li><li>\u2022 Two doses</li><li>\u2022 protection</li><li>\u2022 cholera</li><li>\u2022 for 2 years.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Steps taken during an outbreak of cholera - Verification of diagnosis , Notification , early case finding, treatment & chemoprophylaxis for household contacts, sanitation measures and health education.</li><li>\u27a4 Steps</li><li>\u27a4 outbreak of cholera</li><li>\u27a4 Verification</li><li>\u27a4 diagnosis</li><li>\u27a4 Notification</li><li>\u27a4 early case</li><li>\u27a4 treatment & chemoprophylaxis</li><li>\u27a4 household contacts,</li><li>\u27a4 sanitation</li><li>\u27a4 health education.</li><li>\u27a4 Mass vaccination is not recommended.</li><li>\u27a4 Mass vaccination</li><li>\u27a4 not</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 680)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab98989e",
      "audio": ""
    },
    {
      "text": "A nurse educator is conducting a training session for a group of nursing students who are about to start their clinical rotations in a travel medicine clinic. The focus of the session is on vaccines, particularly those administered orally, as travellers often seek advice on preventive measures against diseases like cholera. The educator wants to ensure that the students can correctly identify which oral vaccines are specifically for cholera and which are not, as this knowledge is crucial for providing accurate travel health advice. In the context of travel medicine, which of the following oral vaccines is NOT used for the prevention of cholera?",
      "options": [
        {
          "label": "A",
          "text": "Dukoral",
          "correct": false
        },
        {
          "label": "B",
          "text": "Euvichol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lakichol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sanchol",
          "correct": false
        }
      ],
      "correct_answer": "C. Lakichol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Lakichol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 CHOLERA ORAL VACCINES</li><li>\u2022 CHOLERA ORAL VACCINES</li><li>\u2022 Option A. Dukoral (WC-rBS): Monovalent, V cholera O1 plus Recombinant toxin B subunit. Dukoral\u00ae is mainly used for travellers . Two doses of Dukoral \u00ae provide protection against cholera for 2 years .</li><li>\u2022 Option A. Dukoral (WC-rBS):</li><li>\u2022 Monovalent, V cholera O1 plus</li><li>\u2022 Recombinant toxin B subunit.</li><li>\u2022 travellers</li><li>\u2022 Two doses of Dukoral</li><li>\u2022 protection</li><li>\u2022 cholera for 2 years</li><li>\u2022 Option B.  Euvichol and Option D. Sanchol: Bivalent , Serogroups O1 & O139 , No toxin B subunit , No buffer required Shanchol\u2122 and Euvichol\u00ae are essentially the same vaccine produced by two different manufacturers . They do not require a buffer solution for administration. They are given to all individuals over the age of one year . Shanchol\u2122 and Euvichol \u00ae provide protection against cholera for 3 years , while a single dose provides short term protection . Shanchol\u2122 and Euvichol\u00ae are the vaccines currently available for mass vaccination campaigns through the Global OCV Stockpile , which is supported by Gavi, the Vaccine Alliance.</li><li>\u2022 Option B.  Euvichol and Option D. Sanchol: Bivalent</li><li>\u2022 Serogroups O1 & O139</li><li>\u2022 No toxin B subunit</li><li>\u2022 No buffer</li><li>\u2022 same vaccine</li><li>\u2022 two different manufacturers</li><li>\u2022 do not</li><li>\u2022 buffer solution</li><li>\u2022 administration.</li><li>\u2022 all individuals</li><li>\u2022 over</li><li>\u2022 one year</li><li>\u2022 Shanchol\u2122 and Euvichol \u00ae</li><li>\u2022 cholera</li><li>\u2022 3 years</li><li>\u2022 single dose</li><li>\u2022 short term</li><li>\u2022 protection</li><li>\u2022 mass vaccination</li><li>\u2022 Global OCV Stockpile</li><li>\u2022 supported</li><li>\u2022 Gavi,</li><li>\u2022 Other Vaccines:</li><li>\u2022 Other Vaccines:</li><li>\u2022 Morcvax : Bivalent, Serogroups O1 & O139 , No toxin B subunit , No buffer required</li><li>\u2022 Morcvax</li><li>\u2022 Bivalent,</li><li>\u2022 O1 & O139</li><li>\u2022 No toxin B subunit</li><li>\u2022 No buffer</li><li>\u2022 CVD103-HgR : Live attenuated, single dose , NOT produced now</li><li>\u2022 CVD103-HgR</li><li>\u2022 Live attenuated, single dose</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Three types of oral cholera vaccines are available: (A) Dukoral (WC-rBS). (D) Sanchol and mORCVAX and (B) Euvichol. The live attenuated single-dose vaccine (CVD103-HgR) is no longer produced.</li><li>\u27a4 oral cholera vaccines</li><li>\u27a4 Ref : Park 26 th edition (page 267)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 267)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "27b8c081",
      "audio": ""
    },
    {
      "text": "A medical researcher is reviewing diagnostic protocols for various bacterial infections. One of the conditions under discussion is typhoid fever, caused by Salmonella typhi. Accurate and timely diagnosis is crucial for the effective management of typhoid fever. The researcher is learning about the various methods used to diagnose this condition and is asked to identify the mainstay of diagnosis for typhoid fever. What is the mainstay of diagnosis for typhoid fever?",
      "options": [
        {
          "label": "A",
          "text": "Blood culture",
          "correct": true
        },
        {
          "label": "B",
          "text": "Gastric aspirate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stool culture",
          "correct": false
        },
        {
          "label": "D",
          "text": "Widal test",
          "correct": false
        }
      ],
      "correct_answer": "A. Blood culture",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-124354.png"
      ],
      "explanation": "<p><strong>Ans. A. Blood culture</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Gastric aspirate: Not used due to low yield</li><li>\u2022 Option B. Gastric aspirate:</li><li>\u2022 Option C. Stool Culture :  Stool cultures can be used for the diagnosis of typhoid fever, particularly in the later stages (3rd week) of the disease.</li><li>\u2022 Option C. Stool Culture</li><li>\u2022 diagnosis</li><li>\u2022 typhoid fever,</li><li>\u2022 later stages (3rd week)</li><li>\u2022 Option D. Widal test: The Widal test, which measures agglutinating antibody levels against Salmonella antigens , It has Moderate sensitivity & specificity .  It is used in settings where blood culture facilities are not available.</li><li>\u2022 Option D. Widal test:</li><li>\u2022 agglutinating antibody levels</li><li>\u2022 Salmonella antigens</li><li>\u2022 Moderate sensitivity & specificity</li><li>\u2022 blood culture</li><li>\u2022 not</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mainstay of diagnosis of Typhoid fever - Blood Culture</li><li>\u27a4 Laboratory Diagnosis: \u2018BASU\u2019 Mnemonic</li><li>\u27a4 \u2018BASU\u2019</li><li>\u27a4 Ref : Park 26 th edition (page 273)</li><li>\u27a4 Ref : Park 26 th edition (page 273)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "735c2213",
      "audio": ""
    },
    {
      "text": "During a session on vaccine-preventable diseases in a medical school, a professor is discussing various vaccines used for the prevention of typhoid fever. Typhoid fever, caused by Salmonella typhi, can be effectively prevented with vaccination. However, not all types of vaccines are used for this purpose. The professor presents a question to the medical students to identify which of the listed vaccines is not typically used for the prevention of typhoid fever. Which of the following vaccines is NOT used for the prevention of typhoid fever?",
      "options": [
        {
          "label": "A",
          "text": "Heat killed whole cell vaccine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Live oral vaccine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Typhoid conjugate vaccine",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Heat killed whole cell vaccine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123808.png"
      ],
      "explanation": "<p><strong>Ans. A. Heat killed whole cell vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B.  Live Oral Vaccine : Typhoral Ty21a vaccine . Contains >109 viable organism of attenuated S. typhi . Schedule: One capsule each on days 1, 3, 5 ( booster of 3 doses , once every 3 years ).</li><li>\u2022 Option B.  Live Oral Vaccine</li><li>\u2022 Typhoral Ty21a vaccine</li><li>\u2022 >109</li><li>\u2022 attenuated S. typhi</li><li>\u2022 days 1, 3, 5</li><li>\u2022 booster</li><li>\u2022 3 doses</li><li>\u2022 once</li><li>\u2022 3 years</li><li>\u2022 Option C.  Typhoid conjugate vaccine - TYPHIM Vi Vaccine. Vi- Polysaccharide containing single dose I/m or subcutaneous. Not given in age < 2 years.</li><li>\u2022 Option C.  Typhoid conjugate vaccine</li><li>\u2022 TYPHIM Vi</li><li>\u2022 Vi- Polysaccharide</li><li>\u2022 single</li><li>\u2022 I/m or subcutaneous.</li><li>\u2022 Not</li><li>\u2022 < 2 years.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Two safe and effective vaccines are now licensed and available against typhoid - Vi polysaccharide vaccine and Ty21a vaccine</li><li>\u27a4 Two safe and effective</li><li>\u27a4 licensed</li><li>\u27a4 available</li><li>\u27a4 typhoid - Vi polysaccharide vaccine</li><li>\u27a4 Ty21a vaccine</li><li>\u27a4 Immunization for Typhoid Fever -</li><li>\u27a4 Ref : Park 26 th edition (page 275)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 275)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3252dc0a",
      "audio": ""
    },
    {
      "text": "An infectious disease specialist is giving a lecture to medical students about various vaccination strategies for preventing globally prevalent diseases. The discussion includes vaccines that are not routinely administered in all countries but are crucial for specific diseases in endemic areas or for travelers. A focus of the lecture is on the Ty21a vaccine for typhoid fever. The specialist aims to test the students' understanding of the unique attributes of the Ty21a vaccine, particularly how it differs from other common vaccines in terms of administration and scheduling. In a lecture about vaccination strategies against typhoid fever, which point should the infectious disease specialist emphasize to highlight a unique characteristic of the Ty21a vaccine?",
      "options": [
        {
          "label": "A",
          "text": "Is orally administered.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Given for individuals aged more than 2 years.",
          "correct": true
        },
        {
          "label": "C",
          "text": "3 dose regimen is recommended on alternate days.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Protective immunity is achieved 7 days after last dose.",
          "correct": false
        }
      ],
      "correct_answer": "B. Given for individuals aged more than 2 years.",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/24/screenshot-2024-08-24-155851.png"
      ],
      "explanation": "<p><strong>Ans. B. Given for individuals aged more than 2 years.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The vaccine is licensed for use in individual aged > 5 years.</li><li>\u2022 licensed</li><li>\u2022 individual aged > 5 years.</li><li>\u2022 Other 3 options are correct</li><li>\u2022 Other 3 options</li><li>\u2022 correct</li><li>\u2022 Ty21a vaccine:</li><li>\u2022 Ty21a vaccine:</li><li>\u2022 Orally administered (Option A) live attenuated , lyophilized vaccine for Typhoid.  Contains >10 9 viable organism of attenuated S. typhi.</li><li>\u2022 Orally administered (Option A)</li><li>\u2022 live attenuated</li><li>\u2022 lyophilized</li><li>\u2022 >10 9 viable organism</li><li>\u2022 attenuated S. typhi.</li><li>\u2022 The capsules are licensed for use in individuals aged >5 years.</li><li>\u2022 capsules</li><li>\u2022 licensed</li><li>\u2022 aged >5 years.</li><li>\u2022 The vaccine is administered every other day; on 1, 3, and 5th day ; a 3-dose regimen is recommended . (Option C)</li><li>\u2022 vaccine</li><li>\u2022 administered</li><li>\u2022 1, 3, and 5th day</li><li>\u2022 3-dose</li><li>\u2022 regimen</li><li>\u2022 . (Option C)</li><li>\u2022 With the 3-dose regimen , protective immunity is achieved 7 days after the last dose . (Option D)</li><li>\u2022 3-dose regimen</li><li>\u2022 immunity</li><li>\u2022 7 days after</li><li>\u2022 last dose</li><li>\u2022 (Option D)</li><li>\u2022 The recommendation is to repeat this series every 3 years for people living in endemic areas , and every year for individuals travelling ; from non-endemic to endemic countries .</li><li>\u2022 recommendation</li><li>\u2022 3 years</li><li>\u2022 endemic areas</li><li>\u2022 every year</li><li>\u2022 individuals travelling</li><li>\u2022 non-endemic</li><li>\u2022 endemic countries</li><li>\u2022 The Ty21a vaccine may be given simultaneously with other vaccines , including live vaccines against polio, cholera, and yellow fever , or the measles, mumps and rubella (MMR) combination.</li><li>\u2022 Ty21a vaccine</li><li>\u2022 simultaneously</li><li>\u2022 other vaccines</li><li>\u2022 live vaccines</li><li>\u2022 polio, cholera, and yellow fever</li><li>\u2022 measles, mumps</li><li>\u2022 rubella (MMR)</li><li>\u2022 Note - Stop Proguanil and antibacterial drugs 3 days before and until 3 days later of administration.</li><li>\u2022 Stop Proguanil</li><li>\u2022 antibacterial drugs 3 days before</li><li>\u2022 3 days</li><li>\u2022 later of administration.</li><li>\u2022 Immunization for Typhoid Fever</li><li>\u2022 Immunization for Typhoid Fever</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ty21a vaccine - Orally administered, live attenuated, lyophilized vaccine , for individuals aged >5 years , 3-dose regimen (administered every other day</li><li>\u27a4 Ty21a vaccine</li><li>\u27a4 Orally</li><li>\u27a4 live attenuated, lyophilized vaccine</li><li>\u27a4 >5 years</li><li>\u27a4 3-dose regimen</li><li>\u27a4 on 1, 3, and 5th day ), protective immunity is achieved 7 days after the last dose .</li><li>\u27a4 1, 3, and 5th day</li><li>\u27a4 protective immunity</li><li>\u27a4 7 days after the last dose</li><li>\u27a4 Ref : Park 26 th edition (page 275)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 275)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e11a4958",
      "audio": ""
    },
    {
      "text": "A group of individuals presented to a clinic with symptoms of abdominal cramps, diarrhea, and vomiting approximately 2 hours after consuming a milkshake from a local eatery. As a medical resident in gastroenterology, you are tasked with determining the most likely etiological agent responsible for these symptoms. Given the rapid onset of symptoms and the nature of the consumed product, you consider various foodborne pathogens that could be involved. Based on the symptoms and their rapid onset following the consumption of a milkshake, what is the most likely etiological agent responsible for the illness in these individuals?",
      "options": [
        {
          "label": "A",
          "text": "Campylobacter",
          "correct": false
        },
        {
          "label": "B",
          "text": "Clostridium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Salmonella",
          "correct": false
        },
        {
          "label": "D",
          "text": "Staphylococcus",
          "correct": true
        }
      ],
      "correct_answer": "D. Staphylococcus",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123108_XcxG8VU.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123453.png"
      ],
      "explanation": "<p><strong>Ans. D. Staphylococcus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Campylobacter: An infection caused by gram negative bacteria usually from contaminated food and water. Infections are often associated with international travel, undercooked poultry, unpasteurized milk, untreated water, and contact with farm animals . It causes diarrhea which may be bloody, cramping, abdominal pain, and fever within two to five days after exposure to the bacteria . Nausea (a feeling of sickness in the stomach) and vomiting may also occur. The illness typically lasts about one week.</li><li>\u2022 Option A. Campylobacter:</li><li>\u2022 gram negative bacteria</li><li>\u2022 contaminated food and water.</li><li>\u2022 undercooked poultry, unpasteurized milk, untreated</li><li>\u2022 water, and contact</li><li>\u2022 farm animals</li><li>\u2022 diarrhea</li><li>\u2022 bloody,</li><li>\u2022 cramping, abdominal pain, and fever</li><li>\u2022 two to five days</li><li>\u2022 . Nausea</li><li>\u2022 vomiting</li><li>\u2022 lasts</li><li>\u2022 one week.</li><li>\u2022 Option B. Clostridium 2 types:  Botulism food poisoning by Clostridium botulinum type A, B, E ; IP 12\u201336 hours ; food poisoning is due to Intra-dietetic toxins ; prominent symptoms are Dysphagia, Diplopia and Dysarthria (GIT SYMPOTOMS ARE SLIGHT).</li><li>\u2022 Option</li><li>\u2022 B. Clostridium 2 types:  Botulism food poisoning</li><li>\u2022 Clostridium botulinum</li><li>\u2022 A, B, E</li><li>\u2022 IP 12\u201336 hours</li><li>\u2022 Intra-dietetic</li><li>\u2022 toxins</li><li>\u2022 Dysphagia, Diplopia and Dysarthria</li><li>\u2022 Clostridium perfringens food poisoning by Clostridium perfringens (welchii); IP 6\u201324 hours , found on raw meat and poultry , in the soil , excreta . Symptoms are watery diarrhea and abdominal cramps . Rapid recovery with no deaths.</li><li>\u2022 Clostridium perfringens food poisoning</li><li>\u2022 Clostridium perfringens</li><li>\u2022 IP 6\u201324 hours</li><li>\u2022 raw meat and poultry</li><li>\u2022 soil</li><li>\u2022 excreta</li><li>\u2022 watery diarrhea and abdominal cramps</li><li>\u2022 Rapid recovery</li><li>\u2022 no deaths.</li><li>\u2022 Option C. Salmonella: Salmonella bacteria spread by improper handling and cooking of food . Occurs by eating contaminated food such as undercooked pork and poultry meat, dairy products made from unpasteurized milk , chocolate or raw fruit and vegetables . IP 12-24 hr . Some people with salmonella infection have no symptoms . Most people develop diarrhea , fever and stomach (abdominal) cramps within 12 to 72 hours after exposure. Most healthy people recover within a few days to a week without specific treatment.</li><li>\u2022 Option C. Salmonella:</li><li>\u2022 improper handling</li><li>\u2022 cooking of food</li><li>\u2022 eating contaminated food</li><li>\u2022 undercooked pork</li><li>\u2022 poultry meat, dairy products</li><li>\u2022 unpasteurized milk</li><li>\u2022 chocolate</li><li>\u2022 raw fruit and vegetables</li><li>\u2022 12-24 hr</li><li>\u2022 Some people</li><li>\u2022 no symptoms</li><li>\u2022 develop diarrhea</li><li>\u2022 fever and stomach</li><li>\u2022 cramps</li><li>\u2022 12 to 72 hours</li><li>\u2022 healthy</li><li>\u2022 recover within a few days</li><li>\u2022 week</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Incubation period of food poisoning:</li><li>\u27a4 Incubation period of food poisoning:</li><li>\u27a4 Some food poisoning causing organisms</li><li>\u27a4 Some food poisoning causing organisms</li><li>\u27a4 Ref : Park 26 th edition (page 276)</li><li>\u27a4 Ref : Park 26 th edition (page 276)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7f3a544a",
      "audio": ""
    },
    {
      "text": "As part of an epidemiology class focusing on foodborne illnesses, medical students are learning about various pathogens and their associated incubation periods. Understanding these incubation periods is crucial for diagnosing foodborne illnesses and identifying the likely causative agents. The professor has provided a list of common foodborne pathogens and a separate list of their typical incubation periods. The students are asked to match each pathogen with its corresponding incubation period. Task: Match the following pathogens with their respective incubation periods for food poisoning.",
      "options": [
        {
          "label": "A",
          "text": "i- c, ii- b, iii- a, iv-d",
          "correct": true
        },
        {
          "label": "B",
          "text": "i- c, ii- a, iii- b, iv-d",
          "correct": false
        },
        {
          "label": "C",
          "text": "i- d, ii- b, iii- a, iv-c",
          "correct": false
        },
        {
          "label": "D",
          "text": "i- d, ii- a, iii- b, iv-c",
          "correct": false
        }
      ],
      "correct_answer": "A. i- c, ii- b, iii- a, iv-d",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-120803.png"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-123108.png"
      ],
      "explanation": "<p><strong>Ans. A. i- c, ii- b, iii- a, iv-d</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Incubation Period of Food Poisonings</li><li>\u2022 Some Important Pointers on Food Poisoning -</li><li>\u2022 MC food poisoning - Staphylococcus Food poisoning in less than 6 hours - Staphylococcal FP Prominent symptoms in Botulism FP: Dysphagia, Diplopia, Dysarthria (GIT sympotoms are slight) Food poisoning is an example of: Common source, single exposure epidemic.</li><li>\u2022 MC food poisoning - Staphylococcus</li><li>\u2022 MC food poisoning</li><li>\u2022 Staphylococcus</li><li>\u2022 Food poisoning in less than 6 hours - Staphylococcal FP</li><li>\u2022 less than 6 hours</li><li>\u2022 Staphylococcal FP</li><li>\u2022 Prominent symptoms in Botulism FP: Dysphagia, Diplopia, Dysarthria (GIT sympotoms are slight)</li><li>\u2022 Botulism FP:</li><li>\u2022 Dysphagia, Diplopia, Dysarthria</li><li>\u2022 Food poisoning is an example of: Common source, single exposure epidemic.</li><li>\u2022 Food poisoning</li><li>\u2022 Common source, single exposure epidemic.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Incubation period of food poisoning : Salmonella 12\u201324 hours , Staphylococcal 1\u20136 hours, Botulism 12\u201336 hours, Cl. perfirengens 6\u201324 hours, B. cereus (emetic form) 1\u20136 hours , B. cereus (diarrhoel form) 12\u201324 hours</li><li>\u27a4 Incubation period</li><li>\u27a4 food poisoning</li><li>\u27a4 Salmonella 12\u201324 hours</li><li>\u27a4 Staphylococcal 1\u20136 hours, Botulism 12\u201336 hours, Cl. perfirengens 6\u201324 hours, B. cereus</li><li>\u27a4 1\u20136 hours</li><li>\u27a4 B. cereus</li><li>\u27a4 12\u201324 hours</li><li>\u27a4 Ref: Park 26 th edition (page 277)</li><li>\u27a4 Ref: Park 26 th edition (page 277)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "370eba51",
      "audio": ""
    },
    {
      "text": "A medical resident is participating in an epidemiology training focused on the investigation of food poisoning outbreaks. Understanding the investigative process is crucial for identifying the source of the outbreak, implementing control measures, and preventing future occurrences. The training covers various aspects of outbreak investigation, including the identification of the pathogen, interviewing affected individuals, and inspecting food handling facilities. The resident is asked to identify a true statement regarding the investigation of a food poisoning outbreak. Which of the following statements is true regarding the investigation of a food poisoning outbreak?",
      "options": [
        {
          "label": "A",
          "text": "Both affected and not affected persons are interviewed",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hospitalized persons are interviewed",
          "correct": false
        },
        {
          "label": "C",
          "text": "Only affected persons are interviewed",
          "correct": false
        },
        {
          "label": "D",
          "text": "Only not affected persons are interviewed",
          "correct": false
        }
      ],
      "correct_answer": "A. Both affected and not affected persons are interviewed",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Both affected and not affected persons are interviewed</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Getting food history about suspected meal in a food poisoning outbreak:</li><li>\u2022 food history</li><li>\u2022 suspected meal in a food poisoning</li><li>\u2022 List of each and every dish which was served during that meal is made. Each and every person who attended the meal is interviewed. History of consumption of each and every food item that was served during that meal is noted. Information is recorded.</li><li>\u2022 List of each and every dish which was served during that meal is made.</li><li>\u2022 List of each and every dish</li><li>\u2022 served</li><li>\u2022 meal</li><li>\u2022 made.</li><li>\u2022 Each and every person who attended the meal is interviewed.</li><li>\u2022 Each</li><li>\u2022 every person</li><li>\u2022 attended the meal</li><li>\u2022 interviewed.</li><li>\u2022 History of consumption of each and every food item that was served during that meal is noted.</li><li>\u2022 History of consumption</li><li>\u2022 food item</li><li>\u2022 served</li><li>\u2022 meal is noted.</li><li>\u2022 Information is recorded.</li><li>\u2022 Information</li><li>\u2022 recorded.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 During the Investigation of food poisoning outbreak - Both affected and not affected persons must be interviewed</li><li>\u27a4 During the Investigation</li><li>\u27a4 food poisoning outbreak</li><li>\u27a4 Both affected and not affected</li><li>\u27a4 must</li><li>\u27a4 interviewed</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 672)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 672)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "89ebbd14",
      "audio": ""
    },
    {
      "text": "A health policy analyst is evaluating various national health initiatives to provide recommendations for resource allocation. One of the programs under review is the National Viral Hepatitis Control Program, which aims to address the public health challenge of viral hepatitis. The analyst is assessing the program's objectives to determine how well they align with broader public health goals. Understanding the specific aims of the program is crucial for this evaluation, and the analyst needs to identify a goal that is not a part of the program\u2019s objectives. In the context of evaluating the National Viral Hepatitis Control Program, which of the following is NOT an objective of the program?",
      "options": [
        {
          "label": "A",
          "text": "To eliminate viral hepatitis as a public health problem.",
          "correct": false
        },
        {
          "label": "B",
          "text": "To ensure universal access to hepatitis C vaccines",
          "correct": true
        },
        {
          "label": "C",
          "text": "To provide accessible and affordable treatment for hepatitis B and C.",
          "correct": false
        },
        {
          "label": "D",
          "text": "To promote awareness and screening for viral hepatitis",
          "correct": false
        }
      ],
      "correct_answer": "B. To ensure universal access to hepatitis C vaccines",
      "question_images": [],
      "explanation_images": [
        "https://nvhcp.mohfw.gov.in/assets/images/mainlogo.png"
      ],
      "explanation": "<p><strong>Ans. B. To ensure universal access to hepatitis C vaccines</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. To eliminate viral hepatitis as a public health problem: This is typically a primary objective of national viral hepatitis programs , aiming to reduce the incidence and impact of the disease to non-threatening levels .</li><li>\u2022 Option A. To eliminate viral hepatitis as a public health problem:</li><li>\u2022 primary objective of national viral hepatitis programs</li><li>\u2022 reduce</li><li>\u2022 incidence and impact</li><li>\u2022 disease</li><li>\u2022 non-threatening levels</li><li>\u2022 Option C. To provide accessible and affordable treatment for hepatitis B and C : One of the key objectives of program is to ensure that treatment for Hepatitis B and Hepatitis C is accessible and affordable , aiming to ending Viral Hepatitis by 2030 (SDG 3.3).</li><li>\u2022 Option C.</li><li>\u2022 To provide accessible and affordable treatment for hepatitis B and C</li><li>\u2022 treatment</li><li>\u2022 Hepatitis B and Hepatitis C</li><li>\u2022 accessible and affordable</li><li>\u2022 ending Viral Hepatitis</li><li>\u2022 2030 (SDG 3.3).</li><li>\u2022 Option D. To promote awareness and screening for viral hepatitis: Raising awareness and promoting screening are common objectives, as early detection and public knowledge are crucial for control and prevention.</li><li>\u2022 Option D. To promote awareness and screening for viral hepatitis:</li><li>\u2022 Raising awareness</li><li>\u2022 promoting screening</li><li>\u2022 early detection</li><li>\u2022 public knowledge</li><li>\u2022 control and prevention.</li><li>\u2022 Some important Pointers</li><li>\u2022 Some important Pointers</li><li>\u2022 The National Viral Hepatitis Control Program has been launched by Ministry of Health and Family Welfare , Government of India on the occasion of the World Hepatitis Day, 28th July 2018.</li><li>\u2022 National Viral Hepatitis Control Program</li><li>\u2022 Ministry of</li><li>\u2022 Health and Family Welfare</li><li>\u2022 India</li><li>\u2022 World Hepatitis Day, 28th July 2018.</li><li>\u2022 Aim:</li><li>\u2022 Combat hepatitis and achieve country-wide elimination of Hepatitis C by 2030; Achieve significant reduction in the infected population , morbidity , and mortality associated with Hepatitis B and C Viz. Cirrhosis and Hepatocellular carcinoma (liver cancer); Reduce the risk, morbidity and mortality due to Hepatitis A and E.</li><li>\u2022 Combat hepatitis and achieve country-wide elimination of Hepatitis C by 2030;</li><li>\u2022 Combat hepatitis</li><li>\u2022 country-wide elimination of Hepatitis C</li><li>\u2022 2030;</li><li>\u2022 Achieve significant reduction in the infected population , morbidity , and mortality associated with Hepatitis B and C Viz. Cirrhosis and Hepatocellular carcinoma (liver cancer);</li><li>\u2022 reduction</li><li>\u2022 infected population</li><li>\u2022 morbidity</li><li>\u2022 mortality</li><li>\u2022 Hepatitis B and C</li><li>\u2022 Cirrhosis and Hepatocellular carcinoma (liver cancer);</li><li>\u2022 Reduce the risk, morbidity and mortality due to Hepatitis A and E.</li><li>\u2022 Reduce</li><li>\u2022 risk, morbidity and mortality</li><li>\u2022 Hepatitis A and E.</li><li>\u2022 The key components include:</li><li>\u2022 1. Preventive component : This remains the cornerstone of the NVHCP . It will include</li><li>\u2022 Preventive component</li><li>\u2022 NVHCP</li><li>\u2022 Awareness generation Immunization of Hepatitis B (birth dose, high risk groups, health care workers) Safety of blood and blood products Injection safety , safe socio-cultural practices Safe drinking water, hygiene and sanitary toilets</li><li>\u2022 Awareness generation</li><li>\u2022 Immunization of Hepatitis B (birth dose, high risk groups, health care workers)</li><li>\u2022 Hepatitis B</li><li>\u2022 Safety of blood and blood products</li><li>\u2022 Safety of blood and blood products</li><li>\u2022 Injection safety , safe socio-cultural practices</li><li>\u2022 Injection safety</li><li>\u2022 Safe drinking water, hygiene and sanitary toilets</li><li>\u2022 Safe drinking water, hygiene and sanitary toilets</li><li>\u2022 2 . Diagnosis and Treatment :</li><li>\u2022 . Diagnosis and Treatment</li><li>\u2022 Screening of pregnant women for HBsAg to be done in areas where institutional deliveries are < 80% to ensure their referral for institutional delivery for birth dose Hepatitis B vaccination. Free screening, diagnosis and treatment for both hepatitis B and C would be made available at all levels of health care in a phased manner. Provision of linkages , including with private sector and not-for-profit institutions , for diagnosis and treatment. Engagement with community/peer support to enhance and ensure adherence to treatment and demand generation .</li><li>\u2022 Screening of pregnant women for HBsAg to be done in areas where institutional deliveries are < 80% to ensure their referral for institutional delivery for birth dose Hepatitis B vaccination.</li><li>\u2022 Screening</li><li>\u2022 pregnant women</li><li>\u2022 HBsAg</li><li>\u2022 < 80%</li><li>\u2022 referral</li><li>\u2022 institutional delivery for birth</li><li>\u2022 Hepatitis B vaccination.</li><li>\u2022 Free screening, diagnosis and treatment for both hepatitis B and C would be made available at all levels of health care in a phased manner.</li><li>\u2022 Free screening, diagnosis and treatment</li><li>\u2022 both hepatitis B and C</li><li>\u2022 at all levels</li><li>\u2022 health care</li><li>\u2022 Provision of linkages , including with private sector and not-for-profit institutions , for diagnosis and treatment.</li><li>\u2022 linkages</li><li>\u2022 private sector</li><li>\u2022 not-for-profit</li><li>\u2022 institutions</li><li>\u2022 diagnosis and treatment.</li><li>\u2022 Engagement with community/peer support to enhance and ensure adherence to treatment and demand generation .</li><li>\u2022 Engagement</li><li>\u2022 community/peer support</li><li>\u2022 treatment and demand generation</li><li>\u2022 3. Monitoring and Evaluation, Surveillance and Research Effective linkages to the surveillance system would be established and operational research would be undertaken through Department of Health Research (DHR). Standardised M&E framework would be developed and an online web based system established.</li><li>\u2022 Monitoring and Evaluation, Surveillance</li><li>\u2022 Research Effective</li><li>\u2022 surveillance system</li><li>\u2022 established</li><li>\u2022 operational research</li><li>\u2022 Department of Health Research (DHR).</li><li>\u2022 Standardised M&E</li><li>\u2022 developed</li><li>\u2022 online web</li><li>\u2022 established.</li><li>\u2022 4. Training and Capacity Building:</li><li>\u2022 Training and Capacity Building:</li><li>\u2022 This would be a continuous process and will be supported by NCDC, ILBS and state tertiary care institutes and coordinated by NVHCP . The hepatitis induction and update programs for all level of health care workers would be made available using both, the traditional cascade model of training through master trainers and various platforms available for enabling electronic , e-learning and e-courses.</li><li>\u2022 continuous process</li><li>\u2022 NCDC, ILBS</li><li>\u2022 state tertiary care institutes</li><li>\u2022 coordinated by NVHCP</li><li>\u2022 hepatitis induction</li><li>\u2022 update programs</li><li>\u2022 all level of health care workers</li><li>\u2022 traditional cascade</li><li>\u2022 training</li><li>\u2022 master trainers</li><li>\u2022 enabling electronic</li><li>\u2022 e-learning and e-courses.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National viral hepatitis control programs aim to eliminate the disease as a public health problem , provide treatment, and promote awareness and screening , they do not typically include the objective of ensuring universal access to hepatitis C vaccines , mainly due to the current unavailability of such vaccines.</li><li>\u27a4 National viral hepatitis</li><li>\u27a4 aim</li><li>\u27a4 eliminate</li><li>\u27a4 disease</li><li>\u27a4 public health problem</li><li>\u27a4 provide treatment,</li><li>\u27a4 promote awareness</li><li>\u27a4 screening</li><li>\u27a4 do not</li><li>\u27a4 objective</li><li>\u27a4 ensuring universal access to hepatitis C vaccines</li><li>\u27a4 due</li><li>\u27a4 unavailability</li><li>\u27a4 vaccines.</li><li>\u27a4 Ref: https://www.nhp.gov.in/national-viral-hepatitis-control-program-(nvhcp)_pg</li><li>\u27a4 Ref:</li><li>\u27a4 https://www.nhp.gov.in/national-viral-hepatitis-control-program-(nvhcp)_pg</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "05d4136e",
      "audio": ""
    },
    {
      "text": "A medical intern is conducting a session for healthcare workers on the management of dehydration in diarrheal diseases, emphasizing the use of Oral Rehydration Solutions (ORS). The session includes a discussion on the composition of reduced osmolarity ORS, which is designed to be more effective and have fewer side effects than standard ORS formulations. The intern is aware of some common misconceptions about the composition of reduced osmolarity ORS and aims to address these during the session. Which of the following statements about the composition of reduced osmolarity ORS is NOT correct?",
      "options": [
        {
          "label": "A",
          "text": "Chloride \u2013 65 mmol/ litre",
          "correct": false
        },
        {
          "label": "B",
          "text": "Citrate \u2013 10 mmol/ litre",
          "correct": false
        },
        {
          "label": "C",
          "text": "Potassium \u2013 10 mmol/ litre",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sodium \u2013 75 mmol/ litre",
          "correct": false
        }
      ],
      "correct_answer": "C. Potassium \u2013 10 mmol/ litre",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture32_SCVUL8k.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Potassium \u2013 10 mmol/litre</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chloride \u2013 65 mmol/ litre. Correct</li><li>\u2022 Option A. Chloride \u2013 65 mmol/ litre. Correct</li><li>\u2022 Option B. Citrate \u2013 10 mmol/ litre. Correct</li><li>\u2022 Option B. Citrate \u2013 10 mmol/ litre. Correct</li><li>\u2022 Option D. Sodium \u2013 75 mmol/ litre. Correct</li><li>\u2022 Option D. Sodium \u2013 75 mmol/ litre. Correct</li><li>\u2022 Reduced osmolarity ORS: Total osmolarity - 245 mmol/ litre</li><li>\u2022 Comparison of different types of ORS solutions -</li><li>\u2022 -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 WHO Reduced Osmolarity ORS contains (in mmol/L) - Sodium 75, Potassium 20 , Chloride 65 , Citrate 10 , Glucose 75; Total Osmolar concentration is 245 mmol/L. Ratio of Sodium : Glucose in WHO Reduced Osmolarity ORS - 1 : 1</li><li>\u27a4 WHO Reduced Osmolarity ORS contains (in mmol/L) - Sodium 75, Potassium 20 , Chloride 65 , Citrate 10 , Glucose 75; Total Osmolar concentration is 245 mmol/L.</li><li>\u27a4 WHO</li><li>\u27a4 Reduced Osmolarity ORS</li><li>\u27a4 Sodium 75,</li><li>\u27a4 Potassium 20</li><li>\u27a4 Chloride 65</li><li>\u27a4 Citrate 10</li><li>\u27a4 Glucose 75;</li><li>\u27a4 Total Osmolar</li><li>\u27a4 concentration</li><li>\u27a4 245 mmol/L.</li><li>\u27a4 Ratio of Sodium : Glucose in WHO Reduced Osmolarity ORS - 1 : 1</li><li>\u27a4 Ratio of Sodium</li><li>\u27a4 Glucose</li><li>\u27a4 WHO</li><li>\u27a4 1 : 1</li><li>\u27a4 Ref : Park 26 th edition (page 261)</li><li>\u27a4 Ref : Park 26 th edition (page 261)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4da21c4f",
      "audio": ""
    },
    {
      "text": "A two-year-old child is brought to the emergency department by his parents with symptoms of diarrhea and vomiting for the past 24 hours. The child appears lethargic, and the parents report that he has not had a wet diaper in over 6 hours. The medical team is assessing the child for dehydration, a common complication of gastrointestinal illness in young children. One of the residents is tasked with evaluating the severity of the child's dehydration to determine the appropriate treatment plan. In assessing the severity of dehydration in this two-year-old child, which of the following is NOT a clinical findings would most likely indicate SEVERE dehydration?",
      "options": [
        {
          "label": "A",
          "text": "Rapid and feeble pulse",
          "correct": false
        },
        {
          "label": "B",
          "text": "Skin pinch retracts on 4 seconds",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thirsty and restless",
          "correct": true
        },
        {
          "label": "D",
          "text": "Very dry tongue",
          "correct": false
        }
      ],
      "correct_answer": "C. Thirsty and restless",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture33.jpg"
      ],
      "explanation": "<p><strong>Ans. C. Thirsty and restless</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Thirsty and restless is symptom of Some Dehydration , NOT Severe</li><li>\u2022 Thirsty and restless</li><li>\u2022 Some Dehydration</li><li>\u2022 NOT</li><li>\u2022 Other 3 options are sign/ symptoms of Severe Dehydration.</li><li>\u2022 Other 3 options</li><li>\u2022 sign/ symptoms</li><li>\u2022 Severe Dehydration.</li><li>\u2022 Sign/ symptom of Severe dehydration :</li><li>\u2022 Sign/ symptom</li><li>\u2022 Severe dehydration</li><li>\u2022 Patient appearance- Drowsy, limp, cold, sweaty, maybe comatose. Radial pulse- Rapid, feeble , sometimes impalpable Blood pressure- Less than 80 mmHg , may be unrecordable Skin elasticity - Pinch retracts very slowly (more than 2 seconds) Tongue- Very dry Anterior fontanelle - Very sunken</li><li>\u2022 Patient appearance- Drowsy, limp, cold, sweaty, maybe comatose.</li><li>\u2022 Drowsy, limp, cold, sweaty,</li><li>\u2022 comatose.</li><li>\u2022 Radial pulse- Rapid, feeble , sometimes impalpable</li><li>\u2022 Rapid, feeble</li><li>\u2022 impalpable</li><li>\u2022 Blood pressure- Less than 80 mmHg , may be unrecordable</li><li>\u2022 Less than 80 mmHg</li><li>\u2022 unrecordable</li><li>\u2022 Skin elasticity - Pinch retracts very slowly (more than 2 seconds)</li><li>\u2022 Skin elasticity</li><li>\u2022 Pinch retracts very slowly</li><li>\u2022 Tongue- Very dry</li><li>\u2022 Tongue- Very dry</li><li>\u2022 Anterior fontanelle - Very sunken</li><li>\u2022 Anterior fontanelle</li><li>\u2022 Very sunken</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 IMNCI guidelines for dehydration and diarrhoea</li></ul>\n<p><strong>References:</strong></p><ul><li>\u21b3 Reference: Park 26 th edition (page 262)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d29eb03",
      "audio": ""
    },
    {
      "text": "A 3-year-old child presents to the pediatric clinic with a 2-day history of diarrhea. The mother reports that the child has had several episodes of loose stools, some of which contained blood. The child does not have a fever and appears otherwise healthy. The pediatric resident examining the child is considering various infectious causes of bloody diarrhea (dysentery) and recalls that certain pathogens are more commonly associated with this presentation than others. The resident needs to identify which pathogen is least likely to be the cause of this child's bloody diarrhea. Based on the clinical presentation, which of the following pathogens is the least likely cause of bloody diarrhea in this child?",
      "options": [
        {
          "label": "A",
          "text": "Campylobacter jejuni",
          "correct": false
        },
        {
          "label": "B",
          "text": "Entamoeba histolytica",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rotavirus",
          "correct": true
        },
        {
          "label": "D",
          "text": "Shigella",
          "correct": false
        }
      ],
      "correct_answer": "C. Rotavirus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Rotavirus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Campylobacter jejuni - Campylobacter infection usually have diarrhea (often bloody) , fever , and stomach cramps . Nausea and vomiting may accompany the diarrhea . Symptoms usually start two to five days after infection and last about one week .</li><li>\u2022 Option A. Campylobacter jejuni</li><li>\u2022 Campylobacter infection</li><li>\u2022 diarrhea</li><li>\u2022 bloody)</li><li>\u2022 fever</li><li>\u2022 stomach cramps</li><li>\u2022 Nausea and vomiting</li><li>\u2022 accompany</li><li>\u2022 diarrhea</li><li>\u2022 start two to five days</li><li>\u2022 infection</li><li>\u2022 last about one week</li><li>\u2022 Option B. Entamoeba histolytica: Invasive intestinal parasitic infection can result in symptoms of fulminant dysentery , such as fever, chills, bloody or mucous diarrhea , and abdominal discomfort .</li><li>\u2022 Option B. Entamoeba histolytica: Invasive intestinal parasitic infection</li><li>\u2022 fulminant dysentery</li><li>\u2022 fever, chills, bloody</li><li>\u2022 mucous diarrhea</li><li>\u2022 abdominal discomfort</li><li>\u2022 Option D. Shigella: Shigellosis usually start experiencing symptoms 1 to 2 days after contact with the germ . These symptoms include: Diarrhea that can be bloody or prolonged (lasting more than 3 days ).</li><li>\u2022 Option D. Shigella: Shigellosis</li><li>\u2022 symptoms 1 to 2 days</li><li>\u2022 contact</li><li>\u2022 the germ</li><li>\u2022 Diarrhea</li><li>\u2022 bloody or prolonged</li><li>\u2022 more than 3 days</li><li>\u2022 Causes of acute gastroenteritis with blood in stool:</li><li>\u2022 Causes of acute gastroenteritis with blood in stool:</li><li>\u2022 Bacteria - Shigellosis, enterohemorrhagic E coli, C. jejuni, Salmonella spp, Yersinia enterocolitica</li><li>\u2022 Bacteria</li><li>\u2022 Protozoa- Entamoeba histolytica, Balantidium coli</li><li>\u2022 Protozoa-</li><li>\u2022 Helminths - Massive trichuris infection, Schistosoma mansoni, S.japonicum</li><li>\u2022 Helminths</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rota virus , Noro virus is the least likely cause of bloody diarrhea.</li><li>\u27a4 Rota virus</li><li>\u27a4 Noro virus</li><li>\u27a4 least</li><li>\u27a4 bloody diarrhea.</li><li>\u27a4 Causes of acute gastroenteritis with blood in stool - Shigellosis, enterohemorrhagic E coli, C. jejuni , Salmonella spp, Yersinia enterocolitica, Entamoeba histolytica, Balantidium coli, Massive trichuris infection, Schistosoma mansoni, S.japonicum</li><li>\u27a4 acute gastroenteritis</li><li>\u27a4 blood in stool</li><li>\u27a4 Shigellosis,</li><li>\u27a4 enterohemorrhagic E coli, C. jejuni</li><li>\u27a4 Salmonella spp, Yersinia enterocolitica, Entamoeba histolytica, Balantidium coli, Massive trichuris infection, Schistosoma mansoni, S.japonicum</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 661)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 661)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b042c6d2",
      "audio": ""
    },
    {
      "text": "A pediatric resident is managing a 7-month-old child who presented to the clinic with acute diarrhea. As part of the treatment plan, the resident decides to include zinc supplementation, which is recommended for the management of acute diarrhea in children to reduce the duration and severity of the episode. The resident is aware that the dose of zinc supplementation varies based on the age of the child and is determining the appropriate dose for this 7-month-old patient. What is the recommended dose of zinc supplementation for a 7-month-old child with acute diarrhea, to be given for a duration of 14 days?",
      "options": [
        {
          "label": "A",
          "text": "1 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "5 mg",
          "correct": false
        },
        {
          "label": "C",
          "text": "10 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "20 mg",
          "correct": true
        }
      ],
      "correct_answer": "D. 20 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. 20 mg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 When a zinc supplement is given during an episode of acute diarrhoea , it reduces the episode's duration and severity . In addition, zinc supplements given for 10 to 14 days to lower the incidence of diarrhoea in the following 2 to 3 months.</li><li>\u2022 zinc supplement</li><li>\u2022 acute diarrhoea</li><li>\u2022 reduces</li><li>\u2022 episode's duration and severity</li><li>\u2022 zinc supplements</li><li>\u2022 10 to 14 days</li><li>\u2022 lower</li><li>\u2022 incidence of diarrhoea</li><li>\u2022 2 to 3 months.</li><li>\u2022 WHO and UNICEF therefore recommend daily - 10 mg of zinc for infants under 6 months of age , and 20 mg for children older than 6 months for 10-14 days.</li><li>\u2022 WHO and UNICEF</li><li>\u2022 10 mg of zinc</li><li>\u2022 infants</li><li>\u2022 6 months of age</li><li>\u2022 20 mg</li><li>\u2022 children older</li><li>\u2022 6 months for 10-14 days.</li><li>\u2022 Some important Pointers -</li><li>\u2022 Micronutrient Zinc deficiency associated with rash and diarrhea Acrodermatitis enteropathica is due to Zinc deficiency (Clinical triad of acral dermatitis, alopecia and diarrhea ) Zinc deficiency : Growth failure, Sexual infantilism , Loss of taste , Delayed wound healing , Loss of integrity of immune system , Spontaneous abortions, Congenital malformations, Low birth weight , IUGR, Preterm delivery, Skin lesions , Depressed appetite , Skeletal abnormalities Banana is not a good source of: Calcium, Iron (Due to presence of phytates ) and Zinc.</li><li>\u2022 Micronutrient Zinc deficiency associated with rash and diarrhea</li><li>\u2022 Micronutrient Zinc deficiency associated with rash and diarrhea</li><li>\u2022 Micronutrient Zinc deficiency</li><li>\u2022 rash and diarrhea</li><li>\u2022 Acrodermatitis enteropathica is due to Zinc deficiency (Clinical triad of acral dermatitis, alopecia and diarrhea )</li><li>\u2022 Acrodermatitis enteropathica is due to Zinc deficiency (Clinical triad of acral dermatitis, alopecia and diarrhea )</li><li>\u2022 Acrodermatitis enteropathica</li><li>\u2022 Zinc deficiency</li><li>\u2022 acral dermatitis, alopecia and diarrhea</li><li>\u2022 Zinc deficiency : Growth failure, Sexual infantilism , Loss of taste , Delayed wound healing , Loss of integrity of immune system , Spontaneous abortions, Congenital malformations, Low birth weight , IUGR, Preterm delivery, Skin lesions , Depressed appetite , Skeletal abnormalities</li><li>\u2022 Zinc deficiency : Growth failure, Sexual infantilism , Loss of taste , Delayed wound healing , Loss of integrity of immune system , Spontaneous abortions, Congenital malformations, Low birth weight , IUGR, Preterm delivery, Skin lesions , Depressed appetite , Skeletal abnormalities</li><li>\u2022 Zinc deficiency</li><li>\u2022 Growth failure, Sexual infantilism</li><li>\u2022 Loss of taste</li><li>\u2022 wound healing</li><li>\u2022 immune system</li><li>\u2022 Low birth weight</li><li>\u2022 Skin lesions</li><li>\u2022 Depressed appetite</li><li>\u2022 Banana is not a good source of: Calcium, Iron (Due to presence of phytates ) and Zinc.</li><li>\u2022 Banana is not a good source of: Calcium, Iron (Due to presence of phytates ) and Zinc.</li><li>\u2022 Banana</li><li>\u2022 not</li><li>\u2022 good source</li><li>\u2022 presence</li><li>\u2022 phytates</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Zinc supplementation :</li><li>\u27a4 Zinc supplementation</li><li>\u27a4 Infants < 6 months age: 10 mg/day \u00d7 10\u201314 days. Children > 6 months age: 20 mg/day \u00d7 10\u201314 days.</li><li>\u27a4 Infants < 6 months age: 10 mg/day \u00d7 10\u201314 days.</li><li>\u27a4 Infants < 6 months</li><li>\u27a4 10 mg/day \u00d7 10\u201314 days.</li><li>\u27a4 Children > 6 months age: 20 mg/day \u00d7 10\u201314 days.</li><li>\u27a4 Children > 6 months</li><li>\u27a4 20 mg/day \u00d7 10\u201314 days.</li><li>\u27a4 Ref : Park 26 th edition (page 264)</li><li>\u27a4 Ref : Park 26 th edition (page 264)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "edc68af9",
      "audio": ""
    },
    {
      "text": "A medical resident is consulting on a case in the emergency department involving a group of individuals who presented with symptoms of food poisoning after attending a buffet. The resident is considering the various pathogens that could be responsible based on the type of onset and nature of the toxins involved. While some foodborne illnesses are caused by preformed toxins, others result from toxins produced in the body after consuming contaminated food. The resident needs to determine which pathogen in this scenario is least likely to be associated with preformed toxins in the context of food poisoning. In the case of the group presenting with food poisoning after a buffet, which pathogen is least likely to be associated with illness caused by preformed toxins?",
      "options": [
        {
          "label": "A",
          "text": "Bacillus cereus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Botulism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Clostridium Perfringens",
          "correct": true
        },
        {
          "label": "D",
          "text": "Staphylococcus",
          "correct": false
        }
      ],
      "correct_answer": "C. Clostridium Perfringens",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Clostridium perfringens</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bacillus cereus: Emetic type causes illness through the ingestion of preformed toxins</li><li>\u2022 Option A. Bacillus cereus: Emetic type</li><li>\u2022 preformed toxins</li><li>\u2022 Option B. Botulism: Is caused by the ingestion of a preformed toxin in contaminated food . The toxin is produced when the bacteria grow in food that has been improperly preserved , or stored under anaerobic conditions .</li><li>\u2022 Option B. Botulism:</li><li>\u2022 preformed toxin</li><li>\u2022 contaminated food</li><li>\u2022 bacteria grow in food</li><li>\u2022 improperly preserved</li><li>\u2022 stored under anaerobic conditions</li><li>\u2022 Option D. Staphylococcus - Mechanism of food poisoning: Intra-dietetic toxins (ingestion of toxins pre-formed in food, in which bacteria have grown ). Incubation period ( 1\u20136 hours ) is short because of \u2018preformed toxin \u2019. Toxins are relatively heat stable and resist boiling for 30 min or more.</li><li>\u2022 Option D. Staphylococcus</li><li>\u2022 Mechanism</li><li>\u2022 Intra-dietetic toxins</li><li>\u2022 bacteria</li><li>\u2022 grown</li><li>\u2022 1\u20136 hours</li><li>\u2022 short</li><li>\u2022 \u2018preformed</li><li>\u2022 toxin</li><li>\u2022 relatively heat stable</li><li>\u2022 resist</li><li>\u2022 30 min</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Clostridium botulinum, Staphylococcus aureus, and Bacillus cereus ( emetic type ) cause illness through the ingestion of preformed toxins present in the food .</li><li>\u27a4 Clostridium botulinum, Staphylococcus aureus, and Bacillus cereus</li><li>\u27a4 emetic type</li><li>\u27a4 illness</li><li>\u27a4 ingestion</li><li>\u27a4 preformed toxins</li><li>\u27a4 food</li><li>\u27a4 Ref: Park 26 th edition (page 276)</li><li>\u27a4 Ref: Park 26 th edition (page 276)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb37d50f",
      "audio": ""
    },
    {
      "text": "A public health physician is managing a recent outbreak of cholera in a coastal community. One of the patients, a 40-year-old man, has recently recovered from a severe case of cholera. Despite clinical recovery, follow-up testing reveals that he is still excreting Vibrio cholerae in his stool. This information is critical for the public health team in understanding the dynamics of disease transmission post-recovery. The physician needs to categorize this patient correctly in terms of carrier status to inform further public health actions. In the context of a cholera outbreak, how should the public health physician categorize a patient who continues to excrete Vibrio cholerae in his stool 2 to 3 weeks after clinical recovery?",
      "options": [
        {
          "label": "A",
          "text": "Chronic carrier",
          "correct": false
        },
        {
          "label": "B",
          "text": "Contact carrier",
          "correct": false
        },
        {
          "label": "C",
          "text": "Convalescent carrier",
          "correct": true
        },
        {
          "label": "D",
          "text": "Incubatory carrier",
          "correct": false
        }
      ],
      "correct_answer": "C. Convalescent carrier",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-122809.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0C. Convalescent carrier</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chronic carrier:  Excretes infectious agents for indefinite periods (> 6 months). Example - Typhoid, Hepatitis-B, Dysentery, Meningococcal Meningitis, Malaria, Gonorrhoea, etc.</li><li>\u2022 Option A. Chronic carrier:  Excretes infectious agents</li><li>\u2022 indefinite periods</li><li>\u2022 Option B. Contact carrier: Carrier who gets infected from a case.</li><li>\u2022 Option B. Contact carrier:</li><li>\u2022 infected from a case.</li><li>\u2022 Option D. Incubatory carrier: Shed infectious agent during incubation period of disease. Example - Measles, Mumps, Polio, Pertussis, Influenza, Diphtheria, Hepatitis-B</li><li>\u2022 Option D. Incubatory carrier: Shed infectious agent</li><li>\u2022 incubation period</li><li>\u2022 Measles, Mumps, Polio, Pertussis, Influenza, Diphtheria, Hepatitis-B</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Convalescent Carriers : Shed the disease agent during the period of Convalescence , e.g. Typhoid, Bacillary Dysentery, Amoebic Dysentery, Cholera, Diphtheria & Pertussis (Clinical recovery does not coincide with bacteriological recovery)</li><li>\u27a4 Convalescent Carriers</li><li>\u27a4 disease agent</li><li>\u27a4 period</li><li>\u27a4 Convalescence</li><li>\u27a4 Typhoid, Bacillary Dysentery, Amoebic Dysentery, Cholera, Diphtheria & Pertussis</li><li>\u27a4 Different types of carriers of a disease</li><li>\u27a4 Different types of carriers of a disease</li></ul>\n<p><strong>References:</strong></p><ul><li>\u21b3 Reference: Park 26 th edition (page 267)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f8cdcd7a",
      "audio": ""
    }
  ]
}